2016 European Guidelines on cardiovascular disease prevention in clinical practice

The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)

Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)

Authors/Task Force Members: Massimo F. Piepoli* (Chairperson) (Italy), Arno W. Hoes* (Co-Chairperson) (The Netherlands), Stefan Agewall (Norway), Christian Albus (Germany), Carlos Brotons (Spain), Alberico L. Catapano (Italy), Marie-Therese Cooney (Ireland), Ugo Corrà (Italy), Bernard Cosyns (Belgium), Christi Deaton (UK), Ian Graham (Ireland), Michael Stephen Hall (UK), F. D. Richard Hobbs (UK), Maja-Lisa Løchen (Norway), Herbert Løllgen (Germany), Pedro Marques-Vidal (Switzerland), Joep Perk (Sweden), Eva Prescott (Denmark), Josep Redon (Spain), Dimitrios J. Richter (Greece), Naveed Sattar (UK), Yvo Smulders (The Netherlands), W. M. Monique Verschuren (The Netherlands), H. Bart van der Worp (The Netherlands), Ineke van Dis (The Netherlands), Simone Binno (Italy)

Additional Contributor: Simone Binno (Italy)

ESC entities having participated in the development of this document:

Associations: European Association for Cardiovascular Prevention & Rehabilitation (EACPR), European Association of Cardiovascular Imaging (EACVI), European Association of Percutaneous Cardiovascular Interventions (EAPCI), Heart Failure Association (HFA).

Councils: Council on Cardiovascular Nursing and Allied Professions, Council for Cardiology Practice, Council on Cardiovascular Primary Care.

Working Groups: Cardiovascular Pharmacotherapy

The content of these European Society of Cardiology (ESC) Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of the ESC Guidelines may be translated or reproduced in any form without written permission from the ESC. Permission can be obtained upon submission of a written request to Oxford University Press, the publisher of the European Heart Journal and the party authorized to handle such permissions on behalf of the ESC.

Disclaimer: The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientific and medical knowledge and the evidence available at the time of their publication. The ESC is not responsible in the event of any contradiction, discrepancy and/or ambiguity between the ESC Guidelines and any other official recommendations or guidelines issued by the competent public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the ESC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic or therapeutic medical strategies; however, the ESC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s caregiver. Nor do the ESC Guidelines exempt health professionals from taking into full and careful consideration the relevant official updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient’s case in light of the scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional’s responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.

© The European Society of Cardiology 2016. All rights reserved. For permissions please email: journals.permissions@oup.com.
Document Reviewers: Guy De Backer (CPG Review Coordinator) (Belgium), Marco Roffi (CPG Review Coordinator) (Switzerland), Victor Aboyans (France), Norbert Bachl (Austria), Héctor Bueno (Spain), Scipione Carerj (Italy), Leslie Cho (USA), John Cox (Ireland), Johan De Sutter (Belgium), Günther Egidi (Germany), Miles Fisher (UK), Donna Fitzsimons (UK), Oscar H. Franco (The Netherlands), Maxime Guenoun (France), Caterina Jennings (UK), Borut Jug (Slovenia), Paulus Kirchhof (UK/Germany), Kornelia Kotsева (UK), Gregory Y.H. Lip (UK), François Mach (Switzerland), Giuseppe Mancia (Italy), Franz Martin Bermudo (Spain), Alessandro Mezzani (Italy), Alexander Niessner (Austria), Piotr Ponikowski (Poland), Bernhard Rauch (Germany), Lars Rydén (Sweden), Adrienne Stauder (Hungary), Guillaume Turc (France), Olov Wiklund (Sweden), Stephan Windecker (Switzerland), Jose Luis Zamorano (Spain)

Societies: 1European Society of Cardiology (ESC); 2European Association for the Study of Diabetes (EASD); 3European Atherosclerosis Society (EAS); 4European Heart Network (EHN); 5European Society of Hypertension (ESH); 6European Stroke Organisation (ESO); 7International Diabetes Federation European Region (IDF Europe); 8International Federation of Sport Medicine (FIMS); 9International Society of Behavioural Medicine (ISBM); 10WONCA Europe.

The disclosure forms of all experts involved in the development of these guidelines are available on the ESC website http://www.escardio.org/guidelines.

Online publish-ahead-of-print 23 May 2016

---

**Keywords**
- Guidelines
- Blood pressure
- Clinical settings
- Diabetes
- Healthy lifestyle
- Lipid
- Nutrition
- Physical activity
- Population
- Prevention
- Primary care
- Psychosocial factors
- Rehabilitation
- Risk assessment
- Risk management
- Smoking
- Stakeholder

---

**Table of Contents**

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abbreviations and acronyms</td>
<td>2318</td>
</tr>
<tr>
<td>1. What is cardiovascular disease prevention?</td>
<td>2319</td>
</tr>
<tr>
<td>1.1 Definition and rationale</td>
<td>2319</td>
</tr>
<tr>
<td>1.2 Development of the 6th Joint Task Force guidelines</td>
<td>2320</td>
</tr>
<tr>
<td>1.3 Cost-effectiveness of prevention</td>
<td>2320</td>
</tr>
<tr>
<td>2. Who will benefit from prevention? When and how to assess risk and</td>
<td>2321</td>
</tr>
<tr>
<td>prioritize</td>
<td></td>
</tr>
<tr>
<td>2.1 Estimation of total cardiovascular risk</td>
<td>2321</td>
</tr>
<tr>
<td>2.2 When to assess total cardiovascular risk</td>
<td>2321</td>
</tr>
<tr>
<td>2.3 How to estimate total cardiovascular risk</td>
<td>2321</td>
</tr>
<tr>
<td>2.3.1 Ten-year cardiovascular risk</td>
<td>2325</td>
</tr>
<tr>
<td>2.3.2 Cardiovascular risk age</td>
<td>2326</td>
</tr>
<tr>
<td>2.3.3 Lifetime vs. 10-year cardiovascular risk estimation</td>
<td>2326</td>
</tr>
<tr>
<td>2.3.4 Low-risk, high-risk and very-high-risk countries</td>
<td>2326</td>
</tr>
<tr>
<td>2.3.4.1 What are low-risk countries?</td>
<td>2326</td>
</tr>
<tr>
<td>2.3.4.2 What are high-risk and very-high-risk countries?</td>
<td>2326</td>
</tr>
<tr>
<td>2.3.5 How to use the risk estimation charts</td>
<td>2326</td>
</tr>
<tr>
<td>2.3.6 Modifiers of calculated total cardiovascular risk</td>
<td>2330</td>
</tr>
<tr>
<td>2.3.7 Risk categories: priorities</td>
<td>2330</td>
</tr>
<tr>
<td>2.3.8 Risk factor targets</td>
<td>2330</td>
</tr>
<tr>
<td>2.3.9 Conclusions</td>
<td>2330</td>
</tr>
<tr>
<td>2.4 Other risk markers</td>
<td>2331</td>
</tr>
<tr>
<td>2.4.1 Family history(epi)genetics</td>
<td>2331</td>
</tr>
<tr>
<td>2.4.1.1 Family history</td>
<td>2331</td>
</tr>
<tr>
<td>2.4.1.2 Genetic markers</td>
<td>2331</td>
</tr>
<tr>
<td>2.4.1.3 Epigenetics</td>
<td>2332</td>
</tr>
<tr>
<td>2.4.2 Psychosocial risk factors</td>
<td>2332</td>
</tr>
<tr>
<td>2.4.3 Circulating and urinary biomarkers</td>
<td>2333</td>
</tr>
<tr>
<td>2.4.4 Measurement of preclinical vascular damage</td>
<td>2334</td>
</tr>
<tr>
<td>2.4.4.1 Coronary artery calcium</td>
<td>2334</td>
</tr>
<tr>
<td>2.4.4.2 Carotid ultrasound</td>
<td>2335</td>
</tr>
<tr>
<td>2.4.4.3 Arterial stiffness</td>
<td>2335</td>
</tr>
<tr>
<td>2.4.4.4 Ankle–brachial index</td>
<td>2335</td>
</tr>
<tr>
<td>2.4.4.5 Echocardiography</td>
<td>2335</td>
</tr>
<tr>
<td>2.4.5 Clinical conditions affecting cardiovascular disease risk</td>
<td>2335</td>
</tr>
<tr>
<td>2.4.5.1 Chronic kidney disease</td>
<td>2335</td>
</tr>
<tr>
<td>2.4.5.2 Influenza</td>
<td>2336</td>
</tr>
<tr>
<td>2.4.5.3 Periodontitis</td>
<td>2336</td>
</tr>
<tr>
<td>2.4.5.4 Patients treated for cancer</td>
<td>2336</td>
</tr>
<tr>
<td>2.4.5.5 Autoimmune disease</td>
<td>2337</td>
</tr>
<tr>
<td>2.4.5.6 Obstructive sleep apnoea syndrome</td>
<td>2337</td>
</tr>
<tr>
<td>2.4.5.7 Erectile dysfunction</td>
<td>2338</td>
</tr>
<tr>
<td>2.5 Relevant groups</td>
<td>2338</td>
</tr>
<tr>
<td>2.5.1 Individuals &lt;50 years of age</td>
<td>2338</td>
</tr>
<tr>
<td>2.5.1.1 Assessing cardiovascular disease risk in people &lt;50 years of age</td>
<td>2338</td>
</tr>
<tr>
<td>2.5.1.2 Management of cardiovascular disease risk in people &lt;50 years of age</td>
<td>2338</td>
</tr>
<tr>
<td>2.5.2 Elderly</td>
<td>2339</td>
</tr>
<tr>
<td>2.5.2.1 Hypertension</td>
<td>2339</td>
</tr>
<tr>
<td>2.5.2.2 Diabetes mellitus</td>
<td>2339</td>
</tr>
<tr>
<td>2.5.2.3 Hyperlipidaemia</td>
<td>2339</td>
</tr>
<tr>
<td>2.5.3 Female-specific conditions</td>
<td>2339</td>
</tr>
<tr>
<td>2.5.3.1 Obstetric conditions</td>
<td>2339</td>
</tr>
<tr>
<td>2.5.3.2 Non-obstetric conditions</td>
<td>2340</td>
</tr>
<tr>
<td>2.5.4 Ethnic minorities</td>
<td>2340</td>
</tr>
<tr>
<td>3a. How to intervene at the individual level: risk factor intervention</td>
<td>2341</td>
</tr>
<tr>
<td>3a.1 Behaviour change</td>
<td>2341</td>
</tr>
<tr>
<td>3a.2 Psychosocial factors</td>
<td>2342</td>
</tr>
<tr>
<td>3a.3 Sedentary behaviour and physical activity</td>
<td>2343</td>
</tr>
<tr>
<td>3a.3.1 Introduction</td>
<td>2343</td>
</tr>
</tbody>
</table>
3a.3.2 Physical activity prescription .................................. 2344
3a.3.2.1 Aerobic physical activity .................................. 2344
3a.3.2.2 Muscle strength/resistance physical activity ............ 2344
3a.3.2.3 Neuromotor physical activity .................................. 2345
3a.3.2.4 Phases and progression of physical activity .......... 2345
3a.3.3 Risk assessment .................................................. 2345
3a.4 Smoking intervention ............................................. 2345
3a.4.1 Introduction ..................................................... 2345
3a.4.2 Dosage and type ................................................ 2346
3a.4.3 Passive smoking ................................................ 2346
3a.4.4 Mechanisms by which tobacco smoking increases risk ...................................................... 2346
3a.4.5 Smoking cessation .............................................. 2346
3a.4.6 Evidence-based drug interventions .................................. 2346
3a.4.7 Electronic cigarettes ........................................... 2347
3a.4.8 Other smoking cessation interventions ................... 2347
3a.5 Nutrition .......................................................... 2347
3a.5.1 Introduction ..................................................... 2347
3a.5.2 Fatty acids ..................................................... 2347
3a.5.3 Minerals ....................................................... 2348
3a.5.4 Vitamins ....................................................... 2348
3a.5.5 Fibre .......................................................... 2348
3a.5.6 Foods and food groups ........................................ 2349
3a.5.6.1 Fruits and vegetables ..................................... 2349
3a.5.6.2 Nuts ...................................................... 2349
3a.5.6.3 Fish ...................................................... 2349
3a.5.6.4 Alcoholic beverages ..................................... 2349
3a.5.6.5 Soft drinks and sugar ...................................... 2349
3a.5.7 Functional foods .............................................. 2349
3a.5.8 Dietary patterns ................................................ 2349
3a.6 Body weight ........................................................ 2349
3a.6.1 Introduction ..................................................... 2350
3a.6.2 Which index of obesity is the best predictor of cardiovascular risk? ...................................................... 2350
3a.6.3 Does ‘metabolically healthy obesity’ exist? ................. 2350
3a.6.4 The obesity paradox in established heart disease ..... 2350
3a.6.5 Treatment goals and modalities .................................. 2350
3a.7 Lipid control ........................................................ 2351
3a.7.1 Introduction ..................................................... 2351
3a.7.2 Total and low-density lipoprotein cholesterol ............ 2351
3a.7.3 Apolipoprotein B .............................................. 2351
3a.7.4 Triglycerides .................................................... 2351
3a.7.5 High-density lipoprotein cholesterol ....................... 2351
3a.7.6 Lipoprotein(a) .................................................. 2352
3a.7.7 Apolipoprotein B/apolipoprotein A1 ratio .................. 2352
3a.7.8 Calculated lipoprotein variables .................................. 2352
3a.7.8.1 Low-density lipoprotein cholesterol .................... 2352
3a.7.8.2 Non-high-density lipoprotein cholesterol (accurate in non-fasting samples) ...................................................... 2352
3a.7.8.3 Remnant cholesterol ...................................... 2352
3a.7.9 Exclusion of secondary and familial dyslipeidemia .......... 2352
3a.7.10 Who should be treated and what are the goals? .......... 2352
3a.7.11 Patients with kidney disease .................................. 2353
3a.7.12 Drugs ....................................................... 2353
3a.7.13 Drug combinations ........................................... 2354
3a.8 Diabetes mellitus (type 2 and type 1) ......................... 2355
3a.8.1 Lifestyle intervention ........................................ 2356
3a.8.2 Cardiovascular risk .......................................... 2356
3a.8.3 Glucose control ............................................... 2356
3a.8.4 Blood pressure ................................................. 2356
3a.8.5 Lipid-lowering therapy ........................................ 2356
3a.8.6 Antithrombotic therapy ........................................ 2357
3a.8.7 Microalbuminuria ............................................ 2357
3a.8.8 Type 1 diabetes ............................................... 2357
3a.9 Hypertension ..................................................... 2358
3a.9.1 Introduction ..................................................... 2359
3a.9.2 Definition and classifications of hypertension .......... 2359
3a.9.3 Blood pressure measurement .................................. 2359
3a.9.4 Office or clinic blood pressure measurement ............. 2359
3a.9.5 Out-of-office blood pressure monitoring ................. 2359
3a.9.6 Diagnostic evaluation in hypertensive patients .......... 2359
3a.9.7 Risk stratification in hypertension ......................... 2360
3a.9.8 Who to treat, and when to initiate antihypertensive treatment ...................................................... 2360
3a.9.9 How to treat .................................................... 2360
3a.9.9.1 Lifestyle changes .......................................... 2360
3a.9.9.2 Blood pressure-lowering drugs ........................... 2360
3a.9.9.3 Combination treatment ................................... 2361
3a.9.10 Blood pressure goals ........................................ 2361
3a.9.11 Hypertension in special groups ........................... 2362
3a.9.11.1 Diabetes mellitus ......................................... 2362
3a.9.11.2 Elderly ................................................... 2362
3a.9.12 Resistant hypertension ....................................... 2362
3a.9.13 Duration of treatment and follow-up ...................... 2362
3a.10 Antiplatelet therapy ............................................. 2363
3a.10.1 Antiplatelet therapy in individuals without cardiovascular disease ...................................................... 2363
3a.10.2 Antiplatelet therapy in individuals with cardiovascular or cerebrovascular disease ...................................................... 2363
3a.11 Adherence to medication ........................................ 2364
3a.11.1 Polypill ....................................................... 2365

3b. How to intervene at the individual level: disease-specific intervention—atrial fibrillation, coronary artery disease, chronic heart failure, cerebrovascular disease, peripheral artery disease (web addenda) ...................................................... 2365

3c. How to intervene at the population level .................................. 2365
3c.1 Introduction (healthy lifestyle promotion) .................... 2365
3c.2 Population-based approaches to diet .......................... 2366
3c.3 Population-based approaches to physical activity .......... 2367
3c.4 Population-based approaches to smoking and other tobacco use ...................................................... 2369
3c.5 Alcohol abuse protection ........................................ 2370
3c.6 Healthy environment ............................................. 2371

4a. Where to intervene at the individual level .................................. 2371
4a.1 Clinical settings and stakeholders .................................. 2371
4a.1.1 Cardiovascular disease prevention in primary care .......... 2371
4a.1.2 Acute hospital admission setting .................................. 2372
4a.1.3 Specialized prevention programmes ......................... 2372
4a.1.4 Alternative rehabilitation models ........................... 2373
4a.1.4.1 Telerehabilitation .......................................... 2373
4a.1.5 Maintaining lifestyle changes .................................. 2373
4a.2 How to monitor preventive activities .......................... 2373

4b. Where to intervene at the population level .................................. 2374
4b.1 Government and public health ..................................... 60
4b.2 Non-governmental organizations ................................ 2374

5. To do and not to do messages from the Guidelines .................. 2375
6. Appendix .......................................................... 2376
7. References .......................................................... 2377
Abbreviations and acronyms

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABI</td>
<td>ankle–brachial (blood pressure) index</td>
</tr>
<tr>
<td>ABPM</td>
<td>ambulatory blood pressure monitoring</td>
</tr>
<tr>
<td>ACCORD</td>
<td>Action to Control Cardiovascular Risk in Diabetes</td>
</tr>
<tr>
<td>ACE-I</td>
<td>angiotensin-converting enzyme inhibitor</td>
</tr>
<tr>
<td>ACS</td>
<td>acute coronary syndromes</td>
</tr>
<tr>
<td>ADVANCE</td>
<td>Action in Diabetes and Vascular disease: PreterAx and Diamicron MR Controlled Evaluation</td>
</tr>
<tr>
<td>AF</td>
<td>atrial fibrillation</td>
</tr>
<tr>
<td>AMI</td>
<td>acute myocardial infarction</td>
</tr>
<tr>
<td>apoA1</td>
<td>apolipoprotein A1</td>
</tr>
<tr>
<td>apoB</td>
<td>apolipoprotein B</td>
</tr>
<tr>
<td>ARB</td>
<td>angiotensin receptor blocker</td>
</tr>
<tr>
<td>BEUC</td>
<td>Bureau Européen des Unions de Consommateurs</td>
</tr>
<tr>
<td>BMI</td>
<td>body mass index (weight (kg)/height (m²))</td>
</tr>
<tr>
<td>BP</td>
<td>blood pressure</td>
</tr>
<tr>
<td>CAC</td>
<td>coronary artery calcium</td>
</tr>
<tr>
<td>CAD</td>
<td>coronary artery disease</td>
</tr>
<tr>
<td>CAPRIE</td>
<td>Clopidogrel versus Aspirin in Patients at Risk for Ischaemic Events</td>
</tr>
<tr>
<td>CARDs</td>
<td>Collaborative Atorvastatin Diabetes Study</td>
</tr>
<tr>
<td>CHANCE</td>
<td>Clopidogrel in High-risk patients with Acute Non-disabling Cerebrovascular Events</td>
</tr>
<tr>
<td>CHARISMA</td>
<td>Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilisation, Management, and Avoidance</td>
</tr>
<tr>
<td>CI</td>
<td>confidence interval</td>
</tr>
<tr>
<td>CKD</td>
<td>chronic kidney disease</td>
</tr>
<tr>
<td>CR</td>
<td>cardiac rehabilitation</td>
</tr>
<tr>
<td>CT</td>
<td>computed tomography</td>
</tr>
<tr>
<td>CTT</td>
<td>Cholesterol Treatment Trialists’ Collaboration</td>
</tr>
<tr>
<td>CURE</td>
<td>Clopidogrel vs. Placebo in Patients with ACS without ST-segment elevation</td>
</tr>
<tr>
<td>CV</td>
<td>cardiovascular</td>
</tr>
<tr>
<td>CVD</td>
<td>cardiovascular disease</td>
</tr>
<tr>
<td>DALYs</td>
<td>disability-adjusted life years</td>
</tr>
<tr>
<td>DASH</td>
<td>Dietary Approaches to Stop Hypertension</td>
</tr>
<tr>
<td>DBP</td>
<td>diastolic blood pressure</td>
</tr>
<tr>
<td>DCCT</td>
<td>Diabetes Control and Complications Trial</td>
</tr>
<tr>
<td>DHA</td>
<td>docosahexaenoic acid</td>
</tr>
<tr>
<td>DM</td>
<td>diabetes mellitus</td>
</tr>
<tr>
<td>DPP-4</td>
<td>dipeptidyl peptidase-4</td>
</tr>
<tr>
<td>eGFR</td>
<td>estimated glomerular filtration rate</td>
</tr>
<tr>
<td>ECDA</td>
<td>European Chronic Disease Alliance</td>
</tr>
<tr>
<td>ECG</td>
<td>electrocardiogram</td>
</tr>
<tr>
<td>ED</td>
<td>erectile dysfunction</td>
</tr>
<tr>
<td>EHN</td>
<td>European Heart Network</td>
</tr>
<tr>
<td>EMA</td>
<td>European Medicines Agency</td>
</tr>
<tr>
<td>EPA</td>
<td>eicosapentaenoic acid</td>
</tr>
<tr>
<td>EPIC</td>
<td>European Prospective Investigation into Cancer and Nutrition</td>
</tr>
<tr>
<td>EPODE</td>
<td>Ensemble Prévénons l’Obésité des Enfants</td>
</tr>
<tr>
<td>ESC</td>
<td>European Society of Cardiology</td>
</tr>
<tr>
<td>EU</td>
<td>European Union</td>
</tr>
<tr>
<td>FDA</td>
<td>Food and Drug Administration (USA)</td>
</tr>
<tr>
<td>FDC</td>
<td>fixed dose combination</td>
</tr>
<tr>
<td>FH</td>
<td>familial hypercholesterolaemia</td>
</tr>
<tr>
<td>GLP-1</td>
<td>glucagon-like peptide 1</td>
</tr>
<tr>
<td>GP</td>
<td>general practitioner</td>
</tr>
<tr>
<td>GOSPEL</td>
<td>Global Secondary Prevention Strategies to Limit Event Recurrence After Myocardial Infarction</td>
</tr>
<tr>
<td>HbA1c</td>
<td>glycated haemoglobin</td>
</tr>
<tr>
<td>HBPM</td>
<td>home blood pressure measurements</td>
</tr>
<tr>
<td>HDL-C</td>
<td>high-density lipoprotein cholesterol</td>
</tr>
<tr>
<td>HF</td>
<td>heart failure</td>
</tr>
<tr>
<td>HF-ACTION</td>
<td>Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training</td>
</tr>
<tr>
<td>HOPE</td>
<td>Heart Outcomes Prevention Evaluation</td>
</tr>
<tr>
<td>HPS</td>
<td>Heart Protection Study</td>
</tr>
<tr>
<td>HRQoL</td>
<td>health-related quality of life</td>
</tr>
<tr>
<td>HR</td>
<td>heart rate</td>
</tr>
<tr>
<td>hsCRP</td>
<td>high-sensitivity C-reactive protein</td>
</tr>
<tr>
<td>HYVET</td>
<td>Hypertension in the Very Elderly Trial</td>
</tr>
<tr>
<td>ICD</td>
<td>International Classification of Diseases</td>
</tr>
<tr>
<td>IMT</td>
<td>intima–media thickness</td>
</tr>
<tr>
<td>INVEST</td>
<td>International Verapamil-Trandolapril Study</td>
</tr>
<tr>
<td>LDL-C</td>
<td>low-density lipoprotein cholesterol</td>
</tr>
<tr>
<td>Lp(a)</td>
<td>lipoprotein(a)</td>
</tr>
<tr>
<td>LV</td>
<td>left ventricle/left ventricular</td>
</tr>
<tr>
<td>LVH</td>
<td>left ventricular hypertrophy</td>
</tr>
<tr>
<td>MET</td>
<td>metabolic equivalent</td>
</tr>
<tr>
<td>MHO</td>
<td>metabolically healthy overweight/obesity</td>
</tr>
<tr>
<td>MI</td>
<td>myocardial infarction</td>
</tr>
<tr>
<td>MUFA</td>
<td>monounsaturated fatty acids</td>
</tr>
<tr>
<td>NGO</td>
<td>non-governmental organization</td>
</tr>
<tr>
<td>NHS</td>
<td>National Health Service (UK)</td>
</tr>
<tr>
<td>NICE</td>
<td>National Institute for Health and Care Excellence</td>
</tr>
<tr>
<td>NNT</td>
<td>number needed to treat</td>
</tr>
<tr>
<td>NRI</td>
<td>net reclassification index</td>
</tr>
<tr>
<td>NRT</td>
<td>nicotine replacement therapy</td>
</tr>
<tr>
<td>OASIS</td>
<td>Organization to Assess Strategies in Acute Ischemic Syndromes</td>
</tr>
<tr>
<td>ONTARGET</td>
<td>ONGoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial</td>
</tr>
<tr>
<td>OSAS</td>
<td>obstructive sleep apnoea syndrome</td>
</tr>
<tr>
<td>OR</td>
<td>odds ratio</td>
</tr>
<tr>
<td>PA</td>
<td>physical activity</td>
</tr>
<tr>
<td>PAD</td>
<td>peripheral artery disease</td>
</tr>
<tr>
<td>PLATO</td>
<td>Ticagrelor vs. Clopidogrel in Patients with ACS with and without ST-segment elevation</td>
</tr>
<tr>
<td>PCSK9</td>
<td>proprotein convertase subtilisin/kexin type 9</td>
</tr>
<tr>
<td>PROactive</td>
<td>Prospective Pioglitazone Clinical Trial in Macrovascular Events</td>
</tr>
<tr>
<td>PROGRESS</td>
<td>Perindopril Protection Against Recurrent Stroke Study</td>
</tr>
<tr>
<td>PROCAM</td>
<td>Prospective Cardiovascular Munster Study</td>
</tr>
<tr>
<td>PWV</td>
<td>pulse wave velocity</td>
</tr>
<tr>
<td>RA</td>
<td>rheumatoid arthritis</td>
</tr>
</tbody>
</table>
1. What is cardiovascular disease prevention?

1.1 Definition and rationale

Cardiovascular disease (CVD) prevention is defined as a coordinated set of actions, at the population level or targeted at an individual, that are aimed at eliminating or minimizing the impact of CVDs and their related disabilities.\(^1\) CVD remains a leading cause of morbidity and mortality, despite improvements in outcomes. Age-adjusted coronary artery disease (CAD) mortality has declined since the 1980s, particularly in high-income regions.\(^2\) CAD rates are now less than half what they were in the early 1980s in many countries in Europe, due to preventive measures including the success of smoking legislation. However, inequalities between countries persist and many risk factors, particularly obesity\(^3\) and diabetes mellitus (DM),\(^4\) have been increasing substantially. If prevention was practised as instructed it
would markedly reduce the prevalence of CVD. It is thus not only
prevailing risk factors that are of concern, but poor implementation
of preventive measures as well.5,6 Prevention should be delivered (i)
at the general population level by promoting healthy lifestyle behav-
ior7 and (ii) at the individual level, i.e. in those subjects at moderate
to high risk of CVD or patients with established CVD, by tackling un-
healthy lifestyles (e.g. poor-quality diet, physical inactivity, smoking)
and by optimising risk factors. Prevention is effective: the elimination
of health risk behaviours would make it possible to prevent at least
80% of CVDs and even 40% of cancers.8,9

1.2 Development of the 6th Joint Task Force guidelines
The present guidelines represent an evidence-based consensus
of the 6th European Joint Task Force involving 10 professional
societies.

By appraising the current evidence and identifying remaining
knowledge gaps in managing CVD prevention, the Task Force for-
mulated recommendations to guide actions to prevent CVD in clin-
ical practice. The Task Force followed the quality criteria for
development of guidelines, which can be found at http://www.
escardio.org/Guidelines-%E2%80%93Education/Clinical-Practice-Guidelines/
Guidelines-development/Writing-ESC-Guidelines. For simplifica-
tion and in keeping with other European Society of Cardiology
(ESC) guidelines, the ESC grading system based on classes of recom-
mandation and levels of evidence has been maintained, recognising
that this may be less suitable to measure the impact of prevention
strategies, particularly those related to behavioural issues and
population-based interventions.

This document has been developed to support healthcare profes-
sionals communicating with individuals about their cardiovascular
(CV) risk and the benefits of a healthy lifestyle and early modification
of their CV risk. In addition, the guidelines provide tools for health-
care professionals to promote population-based strategies and inte-
grate these into national or regional prevention frameworks and to
translate these in locally delivered healthcare services, in line with
the recommendations of the World Health Organization (WHO)
global status report on non-communicable diseases 2010.10

As in the present guidelines, the model presented in the previous
document from the Fifth European Joint Task Force11 has been
structured around four core questions: (i) What is CVD prevention?
(ii) Who will benefit from prevention? (iii) How to intervene?
(iv) Where to intervene?

Compared with the previous guidelines, greater emphasis has been
placed on a population-based approach, on disease-specific interven-
tions and on female-specific conditions, younger individuals and eth-
nic minorities. Due to space restrictions for the paper version, the
chapter on disease-specific intervention is on the web, together
with a few tables and figures (for more detail see web addenda).

A lifetime approach to CV risk is important since both CV risk and
prevention are dynamic and continuous as patients age and/or accumu-
late co-morbidities. This implies that, apart from improving lifestyle
and reducing risk factor levels in patients with established CVD and those
at increased risk of developing CVD, healthy people of all ages should
be encouraged to adopt a healthy lifestyle. Healthcare professionals
play an important role in achieving this in their clinical practice.

1.3 Cost-effectiveness of prevention

Key messages
- Prevention of CVD, either by implementation of lifestyle changes
  or use of medication, is cost effective in many scenarios, including
population-based approaches and actions directed at high-risk
individuals.
- Cost-effectiveness depends on several factors, including baseline
  CV risk, cost of drugs or other interventions, reimbursement
  procedures and implementation of preventive strategies.

In 2009, costs related to CVD amounted to €106 billion, represent-
ing ~9% of the total healthcare expenditure across the European
Union (EU).14 Thus, CVD represents a considerable economic bur-
den to society and effective preventive measures are necessary.
There is consensus in favour of an approach combining strategies
to improve CV health across the population at large from childhood
onward, with specific actions to improve CV health in individuals at
increased risk of CVD or with established CVD.

Most studies assessing the cost-effectiveness of CVD prevention
combine evidence from clinical research with simulation ap-
proaches, while cost-effectiveness data from randomized controlled
trials (RCTs) are relatively scarce.15,16 Cost-effectiveness strongly
depends on parameters such as the target population’s age, the
overall population risk of CVD and the cost of interventions. Hence,
results obtained in one country may not be valid in another. Further-
more, changes such as the introduction of generic drugs can consid-
erably change cost-effectiveness.17 According to the WHO, policy
and environmental changes could reduce CVD in all countries for
less than US$1/person/year.18 A report from the National Institute
for Health and Care Excellence (NICE) estimated that a UK national
programme reducing population CV risk by 1% would prevent
25 000 CVD cases and generate savings of €40 million/year. CAD
mortality rates could be halved by only modest risk factor reduc-
tions and it has been suggested that eight dietary priorities alone
could halve CVD death.19

In the last three decades, more than half of the reduction in CV
mortality has been attributed to changes in risk factor levels in
the population, primarily the reduction in cholesterol and blood pres-
sure (BP) levels and smoking. This favourable trend is partly offset
by an increase in other risk factors, mainly obesity and type 2 DM.19,20 Aging of the population also increases CVD events.21

Several population interventions have efficiently modified the life-
style of individuals. For example, increased awareness of how healthy
lifestyles prevent CVD has helped to reduce smoking and cholesterol

---

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>Class</th>
<th>Level</th>
<th>Ref</th>
</tr>
</thead>
<tbody>
<tr>
<td>Measures aimed at promoting healthy lifestyles at the population level</td>
<td>Ila</td>
<td>B</td>
<td>12, 13</td>
</tr>
</tbody>
</table>

---

*Class of recommendation.

†Level of evidence.

†Reference(s) supporting recommendations.
levels. Lifestyle interventions act on several CV risk factors and should be applied prior to or in conjunction with drug therapies. Also, legislation aimed at decreasing salt and the trans fatty acid content of foods and smoking habits is cost effective in preventing CVD.  

Cholesterol lowering using statins and improvement in BP control are cost effective if targeted at persons with high CV risk. Importantly, a sizable portion of patients on lipid-lowering or BP-lowering drug treatment fails to take their treatment adequately or to reach therapeutic goals, with clinical and economic consequences.

**Gap in evidence**
- Most cost-effectiveness studies rely on simulation. More data, mainly from RCTs, are needed.

### 2. Who will benefit from prevention? When and how to assess risk and prioritize

#### 2.1 Estimation of total cardiovascular risk

All current guidelines on the prevention of CVD in clinical practice recommend the assessment of total CVD risk since atherosclerosis is usually the product of a number of risk factors. Prevention of CVD in an individual should be adapted to his or her total CV risk: the higher the risk, the more intense the action should be.

The importance of total risk estimation in apparently healthy people before management decisions are made is illustrated in supplementary Figure A (see web addenda) and in Table 1 derived from the high-risk Systemic Coronary Risk Estimation (SCORE) chart (http://www.escardio.org/Guidelines-&-Education/Practice-tools/CVD-prevention-toolbox/SCORE-Risk-Charts). This shows that a person with a cholesterol level of 7 mmol/L can be at 10 times lower risk than someone with a cholesterol level of 5 mmol/L if the former is a female and the latter is a male hypertensive smoker.

A recent meta-analysis on CV risk reduction by treatment with BP-lowering drugs does, however, support the concept that absolute risk reduction is larger in those individuals at higher baseline risk. This was confirmed in a further meta-analysis that also showed a greater residual risk during treatment in those at higher baseline risk, supporting earlier intervention.

Although clinicians often ask for decisional thresholds to trigger intervention, this is problematic since risk is a continuum and there is no exact point above which, for example, a drug is automatically indicated nor below which lifestyle advice may not usefully be offered.

The risk categories presented later in this section are to assist the physician in dealing with individual people. They acknowledge that although individuals at the highest levels of risk gain most from risk factor interventions, most deaths in a community come from those at lower levels of risk, simply because they are more numerous compared with high-risk individuals. Thus a strategy for individuals at high risk must be complemented by public health measures to encourage a healthy lifestyle and to reduce population levels of CV risk factors.

It is essential for clinicians to be able to assess CV risk rapidly and with sufficient accuracy. This realization led to the development of the risk chart used in the 1994 and 1998 Guidelines. This chart, developed from a concept pioneered by Anderson, used age, sex, smoking status, blood cholesterol and systolic BP (SBP) to estimate the 10-year risk of a first fatal or non-fatal CAD event. There were several problems with this chart, which are outlined in the Fourth Joint European Guidelines on prevention. This led to the presentationscore system, estimating an individual's 10-year risk of fatal CAD. The SCORE charts have been developed to estimate risk in both high- and low-risk European populations; its applicability to non-Caucasian populations has not been examined.

#### 2.2 When to assess total cardiovascular risk?

**Table 1** Impact of combinations of risk factors on risk

<table>
<thead>
<tr>
<th>Gender</th>
<th>Age (years)</th>
<th>Cholesterol (mmol/L)</th>
<th>SBP (mmHg)</th>
<th>Smoker</th>
<th>Risk (10 year risk of fatal CVD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>F</td>
<td>60</td>
<td>7</td>
<td>120</td>
<td>No</td>
<td>2%</td>
</tr>
<tr>
<td>F</td>
<td>60</td>
<td>7</td>
<td>140</td>
<td>Yes</td>
<td>5%</td>
</tr>
<tr>
<td>M</td>
<td>60</td>
<td>6</td>
<td>160</td>
<td>No</td>
<td>9%</td>
</tr>
<tr>
<td>M</td>
<td>60</td>
<td>5</td>
<td>180</td>
<td>Yes</td>
<td>21%</td>
</tr>
</tbody>
</table>

CVD = cardiovascular disease; F = female; M = male; SBP = systolic blood pressure.

**Recommendations for cardiovascular risk assessment**

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Classa</th>
<th>Levelb</th>
</tr>
</thead>
<tbody>
<tr>
<td>Systematic CV risk assessment is recommended in individuals at increased CV risk, i.e. with family history of premature CVD, familial hyperlipidaemia, major CV risk factors (such as smoking, high BP, DM or raised lipid levels) or comorbidities increasing CV risk.</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>It is recommended to repeat CV risk assessment every 5 years, and more often for individuals with risks close to thresholds mandating treatment.</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>Systematic CV risk assessment may be considered in men &gt;40 years of age and in women &gt;50 years of age or post-menopausal with no known CV risk factors.</td>
<td>IIb</td>
<td>C</td>
</tr>
<tr>
<td>Systematic CV risk assessment in men &lt;40 of age and women &lt;50 years of age with no known CV risk factors is not recommended.</td>
<td>III</td>
<td>C</td>
</tr>
</tbody>
</table>

BP = blood pressure; CV = cardiovascular; CVD = cardiovascular disease; DM = diabetes mellitus.

*aClass of recommendation.

bLevel of evidence.

Screening is the identification of unrecognized disease or, in this case, of an unknown increased risk of CVD in individuals without...
symptoms. CV risk assessment or screening can be done opportunistically or systematically. Opportunistic screening means without a predefined strategy, but is done when the opportunity arises [e.g. when the individual is consulting his or her general practitioner (GP) for some other reason]. Systematic screening can be done in the general population as part of a screening programme or in targeted subpopulations, such as subjects with a family history of premature CVD or familial hyperlipidaemia.

While the ideal scenario would be for all adults to have their risk assessed, this is not practical in many societies. The decision about who to screen must be made by individual countries and will be resource dependent.

In a meta-analysis, GP-based health checks on cholesterol, BP, body mass index (BMI) and smoking were effective in improving surrogate outcomes, especially in high-risk patients. A large study of CV risk assessment in the general population found that although there were overall improvements in risk factors, there was no impact on CV outcomes at the population level. A Cochrane review of RCTs using counselling or education to modify CV risk factors in adults from the general population, occupational groups or those with specific risk factors (i.e. DM, hypertension) concluded that risk factor improvements were modest and interventions did not reduce total or CV mortality in general populations, but reduced mortality in high-risk hypertensive and DM populations. Although the benefits of treating asymptomatic conditions such as hypertension, DM and dyslipidaemia on morbidity and mortality outcomes have been documented, a Cochrane review of the existing trials concluded that general health checks (including screening for these conditions) do not reduce all-cause or CV morbidity or mortality. However, most studies were performed three to four decades ago, and thus risk factor interventions were not contemporary. Perhaps application of medical treatment in addition to the lifestyle interventions that were the core component of most trials would improve efficacy.

Most guidelines recommend a mixture of opportunistic and systematic screening. Screening in people at relatively low risk of CVD is not particularly effective in reducing the risk of CV events. The costs of such screening interventions are high and these resources may be better used in people at higher CV risk or with established CVD. In many countries, GPs have a unique role in identifying individuals at risk of but without established CVD and assessing their eligibility for intervention (see section 4a.1.1). A modelling study based on the European Prospective Investigation of Cancer–Norfolk (EPIC-Norfolk) cohort data concluded that, compared with the National Health Service (NHS) national strategy to screen all adults 40–74 years of age for CV risk, inviting the 60% of the population at the highest risk according to an integrated risk score was equally effective in preventing new cases of CVD and had potential cost savings.

A general concern in screening, including CV risk assessment, is its potential to do harm. False positive results can cause unnecessary concern and medical treatment. Conversely, false negative results may lead to inappropriate reassurance and a lack of lifestyle changes. However, current data suggest that participating in CV screening in general does not cause worry in those who are screened. More research is needed on how certain subgroups, such as older people, the socially deprived and ethnic minorities, react to screening.

Despite limited evidence, these guidelines recommend a systematic approach to CV risk assessment targeting populations likely to be at higher CV risk, such as those with a family history of premature CVD. Thus systematic CV risk assessment in men <40 years of age and women <50 years of age with no known CV risk factors is not recommended. Additionally, screening of specific groups with jobs that place other people at risk, e.g. bus drivers and pilots, may be reasonable, as is screening for CV risk factors in women before prescribing combined oral contraception, although there are no data to support the beneficial effects. Beyond this, systematic CV risk assessment in adults <40 years of age with no known CV risk factors is not recommended as a main strategy due to the low cost-effectiveness. Systematic CV assessment may be considered in adult men >40 years of age and in women >50 years of age or post-menopausal with no known CV risk factors. Risk assessment is not a one-time event; it should be repeated, for example, every 5 years.

2.3 How to estimate total cardiovascular risk?

Key messages

- In apparently healthy persons, CV risk in general is the result of multiple, interacting risk factors. This is the basis for the total CV risk approach to prevention.
- SCORE, which estimates the 10 year risk of fatal CVD, is recommended for risk assessment and can assist in making logical management decisions and may help to avoid both under- and overtreatment. Validated local risk estimation systems are useful alternatives to SCORE.
- Individuals automatically at high to very high CV risk (Table 5) do not need the use of a risk score and require immediate attention to risk factors.
- In younger persons, a low absolute risk may conceal a very high relative risk and use of the relative risk chart or calculation of their “risk age” may help in advising them of the need for intensive preventive efforts.
- While women are at lower CV risk than men, their risk is deferred by ~10 years rather than avoided.
- The total risk approach allows flexibility; if perfection cannot be achieved with one risk factor, trying harder with others can still reduce risk.

Recommendation for how to estimate cardiovascular risk

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>Class</th>
<th>Level</th>
<th>Ref</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total CV risk estimation, using a risk estimation system such as SCORE, is recommended for adults &gt;40 years of age, unless they are automatically categorised as being at high-risk or very high-risk based on documented CVD, DM (&gt;40 years of age), kidney disease or highly elevated single risk factor (Table 5).</td>
<td>I</td>
<td>C</td>
<td>11, 25</td>
</tr>
</tbody>
</table>

CV = cardiovascular; DM = diabetes mellitus; SCORE = Systematic Coronary Risk Estimation.

Class of recommendation.

Level of evidence.

Reference(s) supporting recommendations.
<table>
<thead>
<tr>
<th></th>
<th>Framingham&lt;sup&gt;44&lt;/sup&gt;</th>
<th>SCORE&lt;sup&gt;30&lt;/sup&gt;</th>
<th>ASSIGN – SCORE&lt;sup&gt;44&lt;/sup&gt;</th>
<th>QRISK1&lt;sup&gt;146&lt;/sup&gt; &amp; QRISK2&lt;sup&gt;47&lt;/sup&gt;</th>
<th>PROCAM&lt;sup&gt;48&lt;/sup&gt;</th>
<th>Pooled Cohort Studies Equations&lt;sup&gt;50&lt;/sup&gt;</th>
<th>CUORE&lt;sup&gt;49&lt;/sup&gt;</th>
<th>Globorisk&lt;sup&gt;52&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Data</strong></td>
<td>Prospective studies: Framingham Heart Study and Framingham offspring study. Latest version includes both</td>
<td>I2 pooled prospective studies</td>
<td>SHHEC Prospective study</td>
<td>QRESEARCH database</td>
<td>Prospective study</td>
<td>4 Pooled prospective studies</td>
<td>ARIC, CHS, CARDIA, Framingham (original and offspring studies)</td>
<td>CUORE Derivation cohort: 8 pooled prospective studies - Atherosclerosis Risk in Communities, Cardiovascular Health Study, Framingham Heart Study original cohort and offspring cohort, Honolulu Program, Multiple Risk Factor Intervention Trial, Puerto Rico Heart Health Program, and Women's Health Initiative Clinical Trial</td>
</tr>
<tr>
<td><strong>Sample size</strong></td>
<td>3969 men and 4522 women</td>
<td>117 098 men and 88 080 women</td>
<td>6540 men and 6757 women</td>
<td>1.28 million (QRISK1) 2.29 million (QRISK2)</td>
<td>18 460 men and 8515 women</td>
<td>11 240 white women, 9098 white men, 2641 African-American women and 1647 African-American men</td>
<td>7520 men and 13 127 women</td>
<td>33 323 men and 16 806 women</td>
</tr>
<tr>
<td><strong>Calculates</strong></td>
<td>10-year risk of CAD events originally. Latest version: 10-year risk of CVD events NCEP ATP III version: 10-year risk of hard coronary events</td>
<td>10-year risk of CVD mortality</td>
<td>10-year risk of CVD events</td>
<td>10-year risk of CVD events. Lifetime risk</td>
<td>Two separate scores calculate 10-year risks of major coronary events and cerebral ischaemic events</td>
<td>10-year risk for first atherosclerotic CVD event. Lifetime risk</td>
<td>10-year probability of developing a first major CV event (myocardial infarction or stroke)</td>
<td>10 year risk of fatal cardiovascular disease</td>
</tr>
<tr>
<td><strong>Age range (years)</strong></td>
<td>30–75</td>
<td>40–65</td>
<td>30–74</td>
<td>35–74</td>
<td>20–75</td>
<td>20–79</td>
<td>35–69</td>
<td>40–84</td>
</tr>
<tr>
<td><strong>Variables</strong></td>
<td>Sex, age, total cholesterol, HDL-C, SBP, smoking status, DM, hypertensive treatment</td>
<td>Sex, age, total cholesterol or total cholesterol/HDL-C ratio, SBP, smoking status. Versions for use in high and low-risk countries</td>
<td>Sex, age, total cholesterol, HDL-C, SBP, smoking – no. cigs, DM, area based index of deprivation, family history</td>
<td>Age, sex, LDL-C, HDL-C, DM, smoking, SBP</td>
<td>Age, sex, race (white or other/African American), total cholesterol, HDL-C, SBP, antihypertensive therapy and smoking habit</td>
<td>Age, sex, SBP, total cholesterol, HDL-C, DM, smoking, BMI, BP treatment, ethnicity and chronic diseases</td>
<td>Age, sex, smoking, total cholesterol, DM, systolic BP</td>
<td>continued</td>
</tr>
</tbody>
</table>
Table 2  (continued)

<table>
<thead>
<tr>
<th>Comments/developments</th>
<th>Framingham44</th>
<th>SCORE16</th>
<th>ASSIGN – SCORE12</th>
<th>QRISK146 &amp; QRISK247</th>
<th>PROCAM48</th>
<th>Pooled Cohort Studies Equations50</th>
<th>CUORE49</th>
<th>Globorisk52</th>
</tr>
</thead>
<tbody>
<tr>
<td>Latest version includes version based on non-laboratory values only, substituting BMI from lipid measurements</td>
<td>National, updated recalibrations</td>
<td>QRISK2 includes interaction terms to adjust for the interactions between age and some of the variables</td>
<td>Recent change in the methods (Weibull) allows extension of risk estimation to women and broader age range</td>
<td>Race specific beta coefficients for risk factors have been incorporated. Calculator shown to overestimate risk in external validations – this may indicate the need for recalibration in certain populations</td>
<td>Recalibrations have been undertaken for 11 countries</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Recommended by guidelines</td>
<td>NCEP guidelines44, Canadian CV guidelines55, other national guidelines recommend adapted versions including New Zealand56</td>
<td>European Guidelines on CVD Prevention57</td>
<td>NICE guidelines on lipid modification58, QRISK Lifetime recommended by JBS3 guidelines59</td>
<td>International Task Force for Prevention of Coronary Disease Guidelines</td>
<td>2013 AHA ACC Guideline on the assessment of CVD risk60</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

ACC = American College of Cardiology; AHA = American Heart Association; ARIC = Atherosclerosis Risk in Communities; ATP = Adult Treatment Panel; BMI = body mass index; BP = blood pressure; CAD = coronary artery disease; CARDIA = Coronary Artery Risk Development in Young Adults; CHS = Cardiovascular Health Study; CVD = cardiovascular disease; DM = diabetes mellitus; HDL-C = high-density lipoprotein cholesterol; JBS = Joint British Societies; LDL-C = low-density lipoprotein cholesterol; NCEP = National Cholesterol Education Program; NICE = National Institute for Health and Care Excellence; no. cigs = number of cigarettes; PROCAM = Prospective Cardiovascular Munster Study; SBP = systolic blood pressure; SIGN = Scottish Intercollegiate Guidelines Network; SHHEC = Scottish Heart Health Extended Cohort.
2.3.1 Ten-year cardiovascular risk

Many CV risk assessment systems are available for use in apparently healthy individuals (Table 2), including Framingham, \(^{44}\) SCORE, \(^{30}\) AS-SIGN (CV risk estimation model from the Scottish Intercollegiate Guidelines Network), \(^{45}\) Q-Risk, \(^{46,47}\) PROCAM (Prospective Cardiovascular Munster Study), \(^{48}\) CUORE, \(^{49}\) the Pooled Cohort equations, \(^{50}\) Arriba \(^{51}\) and Globorisk. \(^{52}\) In practice, most risk estimation systems perform rather similarly when applied to populations recognizably comparable to those from which the risk estimation system was derived. Since 2003, the European Guidelines on CVD prevention in clinical practice recommend use of the SCORE system, because it is based on large, representative European cohort datasets. The SCORE risk function has been externally validated. \(^{53}\)

Table 3 lists the advantages of the SCORE risk charts.

The SCORE system estimates the 10 year risk of a first fatal atherosclerotic event. All International Classification of Diseases (ICD) codes that could reasonably be assumed to be atherosclerotic are included, including CAD, stroke and aneurysm of the abdominal aorta. Traditionally most systems estimated CAD risk only; however, more recently a number of risk estimation systems have changed to estimate the risk of all CVDs. \(^{44,47,50,58}\)

The choice of CV mortality rather than total (fatal plus non-fatal) events was deliberate, although not universally popular. Non-fatal event rates are critically dependent upon definitions and the methods used in their ascertainment. Critically, the use of mortality allows recalibration to allow for time trends in CV mortality. Any risk estimation system will overpredict in countries in which mortality has fallen and underpredict in those in which it has risen. Recalibration to allow for secular changes can be undertaken if good quality, up-to-date mortality and risk factor prevalence data are available. Data quality does not permit this for non-fatal events. For these reasons, the CV mortality charts were produced and have been recalibrated for a number of European countries.

Naturally, the risk of total fatal and non-fatal events is higher, and clinicians frequently ask for this to be quantified. The SCORE data indicate that the total CV event risk is about three times higher than the risk of fatal CVD for men, so that a SCORE risk of fatal CVD of 5% translates into a fatal plus non-fatal CV risk of \(\approx 15\%\); the multiplier is about four in women and somewhat lower than three in older persons, in whom a first event is more likely to be fatal. \(^{61}\)

As noted in the introduction, thresholds to trigger certain interventions are problematic since risk is a continuum and there is no threshold at which, for example, a drug is automatically indicated. Obviously, decisions on whether treatment is initiated should also be based on patient preferences.

A particular problem relates to young people with high levels of risk factors, where a low absolute risk may conceal a very high relative risk requiring intensive lifestyle advice. Several approaches to communicating about risk to younger people are presented below (refer also to section 2.5.1). These include use of the relative risk chart or ‘risk age’ or ‘lifetime risk’. The aim is to communicate that lifestyle changes can reduce the relative risk substantially as well as reduce the increase in risk that occurs with ageing.

Another problem relates to older people. In some age categories, the vast majority, especially of men, will have estimated CV death risks exceeding the 5–10% level, based on age (and gender) only, even when other CV risk factor levels are low. This could lead to excessive use of drugs in the elderly. This issue is dealt with later (see section 2.3.5). It should be noted that RCT evidence to guide drug treatments in older persons is limited (refer to section 2.5.2).

The role of high-density lipoprotein cholesterol (HDL-C) in risk estimation has been systematically re-examined using the SCORE database. \(^{62–64}\) Overall HDL-C has a modest but useful effect in redefining risk estimation, \(^{63,64}\) but this may not be seen in some low-risk populations. \(^{65}\) Assessing HDL-C is particularly important at levels of risk just below the threshold for intensive risk modification of 5%, where many of these subjects will qualify for intensive advice if their HDL-C is low. \(^{65}\) SCORE charts incorporating HDL-C are illustrated in supplementary Figures B–I (see web addenda). In these charts, HDL-C is used categorically. The electronic version of SCORE, HeartScore (http://www.HeartScore.org), has been modified to take HDL-C into account on a continuous basis and is therefore more accurate.

The role of a plasma triglyceride as a predictor of CVD has been debated for many years. Fasting triglycerides relate to risk in unvariable analyses, but the effect is attenuated by adjustment for other factors, especially HDL-C. \(^{66}\)

Dealing with the impact of additional risk factors such as body weight, family history and newer risk markers is difficult within the constraint of a paper chart. It should be stressed, however, that although many other risk factors have been identified, their contribution is generally very modest to both absolute CV risk estimations and in terms of reclassification of an individual to another risk category \(^{67}\) (Table 4).

The SCORE risk charts are shown in Figures 1–4, including a chart of relative risks (Figure 3). Instructions on their use follow.

Please note that Figure 3 shows relative not absolute risk. Thus a person in the top right-hand box, with multiple CV risk factors, has a risk that is 12 times greater than a person in the bottom left with normal risk.
factor levels. This may be helpful when advising a young person with a low absolute but high relative risk of the need for lifestyle change.

### 2.3.2 Cardiovascular risk age

The risk age of a person with several CV risk factors is the age of a person of the same gender with the same level of risk but with ideal levels of risk factors. Thus a 40-year-old with high levels of some risk factors may have the risk age of a 60-year-old (Figure 4), because the risk equals that of a 60-year-old with ideal risk factor levels (i.e. non-smoking, total cholesterol of 4 mmol/L and BP of 120 mmHg).68 Risk age is an intuitive and easily understood way of illustrating the likely reduction in life expectancy that a young person with a low absolute but high relative risk of CVD will be exposed to if preventive measures are not adopted.68 Table A showing different risk factor combinations is included in the web addenda to provide a more accurate estimation of risk ages. Risk age is also automatically calculated as part of the latest revision of HeartScore.

Risk age has been shown to be independent of the CV endpoint used,68 which bypasses the dilemma of whether to use a risk estimation system based on CV mortality or on total CV events. Risk age can be used in any population regardless of baseline risk and secular changes in mortality, and therefore avoids the need for recalibration.69 At present, risk age is recommended to help communicate about risk, especially to younger people with a low absolute risk but a high relative risk.

### 2.3.3 Lifetime vs. 10-year cardiovascular risk estimation

Conventional CV risk prediction schemes estimate the 10 year risk of CV events. Lifetime CV risk prediction models identify high-risk individuals both in the short and long term. Such models account for predicted risk in the context of competing risks from other diseases over the remaining expected lifespan of an individual.

Notably, 10 year risk identifies individuals who are most likely to benefit from drug therapy in the near term. Drug treatment starts to work quite rapidly, and drug treatment can be largely informed by short-term risk, such as 10 year risk. One problem with short-term risk is that it is mostly governed by age and consequently few younger individuals, in particular women, reach treatment thresholds. It has therefore been argued that lifetime risk estimation may enhance risk communication, particularly among younger individuals and women.

Evidence for the role of lifetime risk in treatment decisions is lacking. Sufficient data for robust lifetime risk estimations, as well as meaningful risk categorization thresholds, are also lacking. Providing lifetime CV risk estimates for some groups at high risk of mortality due to competing non-CVD causes can be difficult to interpret. Importantly, evidence of the benefits of lifelong preventive therapy (e.g. BP- or lipid-lowering drugs) in younger individuals with low short-term but higher lifetime risks is lacking. For these reasons, we do not recommend that risk stratification for treatment decisions be based on lifetime risk. However, like risk age and relative risk, it may be a useful tool in communicating about risk to individuals with high risk factor levels but who are at a low 10 year absolute risk of CV events, such as some younger people. Whatever approach is used, if absolute risk is low, a high relative risk or risk age signals the need for active lifestyle advice and awareness that drug treatment may need consideration as the person ages. Both risk age and lifetime risk are closer to relative than absolute risk, and none provides an evidence base for drug treatment decisions.

### 2.3.4 Low-risk, high-risk and very-high-risk countries

The countries considered here are those with national cardiology societies that belong to the ESC, both European and non-European.

#### 2.3.4.1 What are low-risk countries?

The fact that CVD mortality has declined in many European countries means that more now fall into the low-risk category. While any cut-off point is arbitrary and open to debate, in these guidelines the cut-off points for calling a country ‘low risk’ are based on age-adjusted 2012 CVD mortality rates in those 45–74 years of age (<225/100 000 in men and <175/100 000 in women).70 Thus the following countries are defined as low risk: Andorra, Austria, Belgium, Cyprus, Denmark, Finland, France, Germany, Greece, Iceland, Ireland, Israel, Italy, Luxembourg, Malta, Monaco, the Netherlands, Norway, Portugal, San Marino, Slovenia, Spain, Sweden, Switzerland and the United Kingdom.

#### 2.3.4.2 What are high-risk and very-high-risk countries?

High-risk countries are Bosnia and Herzegovina, Croatia, Czech Republic, Estonia, Hungary, Lithuania, Montenegro, Morocco, Poland, Romania, Serbia, Slovakia, Tunisia and Turkey.

Very-high-risk countries present levels of risk that are more double that of low-risk countries (i.e. CVD mortality >450/100 000 for men and >350/100 000 for women). Additionally, the male:female ratio is smaller than in low-risk countries, suggesting a major problem for women. The very high-risk countries are Albania, Algeria, Armenia, Azerbaijan, Belarus, Bulgaria, Egypt, Georgia, Kazakhstan, Kyrgyzstan, Latvia, former Yugoslav Republic of Macedonia, Moldova, Russian Federation, Syrian Arab Republic, Tajikistan, Turkmenistan, Ukraine and Uzbekistan.

### 2.3.5 How to use the risk estimation charts

- **The SCORE charts** are used in apparently healthy people, not for those with established CVD or at very high risk or high risk for other reasons (e.g. DM (see section 3a.8) or chronic kidney disease (CKD; see section 2.4.5.1)), who need intensive risk advice anyway.
- **Use of the low-risk chart** is recommended for the countries listed above. Use of the high-risk chart is recommended for all other European and Mediterranean countries, taking into account that the high-risk charts may underestimate the risk in very-high-risk countries (see above). Note that several countries have undertaken national recalibrations to allow for time trends.

### Table 4 Examples of risk modifiers that are likely to have reclassification potential (see following sections for details)

<table>
<thead>
<tr>
<th>Risk Modifier</th>
<th>Example</th>
</tr>
</thead>
<tbody>
<tr>
<td>Socio-economic status, social isolation, or lack of social support.</td>
<td></td>
</tr>
<tr>
<td>Family history of premature CVD.</td>
<td></td>
</tr>
<tr>
<td>BMI and central obesity.</td>
<td></td>
</tr>
<tr>
<td>CT coronary calcium score.</td>
<td></td>
</tr>
<tr>
<td>Atherosclerotic plaques determined by carotid artery scanning.</td>
<td></td>
</tr>
<tr>
<td>ABI.</td>
<td></td>
</tr>
</tbody>
</table>

ABI = ankle–brachial pressure index; BMI = body mass index; CVD = cardiovascular disease; CT = computed tomography.
in mortality and risk factor distributions. Such charts are likely to better represent risk levels.

- To estimate a person’s 10 year risk of CV death, find the table for their gender, smoking status and (nearest) age. Within the table, find the cell nearest to the person’s BP and total cholesterol. Risk estimates will need to be adjusted upwards as the person approaches the next age category.

While no threshold is universally applicable, the intensity of advice should increase with increasing risk. The effect of interventions on the absolute probability of developing a CV event

Figure 1  SCORE chart: 10-year risk of fatal cardiovascular disease in populations of countries at high cardiovascular risk based on the following risk factors: age, sex, smoking, systolic blood pressure, total cholesterol. CVD = cardiovascular disease; SCORE = Systematic Coronary Risk Estimation.
increases with an increasing baseline risk; that is, the number of individuals needed to treat (NNT) to prevent one event decreases with increasing risk.

---

**Low-to-moderate-risk persons (calculated SCORE <5%):** should be offered lifestyle advice to maintain their low-to-moderate-risk status.
Figure 3  Relative risk chart, derived from SCORE Conversion of cholesterol mmol/L → mg/dL: 8 = 310; 7 = 270; 6 = 230; 5 = 190; 4 = 155.

Figure 4  SCORE chart (for use in high-risk European countries) illustrating how the approximate risk age can be read off the chart. SCORE = Systematic Coronary Risk Estimation.
- **High-risk persons (calculated SCORE ≥5% and <10%)**: qualify for intensive lifestyle advice and may be candidates for drug treatment.
- **Very-high-risk persons (calculated SCORE ≥10%)**: drug treatment is more frequently required. In persons >60 years of age, these thresholds should be interpreted more leniently, because their age-specific risk is normally around these levels, even when other CV risk factor levels are ‘normal’. In particular, uncritical initiation of drug treatments of all elderly with risks greater than the 10% threshold should be discouraged.

Use of the risk charts should be qualified by knowledge of the following aspects:

- The charts assist in risk estimation but must be interpreted in light of the clinician’s knowledge and experience and in view of the factors that may modify the calculated risk (see below).
- Relative risks may be high in young persons, even if 10 year absolute risks are low, because events usually occur later in life. The relative risk chart or estimating risk age may be helpful in identifying and counselling such persons.

### Table 5 Risk categories

<table>
<thead>
<tr>
<th>Very high-risk</th>
<th>High-risk</th>
<th>Moderate-risk</th>
<th>Low-risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subjects with any of the following:</td>
<td>Subjects with:</td>
<td>SCORE is ≥1% and &lt;5% at 10 years. Many middle-aged subjects belong to this category.</td>
<td>SCORE &lt;1%</td>
</tr>
<tr>
<td>• Documented CVD, clinical or unequivocal on imaging. Documented clinical CVD includes previous AMI, ACS, coronary revascularization and other arterial revascularization procedures, stroke and TIA, aortic aneurysm and PAD. Unequivocally documented CVD on imaging includes significant plaque on coronary angiography or carotid ultrasound. It does not include some increase in continuous imaging parameters such as intima–media thickness of the carotid artery.</td>
<td>• Markedly elevated single risk factors, in particular cholesterol &gt;6 mmol/L (&gt;240 mg/dL) (e.g. in familial hypercholesterolaemia) or BP ≥180/110 mmHg.</td>
<td>• Moderate CKD (GFR 30–59 mL/min/1.73 m²).</td>
<td>• SCORE &lt;5% and &lt;10%.</td>
</tr>
<tr>
<td>• DM with target organ damage such as proteinuria or with a major risk factor such as smoking or marked hypercholesterolaemia or marked hypertension.</td>
<td>• Most other people with DM (with the exception of young people with type 1 DM and without major risk factors that may be at low or moderate risk).</td>
<td>• A calculated SCORE ≥2%.</td>
<td></td>
</tr>
<tr>
<td>• Severe CKD (GFR &lt;30 mL/min/1.73 m²).</td>
<td>• Moderate CKD (GFR 30–59 mL/min/1.73 m²).</td>
<td>• A calculated SCORE ≥2% and &lt;10%.</td>
<td></td>
</tr>
<tr>
<td>• A calculated SCORE ≥10%.</td>
<td>• A calculated SCORE ≥2%.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

ACS = acute coronary syndrome; AMI = acute myocardial infarction; BP = blood pressure; CKD = chronic kidney disease; DM = diabetes mellitus; GFR = glomerular filtration rate; PAD = peripheral artery disease; SCORE = systematic coronary risk estimation; TIA = transient ischaemic attack.

- The lower risk in women is explained by the fact that risk is deferred by 10 years—the risk of a 60-year-old woman is similar to that of a 50-year-old man. Ultimately, more women than men die of CVD.
- The charts may be used to give some indication of the effects of reducing risk factors, given that there will be a time lag before risk reduces and that the results of RCTs in general give better estimates of the benefits of interventions. Those who stop smoking generally halve their risk.

#### 2.3.6 Modifiers of calculated total cardiovascular risk

Apart from the conventional major CV risk factors included in the risk charts, there are other risk factors that could be relevant for assessing total CVD risk. The Task Force recommends additional risk factor assessment if such a risk factor improves risk classification [e.g. by calculation of a net reclassification index (NRI)] and if the assessment is feasible in daily practice. In general, reclassification is of most value when the individual’s risk lies close to a decisional threshold, such as a SCORE risk of 5%. In very-high-risk or very-low-risk situations, the impact of additional risk factors is unlikely to alter management decisions. While the presence of risk modifiers may move an individual’s estimated risk upward, absence of these modifiers should lead to lowering an individual’s estimated risk.

Table 4 lists examples of factors that fulfill the aforementioned criteria. Several other factors that are frequently discussed in the literature, but may not have the ability to reclassify subjects, are discussed in subsequent paragraphs. Also discussed further in this section are the roles of ethnicity and of specific conditions or diseases that may be associated with a higher than calculated risk, such as CKD, autoimmune diseases, etc. The way modifiers are related to CV risk may be very different. Social deprivation and being overweight, for example, are important as ‘causes of the causes’ of CVD, in that they may be associated with higher levels of conventional risk factors. Family history may reflect a shared environment, genetic factors or both. Markers such as computed tomography (CT) calcium scoring are indicators of disease rather than risk factors for future disease.

#### 2.3.7 Risk categories: priorities

Individuals at highest risk gain most from preventive efforts, and this guides the priorities, which are detailed in Table 5.

#### 2.3.8 Risk factor targets

Risk factor goals and target levels for important CV risk factors are presented in Table 6.

#### 2.3.9 Conclusions

Estimation of total CV risk remains a crucial part of the present guidelines. The priorities (risk categories) defined in this section are for clinical use and reflect the fact that those at highest risk of a CVD event gain most from preventive measures. This approach should complement public actions to reduce community risk factor levels and promote a healthy lifestyle. The principles of risk estimation and the definition of priorities reflect an attempt to make complex issues simple and accessible. Their very simplicity makes them vulnerable to criticism. Above all, they must be interpreted in light of
A systematic comparison of current international guidelines is needed to define areas of agreement and the reasons for discrepancies.

2.4 Other risk markers

2.4.1 Family history/(epi)genetics

Key messages

- Family history of premature CVD in first-degree relatives, before 55 years of age in men and 65 years of age in women, increases the risk of CVD.
- Several genetic markers are associated with an increased risk of CVD, but their use in clinical practice is not recommended.

Recommendations for assessment of family history/(epi)genetics

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Classa</th>
<th>Levelb</th>
<th>Refc</th>
</tr>
</thead>
<tbody>
<tr>
<td>Assessment of family history of premature CVD (defined as a fatal or non-fatal CVD event or/and established diagnosis of CVD in first degree male relatives before 55 years or female relatives before 65 years) is recommended as part of cardiovascular risk assessment.</td>
<td>I</td>
<td>C</td>
<td>71</td>
</tr>
<tr>
<td>The generalized use of DNA-based tests for CVD risk assessment is not recommended.</td>
<td>III</td>
<td>B</td>
<td>72, 73</td>
</tr>
</tbody>
</table>

CVD = cardiovascular disease.

aClass of recommendation.

bLevel of evidence.

cReference(s) supporting recommendation.

2.4.1.1 Family history

Familial history of premature CVD is a crude but simple indicator of the risk of developing CVD, reflecting both the genetic trait and the environment shared among household members. A positive family history of premature CV death is associated with an increased risk of early and lifetime CVD. In the few studies that simultaneously assessed and reported the effects of family history and genetic scores, family history remained significantly associated with the incidence of CVD after adjusting for the genetic scores. Limited data exist regarding the ability of family history to improve the prediction of CVD beyond conventional CV risk factors. One possible explanation is the varying definitions of family history applied and that conventional CV risk factors can partly explain the impact of family history.

A family history of premature CVD is simple, inexpensive information that should be part of the CV risk assessment in all subjects. Family history can be a risk modifier to optimal management after the calculated risk using SCORE lies near a decisional threshold: a positive family history would favour more intensive interventions, while a negative family history would translate into less intensive treatment.

2.4.1.2 Genetic markers

Genetic screening and counselling is effective in some conditions, such as familial hypercholesterolaemia (FH) (see section 3a.7.9). This paragraph will focus on genetic screening for high CV risk in the general population.
Several recent genome-wide association studies have identified candidate genes associated with CVD. Since the effect of each genetic polymorphism is small, most studies have used genetic scores to summarize the genetic component. There is a lack of consensus regarding which genes and their corresponding single nucleotide polymorphisms (SNPs) should be included in a genetic risk score and which method should be used to calculate the genetic score.

The association of genetic scores with incident CVD has been prospectively studied, adjusting for the main CV risk factors, and most studies have found a significant association, with the relative risks varying between 1.02 and 1.49 per increase in one score unit. The ability of genetic scores to predict CV events beyond traditional CV risk factors (i.e. defined by the NRI) was found in about half of the studies. The NRI is a statistical measure quantifying the usefulness of adding new variables to a risk prediction equation. The biggest improvements in the NRI were observed in participants at intermediate risk, while little or no improvement was observed in participants at high risk. One study estimated that one additional CAD event for every 318 people screened at intermediate risk could be prevented by measuring the CAD-specific genetic score in addition to established risk factors. Importantly, since the frequency of polymorphisms might differ, the results may vary between populations. Recently, a genetic risk score based on 27 genetic variants enabled the identification of subjects at increased risk of CAD, who would benefit the most from statin therapy, even after adjustment for family history. Still, it is likely that some reported associations might be due to chance, and replication studies are needed to confirm positive findings.

Currently, many commercial tests are available, allowing an almost complete assessment of an individual’s genome, and strong pressure is being applied to use this information to predict genetic risk and to make genetic testing a routine measure. Given the lack of agreement regarding which genetic markers should be included, how genetic risk scores should be calculated and uncertainties about improvement in CV risk prediction, the use of genetic markers for the prediction of CVD is not recommended.

2.4.1.4 Psychosocial risk factors

Psychosocial risk factors act as barriers to treatment adherence and efforts to improve lifestyle, as well as to promoting health in patients and populations. Key messages

- Low socio-economic status, lack of social support, stress at work and in family life, hostility, depression, anxiety and other mental disorders contribute to the risk of developing CVD and a worse prognosis of CVD, with the absence of these items being associated with a lower risk of developing CVD and a better prognosis of CVD.
- Psychosocial risk factors act as barriers to treatment adherence and efforts to improve lifestyle, as well as to promoting health in patients and populations.

Recommendation for assessment of psychosocial risk factors

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>Class</th>
<th>Level</th>
<th>Ref</th>
</tr>
</thead>
<tbody>
<tr>
<td>Psychosocial risk factor assessment, using clinical interview or standardized questionnaires, should be considered to identify possible barriers to lifestyle change or adherence to medication in individuals at high CVD risk or with established CVD.</td>
<td>IIa</td>
<td>B</td>
<td>90–92</td>
</tr>
</tbody>
</table>

Gaps in evidence

- The impact of adding family history to the current SCORE risk equation should be assessed.
- Future studies should assess the power of different genetic risk scores to improve CVD risk prediction in several different populations, the number of events prevented and the cost-effectiveness of including genetic data in the risk assessment.

2.4.1.3 Epigenetics

Epigenetics studies the chemical changes in DNA that affect gene expression. Methylation of genes related to CV risk factors is associated with variation in CV risk factor levels, and lower DNA methylation levels are associated with an increased risk of CAD or stroke. No information exists, however, regarding the effect of epigenetic markers in improving CVD risk prediction beyond conventional risk factors. Thus, epigenetic screening of CVD is not recommended.

2.4.2 Psychosocial risk factors

Key messages

- Low socio-economic status, lack of social support, stress at work and in family life, hostility, depression, anxiety and other mental disorders contribute to the risk of developing CVD and a worse prognosis of CVD, with the absence of these items being associated with a lower risk of developing CVD and a better prognosis of CVD.
- Psychosocial risk factors act as barriers to treatment adherence and efforts to improve lifestyle, as well as to promoting health in patients and populations.

Recommendation for assessment of psychosocial risk factors

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>Class</th>
<th>Level</th>
<th>Ref</th>
</tr>
</thead>
<tbody>
<tr>
<td>Psychosocial risk factor assessment, using clinical interview or standardized questionnaires, should be considered to identify possible barriers to lifestyle change or adherence to medication in individuals at high CVD risk or with established CVD.</td>
<td>IIa</td>
<td>B</td>
<td>90–92</td>
</tr>
</tbody>
</table>

Gaps in evidence

- The impact of adding family history to the current SCORE risk equation should be assessed.
- Future studies should assess the power of different genetic risk scores to improve CVD risk prediction in several different populations, the number of events prevented and the cost-effectiveness of including genetic data in the risk assessment.
incident CAD (RR 1.3),

Meta-analyses reported a 1.5-fold risk of CVD incidence, a 1.2-fold risk of CAD and a 1.7-fold risk for stroke in patients with schizophrenia, and a 1.3-fold risk for incident CAD, even after adjustment for depression, in patients with post-traumatic stress disorder.

Hostility is a personality trait, characterized by extensive experience of mistrust, rage and anger and the tendency to engage in aggressive, maladaptive social relationships. A meta-analysis confirmed that anger and hostility are associated with a small but significant increased risk for CV events in both healthy and CVD populations (RR 1.2). The type D (‘distressed’) personality involves an enduring tendency to experience a broad spectrum of negative emotions (negative affectivity) and to inhibit self-expression in relation to others (social inhibition). The type D personality has been shown to predict poor prognosis in patients with CAD (RR 2.2).

In most situations, psychosocial risk factors cluster in individuals and groups. For example, both women and men of lower socio-economic status and/or with chronic stress are more likely to be depressed, hostile and socially isolated. The INTERHEART study has shown that a group of psychosocial risk factors (i.e. social deprivation, stress at work or in family life and depression) is associated with increased risk for myocardial infarction (MI) (RR 3.5 for women and 2.3 for men). The population attributable risk was 40% in women and 25% in men.

Mechanisms that link psychosocial factors to increased CV risk include unhealthy lifestyle (more frequent smoking, unhealthy food choices and less physical activity (PA)) and low adherence to behaviour change recommendations or CV medication. In addition, depression and/or chronic stress are associated with alterations in autonomic function, in the hypothalamic–pituitary axis and in other endocrine markers, which affect haemostatic and inflammatory processes, endothelial function and myocardial perfusion. Enhanced risk in patients with depression may also be due in part to adverse effects of tricyclic antidepressants.

Assessment of psychosocial factors in patients and persons with CV risk factors should be considered for use as risk modifiers in CV risk prediction, especially in individuals with SCORE risks near decisional thresholds. In addition, psychosocial factors can help identify possible barriers to lifestyle changes and adherence to medication. Standardized methods are available to assess psychosocial factors in many languages and countries. Alternatively, a preliminary assessment of psychosocial factors can be made within the physicians’ clinical interview, as shown in Table 7.

No more than a minimum education according to the requirements of the country and/or a ‘yes’ for one or more items indicate an increased CV risk and could be applied as a modifier of CV risk (see Chapter 2.3.6). The management of psychosocial risk factors should be addressed according to Chapter 3a.2.

Gap in evidence

- There is evidence of publication bias in the field of novel biomarkers of CV risk, leading to inflated estimates of strength of association and potential added value.

2.4.3 Circulating and urinary biomarkers

Key messages

- CV circulating and urinary biomarkers have either no or only limited value when added to CVD risk assessment with the SCORE system.

| Table 7 Core questions for the assessment of psychosocial risk factors in clinical practice |
|---------------------------------|---------------------------------|
| **Low socio-economic status**   | • What is your highest educational degree? |
|                                 | • Are you a manual worker? |
| **Work and family stress**     | • Do you lack control over how to meet the demands at work? |
|                                 | • Is your reward inappropriate for your effort? |
|                                 | • Do you have serious problems with your spouse? |
| **Social isolation**           | • Are you living alone? |
|                                 | • Do you lack a close confidant? |
|                                 | • Have you lost an important relative or friend over the last year? |
| **Depression**                 | • Do you feel down, depressed and hopeless? |
|                                 | • Have you lost interest and pleasure in life? |
| **Anxiety**                   | • Do you suddenly feel fear or panic? |
|                                 | • Are you frequently unable to stop or control worrying? |
| **Hostility**                  | • Do you frequently feel angry over little things? |
|                                 | • Do you often feel annoyed about other people’s habits? |
| **Type D personality**         | • In general, do you often feel anxious, irritable, or depressed? |
|                                 | • Do you avoid sharing your thoughts and feelings with other people? |
| **Post-traumatic stress disorder** | • Have you been exposed to a traumatic event? |
|                                 | • Do you suffer from nightmares or intrusive thoughts? |
| **Other mental disorders**     | • Do you suffer from any other mental disorder? |

**Recommendation for assessment of circulating and urinary biomarkers**

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>Classa</th>
<th>Levelb</th>
<th>Refc</th>
</tr>
</thead>
<tbody>
<tr>
<td>Routine assessment of circulating or urinary biomarkers is not recommended for refinement of CVD risk stratification.</td>
<td>III</td>
<td>B</td>
<td>114, 115</td>
</tr>
</tbody>
</table>

**aClass of recommendation.**

**bLevel of evidence.**

**cReference(s) supporting recommendations.**
glucose- and lipid-related markers (e.g. apolipoproteins) and organ-specific markers (e.g. renal, cardiac). However, for the purpose of overall CV risk estimation, these distinctions are generally not relevant. Also, from the perspective of risk stratification (i.e. prediction of future CV events), the question of whether a biomarker is causally related to CVD or may be a marker of preclinical disease is equally irrelevant.

Among the most extensively studied and discussed biomarkers is hsCRP. This biomarker has shown consistency across large prospective studies as a risk factor integrating multiple metabolic and low-grade inflammatory factors, with RRs approaching those of classical CV risk factors. However, its contribution to the existing methods of CV risk assessment is probably small.

Meta-analyses and systematic reviews suggest that the vast majority of other circulating and urinary biomarkers have no or limited proven ability to improve risk classification. However, the extent to which they have been tested for their ability to add value to risk stratification varies considerably, with strong evidence of reporting bias. Organ-specific biomarkers may be useful to guide therapy in specific circumstances (e.g. albuminuria in hypertension or DM may predict kidney dysfunction and warrant renoprotective interventions) (see section 3a).

If, despite these recommendations, biomarkers are used as risk modifiers, it is important to note that having an unfavourable biomarker profile may be associated with a somewhat higher risk, but also that a favourable profile is associated with a lower risk than calculated. The degree to which the calculated risk is affected by biomarkers is generally unknown, but almost universally smaller than the (adjusted) RRs reported for these biomarkers in the literature. Hence, in these patients, particularly with a moderate risk profile, only relatively small adjustments in calculated risk are justifiable, and patients who are clearly at high or low risk should not be reclassified based on biomarkers.

Gaps in evidence
- Not all potentially useful circulatory and urinary biomarkers have undergone state-of-the-art assessment of their added value in CV risk prediction on top of conventional risk factors.
- Biomarkers may be useful in specific subgroups, but this has been addressed in only a limited number of studies.
- The role of metabolomics as risk factors for CVD and to improve CV risk prediction beyond conventional risk factors should be further assessed.

2.4.4 Measurement of preclinical vascular damage

Key messages
- Routine screening with imaging modalities to predict future CV events is generally not recommended in clinical practice.
- Imaging methods may be considered as risk modifiers in CV risk assessment, i.e. in individuals with calculated CV risks based on the major conventional risk factors around the decisional thresholds.

Although most CVD can be explained by traditional risk factors, there is substantial variation in the amount of atherosclerosis. Thus interest has continued in the use of non-invasive imaging techniques to improve CV risk assessment. In individuals with calculated CV risks based on the major conventional risk factors near the decisional thresholds, some imaging techniques may be considered as risk modifiers to improve risk prediction and decision making.

2.4.4.1 Coronary artery calcium

Coronary artery calcium (CAC) is examined through electron beam or multislice CT. Calcifications indicate late-stage subclinical coronary atherosclerosis. Atherosclerotic coronary arteries do not necessarily always show calcifications. The extent of the calcification correlates with the extent of total coronary plaque burden. CAC is not an indicator of the (in)stability of an atherosclerotic plaque. In patients with ACS, the extent of CAC is more pronounced than in those without CAD. The quantification of CAC scoring is fairly consistent across studies. Most studies use the Agatston score. The value of the score can be further increased if the age and sex distribution within percentiles are taken into account. A CAC score ≥ 300 Agatston units or ≥ 75th percentile for age, sex and ethnicity is considered to indicate increased CV risk. CAC has shown a very high negative predictive value, since an Agatston score of 0 has a negative predictive value of nearly 100% for ruling out significant coronary narrowing. However, studies have questioned the negative predictive value of CAC because significant stenosis in the absence of CAC is possible. Many prospective studies have shown the association of CAC with CAD, and the Agatston score is an independent predictor of CAD. Importantly, including CAC may improve CV risk prediction in addition to conventional risk factors. Thus, CAC scoring may be considered in individuals with calculated SCORE risks around the 5% or 10% thresholds.
Although recent studies also showed the presence of CAC in low-risk populations, the added predictive value on CV events remains to be demonstrated. There are concerns regarding costs and radiation exposure. For CAC scoring, the radiation exposure with properly selected techniques is $\pm 1$ mSv.

2.4.4.2 Carotid ultrasound
Population-based studies have shown correlations between the severity of atherosclerosis in one arterial territory and the involvement of other arteries. Therefore, early detection of arterial disease in apparently healthy individuals has focused on peripheral arteries, and in particular on the carotid arteries. Risk assessment using carotid ultrasound focuses on the measurement of the intima–media thickness (IMT) and the presence and characteristics of plaques.

The IMT is not only a measure of early atherosclerosis, but also of smooth muscle hypertrophy/hyperplasia. There is a graded increase in CV risk with increasing IMT, and a value $>0.9$ mm is considered abnormal. The risk of stroke associated with IMT is non-linear, with hazards increasing more rapidly at lower IMTs than at higher IMTs. The IMT-associated risk of cardiac events is also non-linear. The extent of carotid IMT is an independent predictor of CVD, but seems to be more predictive in women than in men.

The lack of standardization regarding the definition and measurement of IMT, its high variability and low intra-individual reproducibility have raised concerns. A recent meta-analysis failed to demonstrate any added value of IMT compared to the Framingham Risk Score in predicting future CVD, even in the intermediate risk group. Thus, the systematic use of carotid ultrasound IMT to improve risk assessment is not recommended.

Plaque is usually defined as the presence of a focal wall thickening that is at least 50% greater than the surrounding vessel wall or as a focal region with an IMT measurement $\geq 1.5$ mm that protrudes into the lumen. Plaques may be characterized by their number, size, irregularity and echodensity (echolucent vs. calcified). Plaques are related to both coronary and cerebrovascular events, and echo-lucent (as opposed to calcified) plaques increase ischaemic cerebrovascular events. Many studies emphasize the greater value of measures that include plaque area and thickness, rather than IMT alone, in predicting CVD. Therefore, even though formal reclassification analyses have not been undertaken, carotid artery plaque assessment using ultrasonography may be considered to be a risk modifier in CV risk prediction in some cases.

2.4.4.3 Arterial stiffness
Arterial stiffness is commonly measured using either aortic pulse wave velocity (PWV) or arterial augmentation index. An increase in arterial stiffness is usually related to damage in the arterial wall, as has been shown in hypertensive patients. Although the relationship between aortic stiffness and CVD is continuous, a PWV threshold of 12 m/s has been suggested as a conservative estimate of significant alterations of aortic function in middle-aged hypertensive patients. A meta-analysis showed that arterial stiffness predicts future CVD and improves risk classification. However, the validity of this conclusion is offset by evidence of substantial publication bias. The Task Force concludes that arterial stiffness may serve as a useful biomarker to improve CV risk prediction for patients close to decisional thresholds, but its systematic use in the general population to improve risk assessment is not recommended.

2.4.4.4 Ankle–brachial index
The ankle–brachial index (ABI) is an easy-to-perform and reproducible test to detect asymptomatic atherosclerotic disease. An ABI $<0.9$ indicates $\geq 50\%$ stenosis between the aorta and the distal leg arteries. Because of its acceptable sensitivity (79%) and specificity (90%), an ABI $<0.90$ is considered to be a reliable marker of peripheral artery disease (PAD). An ABI value indicating significant PAD adds value to the medical history, because 50–89% of patients with an ABI $<0.9$ do not have typical claudication and it is present in 12–27% of asymptomatic individuals $>55$ years of age.

The ABI is inversely related to CV risk, but there is controversy regarding its potential to reclassify patients into different risk categories.

2.4.4.5. Echocardiography
Echocardiography is more sensitive than electrocardiography in diagnosing left ventricular hypertrophy (LVH) and it precisely quantifies left ventricular (LV) mass and geometric LVH patterns. Cardiac abnormalities detected by echocardiography have an additional predictive power. In view of the lack of convincing evidence that echocardiography improves CV risk reclassification, and because of the logistical challenges in performing it, this imaging tool is not recommended to improve CV risk prediction.

Gaps in evidence
- Currently, most imaging techniques have not been rigorously tested as screening tools in CV risk assessment; more evidence on calibration, reclassification and cost-effectiveness is still needed.
- The reduction of CVD risk in patients treated with lipid- or BP-lowering drugs because of reclassification with, for example, CAC or ABI remains to be demonstrated.

2.4.5 Clinical conditions affecting cardiovascular disease risk
2.4.5.1 Chronic kidney disease
Key message
- CKD is associated with an increased risk of CVD, independent of conventional CVD risk factors.

Hypertension, dyslipidaemia and DM are common among patients with CKD. In addition, inflammatory mediators and promoters of calcification cause vascular injury and may explain why CKD is associated with CVD even after adjustment for conventional risk factors. A decreasing estimated glomerular filtration rate (eGFR) is an important sign of a gradually increasing risk for CVD-related mortality, starting at $<75$ mL/min/1.73 m$^2$ and gradually increasing to an approximate three-fold risk in patients with values of 15 mL/min/1.73 m$^2$. End-stage renal disease is associated with a very high CV risk. Independent of eGFR, increased albumin excretion is also associated with CV mortality risk; the RR is $\sim 2.5$ in overt proteinuria. Studies assessing whether the accuracy of CV risk stratification improves with the addition of eGFR levels are emerging, but there is no consensus on which measure of renal function (i.e. which formula, and creatinine- or cystatine-C-based) best predicts...
CVD. Based on the evidence, the Task Force decided to classify patients with severe CKD (GFR < 30 mL/min/1.73 m²) as ‘very high risk’ and those with moderate CKD (GFR 30–59 mL/min/1.73 m²) as ‘high risk’ (see Table 5).

**Gap in evidence**
- The contribution of various CKD markers to CVD risk stratification remains unclear.

### 2.4.5.2 Influenza

**Key message**
- There is an association between acute respiratory infections, especially those occurring at times of peak influenza virus circulation, and CVD.

#### Recommendation for influenza vaccination

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>Classa</th>
<th>Levelb</th>
<th>Refc</th>
</tr>
</thead>
<tbody>
<tr>
<td>Annual influenza vaccination may be considered in patients with established CVD.</td>
<td>IIb</td>
<td>C</td>
<td>151–154</td>
</tr>
</tbody>
</table>

*aClass of recommendation.  
bLevel of evidence.  
cReference(s) supporting recommendations.

Influenza can trigger a CVD event. Studies show an increase in rates of MI during the annual influenza season. The risk of MI or stroke was more than four times higher after a respiratory tract infection, with the highest risk in the first 3 days. A recent meta-analysis suggests that preventing influenza, particularly by means of vaccination, can prevent influenza-triggered AMI, but there is concern that some studies are biased.

**Gap in evidence**
- Large-scale RCTs are needed to assess the efficacy of influenza vaccination in preventing influenza-triggered AMI.

### 2.4.5.3 Periodontitis

Studies have linked periodontal disease to both atherosclerosis and CVD, and serological studies have linked elevated periodontal bacteria antibody titres to atherosclerotic disease. A longitudinal study has suggested that an improvement in clinical and microbial periodontal status is related to a decreased rate of carotid artery IMT progression during a 3 year follow-up period, but IMT progression does not seem to be associated with CV events. Thus, if active treatment or prevention of periodontitis improves, clinical prognosis is still unclear.

### 2.4.5.4 Patients treated for cancer

**Key messages**
- Patients surviving cancer after treatment with chemotherapy or radiotherapy are at increased risk for CVD.
- The increased incidence of CVD is correlated with the combination of treatments given and the administered dose.
- The presence of traditional CV risk factors in cancer patients further increases CV risk.

#### Recommendations for patients treated for cancer

**Recommendations**

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Classa</th>
<th>Levelb</th>
<th>Refc</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardio-protection in high-risk patients receiving type I chemotherapy should be considered for LV dysfunction prevention</td>
<td>IIa</td>
<td>B</td>
<td>160, 161</td>
</tr>
<tr>
<td>Optimization of the CV risk profile should be considered in cancer treated patients.</td>
<td>IIa</td>
<td>C</td>
<td></td>
</tr>
</tbody>
</table>

CV = cardiovascular; LV = left ventricular.

*aClass of recommendation.  
bLevel of evidence.  
cReference(s) supporting recommendations.

Survivors of cancer represent an increasingly large population, most of whom have received chemotherapy and/or radiotherapy. Cardiotoxicity due to chemotherapy is related to a direct effect on the cell (anthracycline-like) through the generation of reactive oxygen species (ROS). It can be mediated by topoisomerase IIβ in cardiomyocytes through the formation of ternary complexes (topoisomerase IIβ–anthracycline–DNA) inducing DNA double-strand breaks and transcriptome changes responsible for defective mitochondrial biogenesis and ROS formation. Some agents (fluorouracil, bevacizumab, sorafenib and sunitinib) can induce a direct ischaemic effect not related to the premature development of atherosclerotic lesions. Moreover, they can increase risk factors such as hypertension and accelerate atherosclerosis, especially in older patients. These effects can be irreversible (type I agents) or partially reversible (type II agents) and can develop many years after treatment exposure. Typically, anthracyclines are the prototype of type I agents and trastuzumab of type II agents.

Cardiotoxicity due to chest radiotherapy can induce micro- and macrovascular injury. It can accelerate atherosclerosis, but this may occur many years after the initial exposure. The latency and severity of radiotherapy cardiotoxicity is related to multiple factors, including the dose (total per fraction), the volume of the heart irradiated, concomitant administration of other cardiotoxic drugs and patient factors (younger age, traditional risk factors, history of heart disease).

The first step in the identification of higher risk for cardiotoxicity consists of a careful baseline assessment of CV risk factors. Primary care, cardiology and oncology should work together to deliver optimal survivorship care that addresses CVD risk factors as well as prevalent disease. Positive health-promoting behaviour, including lifestyle factors (healthy diet, smoking cessation, regular exercise, weight control) should be strongly advised. In particular, aerobic exercise is considered as a promising non-pharmacological strategy to prevent and/or treat chemotherapy-induced cardiotoxicity.
Signs or symptoms of cardiac dysfunction should be monitored before and periodically during treatment for early detection of even asymptomatic abnormalities in patients receiving potentially cardiotoxic chemotherapy, and heart failure (HF) guideline recommendations should be followed if indicated.\textsuperscript{172} Thus, pretreatment evaluation of LV function is required.\textsuperscript{173} A targeted approach to treat patients with early LV dysfunction, in combination with global longitudinal strain abnormalities and biomarker (notably troponin) elevation, has been proposed.\textsuperscript{173,174}

In the case of a decrease in LV function during or after chemotherapy, the use of cardiotoxic agents should be avoided or delayed, if possible, until after discussion with the oncology team. This calls for adequate communication between oncology and cardiology.

To reduce chemotherapy type I cardiotoxicity, a variety of prophylactic treatments, including β-blockers, angiotensin-converting enzyme inhibitors (ACE-Is), dextrazoxane and statins, has been tested and compiled in a recent meta-analysis.\textsuperscript{161} It has been stressed that early preventive treatment is mandatory to exert a maximum effect.\textsuperscript{173–176}

Gaps in evidence

- Evidence on the effect of early preventive measures to reduce type I cardiotoxicity is inconclusive.
- The most appropriate strategy to improve risk stratification and prevent CVD in patients treated for cancer needs to be tested prospectively.

2.4.5.5 Autoimmune disease

Key messages

- Rheumatoid arthritis (RA) enhances CV risk independently of traditional risk factors, with an RR of 1.4 and 1.5 in men and women, respectively.
- There is mounting evidence that other immune diseases, such as ankylosing spondylitis or early severe psoriasis, also increase CV risk, with RRs approaching those in RA.
- Post hoc analysis of two statin trials suggests that the relative reduction in CVD incidence in autoimmune diseases is comparable to that seen in the other conditions.

**Recommendations for autoimmune disease**

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Class\textsuperscript{a}</th>
<th>Level\textsuperscript{b}</th>
<th>Ref\textsuperscript{c}</th>
</tr>
</thead>
<tbody>
<tr>
<td>The use of a 1.5 factor risk multiplier for CV risk in rheumatoid arthritis should be considered, particularly if disease activity is high.</td>
<td>IIa</td>
<td>B</td>
<td>177</td>
</tr>
<tr>
<td>The use of a 1.5 risk multiplier for CV risk in immune inflammatory diseases other than rheumatoid arthritis may be considered on a patient-by-patient basis, depending on disease activity/severity.</td>
<td>IIIb</td>
<td>C</td>
<td>177</td>
</tr>
</tbody>
</table>

\textsuperscript{a}Class of recommendation.
\textsuperscript{b}Level of evidence.
\textsuperscript{c}Reference(s) supporting recommendations.

There is now clear evidence implicating high-grade inflammation as a pathway for accelerated vascular disease.\textsuperscript{178} Systemic inflammation appears to enhance CV risk directly and indirectly via accentuation of existing risk pathways.\textsuperscript{179} While early small studies suggested RA increases CV risk beyond other risk markers, the recent analysis of the national QRESEARCH database in 2.3 million people provides the best available evidence for this.\textsuperscript{37} Such evidence has now been implemented in some national risk scores\textsuperscript{58} and European guidelines.\textsuperscript{177}

Evidence in psoriasis is less rigorous, but a recent paper demonstrates broadly comparable CV risks in RA and in early severe psoriasis.\textsuperscript{179} Robust data for independently elevated CV risks in other autoimmune conditions are generally lacking. Hence, clinical judgment should be applied on a case-by-case basis. There is evidence from post hoc analysis of randomized trials to support a statin-associated reduction in CV risk in autoimmune conditions.\textsuperscript{180} Finally, in all autoimmune diseases, drug interactions of anti-inflammatory and immunosuppressive drugs with, for example, statins, antiplatelet agents and antihypertensive agents deserve attention.

Gaps in evidence

- The association between non-RA immune inflammatory disease and CVD is less clear than for RA.
- The relationship between anti-rheumatic drugs and CV risk is unknown.

2.4.5.6 Obstructive sleep apnoea syndrome

Key message

- There is evidence of a positive relationship between obstructive sleep apnoea syndrome (OSAS) and hypertension, CAD, atrial fibrillation (AF), stroke, and HF.

OSAS is characterized by recurrent partial or complete collapse of the upper airway during sleep. It affects an estimated 9% of adult women and 24% of adult men and has been associated with an RR of 1.7 for CV morbidity and mortality.\textsuperscript{181} Repetitive bursts of sympathetic activity, surges of BP and oxidative stress brought on by pain and episodic hypoxaemia associated with increased levels of mediators of inflammation are thought to promote endothelial dysfunction and atherosclerosis.\textsuperscript{181} Screening for OSAS can be performed using the Berlin Questionnaire and daytime sleepiness can be assessed by the Epworth Sleepiness Scale and overnight oximetry.\textsuperscript{182} Definitive diagnosis often requires polysomnography, usually during a night in a sleep laboratory during which multiple physiological variables are continuously recorded. Treatment options include behavioural changes, such as avoiding alcohol, caffeine or other stimulants of wakefulness before sleep, increased PA, discontinuation of sedating drugs and obesity control. Continuous positive airway pressure is the gold-standard therapy and reduces CV mortality and events.\textsuperscript{183}

Gap in evidence

- More studies are needed to determine whether routine screening reduces (non)fatal CVD.
2.4.5.7 Erectile dysfunction

Key message
• Erectile dysfunction (ED) is associated with future CV events in men without and with established CVD.

Recommendation for erectile dysfunction

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>Class(^a)</th>
<th>Level(^b)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Assessment of CV risk factors and CVD signs or symptoms in men with ED should be considered.</td>
<td>IIa</td>
<td>C</td>
</tr>
</tbody>
</table>

CV = cardiovascular; CVD = cardiovascular disease; ED = erectile dysfunction.
\(^a\)Class of recommendation.
\(^b\)Level of evidence.

ED, defined as the consistent inability to reach and maintain an erection satisfactory for sexual activity, is common, affecting almost 40% of men >40 years of age (with varying degrees of severity), and increases in frequency with age. ED and CVD share common risk factors, including age, hypercholesterolaemia, hypertension, insulin resistance and DM, smoking, obesity, metabolic syndrome, sedentary lifestyle and depression. CVD and ED also share a common pathophysiological basis of aetiology and progression.\(^{184}\) Numerous studies have established that ED is associated with asymptomatic CAD.\(^{185,186}\) ED precedes CAD, stroke and PAD by a period that usually ranges from 2 to 5 years (average 3 years). A meta-analysis showed that patients with ED compared with subjects without ED have a 44% higher risk for total CV events, 62% for AMI, 39% for stroke and 25% for all-cause mortality.\(^{186}\) The predictive ability of ED is higher in younger ED patients despite the fact that the probability of ED increases with age, and it most likely identifies a group of patients with early and aggressive CVD. Thorough history taking, including CV symptoms and the presence of risk factors and comorbid conditions, assessment of ED severity and physical examination are mandatory first-line elements of investigation. Lifestyle changes are effective in improving sexual function in men: these include physical exercise, improved nutrition, weight control and smoking cessation.\(^{184}\)

Gap in evidence
• The benefit of routine screening for ED and the most effective tool to assess it are still unclear.

2.5 Relevant groups

2.5.1 Individuals <50 years of age

Key messages
• Some people <50 years of age have high relative or lifetime CV risk and should be offered lifestyle advice as a minimum.
• Some younger people will have high single CV risk factors that, of themselves, warrant intervention, such as cholesterol levels >8 mmol/L or BP ≥180/110 mmHg.
• The most important group of people <50 years of age to identify are those with a family history of premature CVD, who should be tested for FH and treated accordingly.

The most powerful driver of risk in all short-term (5 or 10 year) CV risk algorithms is age. As a consequence, all standard CV risk calculators show people <50 as low CV risk, regardless of underlying risk factors. However, some younger individuals are at very high relative risk compared with individuals of a similar age and may have high lifetime risk: they are more likely to develop CVD early and may prematurely suffer fatal or non-fatal CV events. So trying to identify who may be at such risk is an important challenge.

2.5.1.1 Assessing cardiovascular disease risk in people <50 years of age

Information on CV risk factors should be routinely collected in all adults <50 years of age with a first-degree family history (i.e. <55 years of age for male and <65 years of age for female relatives) of premature CVD. There are no data on the right age to begin collecting such information in the general population, but some guidelines advocate starting at age 40 years.\(^{190}\) Repeating such assessments occasionally, such as every 5 years, is recommended, but there are no data to guide this interval.

People <50 years of age should be assessed using the standard algorithm in terms of treatment decisions. However, in the absence of a very high individual risk factor level or diagnosis of FH, their 10-year risk will never be high enough to warrant BP- or lipid-lowering therapy. Physicians may want to further differentiate CV risk in younger people by using a relative risk chart (Figure 3, section 2.3.1); this might be useful in assisting people <50 years of age to judge their risk in relation to someone of the same age with low levels of risk factors.

Alternatively, physicians should consider using a risk age calculator (Figure 4, section 2.3.2) or a lifetime risk calculator, such as the JBS3 web-based tool (Figure J in web addenda),\(^{58}\) which might act as an educational tool in terms of how changing risk factors might change the lifetime risk score as well as illustrate long-term CV risk.

People <50 years of age with a positive family history of premature CVD should be screened for FH (see section 2.4.1) by clinical criteria (or occasionally genetic testing), such as those defined by the Dutch Lipid Clinic Network.\(^{187}\) Alternatives are the Simon Broome Registry criteria\(^{188}\) or the US MedPed Program.\(^{189}\)

2.5.1.2 Management of cardiovascular disease risk in people <50 years of age

All people <50 years of age with elevated CVD risk factors should be counselled on lifestyle factors (with emphasis on avoiding...
whether and how to screen populations for FH.

whether and how to screen populations for FH.

whether and how to screen populations for FH.

Gaps in evidence
• Age to commence formal CV risk estimation.
• Whether and how to screen populations for FH.

2.5.2.1 Hypertension
Most of the elderly-specific evidence is available for BP (section 3a.9). In general, more lenient treatment targets are advocated in the elderly. The hypertension literature also contains increasing evidence that biological rather than calendar age is important.\(^{191}\)

2.5.2.2 Diabetes mellitus
Evidence supporting more lenient glycaemic control targets in the elderly is also available for DM (section 3a.8). The role of biological age/frailty is less well established than for BP, but nonetheless, a Class IIa recommendation is given to relax glycaemic targets in elderly or frail patients.

2.5.2.3 Hyperlipidaemia
Few areas in CVD prevention are more controversial than the mass use of statins in the elderly. As the section on lipid control points out, there is no evidence of decreasing effectiveness of statins in patients >75 years of age (section 3a.7). On the other hand, the cost-effectiveness of statins in these patients is offset by even small geriatric-specific adverse effects.\(^{192}\) Also, evidence supporting effectiveness in the oldest old (i.e. >80 years of age) is very limited. A recent trial suggested no harm of stopping statins in the elderly with a limited life expectancy.\(^{193}\) Taken together, the recommendations of cholesterol-lowering treatment in the elderly should be followed with caution and common sense, adverse effects should be monitored closely and treatment should be reconsidered periodically.

2.5.3 Female-specific conditions

Key messages
• Several obstetric complications, in particular pre-eclampsia and pregnancy-related hypertension, are associated with a higher risk of CVD later in life. This higher risk is explained, at least partly, by hypertension and DM.
• Polycystic ovary syndrome (PCOS) confers a significant risk for future development of DM.

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Class</th>
<th>Level</th>
<th>Ref</th>
</tr>
</thead>
<tbody>
<tr>
<td>In women with a history of pre-eclampsia and/or pregnancy-induced hypertension, periodic screening for hypertension and DM should be considered.</td>
<td>IIa</td>
<td>B</td>
<td>194–197</td>
</tr>
<tr>
<td>In women with a history of polycystic ovary syndrome or gestational DM, periodic screening for DM should be considered.</td>
<td>IIa</td>
<td>B</td>
<td>198–201</td>
</tr>
<tr>
<td>In women with a history of giving birth, periodic screening for hypertension and DM may be considered.</td>
<td>IIb</td>
<td>B</td>
<td>202, 203</td>
</tr>
</tbody>
</table>

DM = diabetes mellitus; PCOS = polycystic ovary syndrome.

Specific conditions that may occur in females only and may have an impact on CVD risk can be separated into obstetric and non-obstetric conditions.

2.5.3.1 Obstetric conditions
Pre-eclampsia (defined as pregnancy-related hypertension accompanied by proteinuria) occurs in 1–2% of all pregnancies. Studies suggest that pre-eclampsia is associated with an increase in CV risk by a factor 1.5–2.\(^{194,195}\) While the RR of developing hypertension is \(~3^{196}\) and DM \(~2^{194,197}\), because most studies did not adjust the elevated risk of future CVD for the development of conventional risk factors, it cannot be established whether the increased CV risk after pre-eclampsia occurs independent of CV risk factors. The rationale for screening these women for the occurrence of hypertension and DM is, however, quite strong.

Pregnancy-related hypertension affects 10–15% of all pregnancies. The associated risk of later CVD is lower than for pre-eclampsia, but is still elevated (RR 1.9–2.5).\(^{202}\) Also, the risk for
sustained or future hypertension is elevated (RRs vary widely, from 2.0 to 7.2 or even higher). Again, however, there was incomplete adjustment for conventional risk factors. The risk of developing DM is probably also elevated in these women, but exact estimates are not available.

There are no data to suggest that recurrent pregnancy loss is associated with an increased CV risk. A history of premature birth is possibly associated with an increased risk of CVD in offspring (RR 1.5–2.0), which may be partially explained by an increased incidence of hypertension and DM.

Finally, gestational diabetes confers a sharply elevated risk of future DM, with up to 50% developing DM within 5 years after pregnancy. Previously, oral glucose tolerance testing was advocated to screen for DM in such patients, but screening by fasting glucose or glycated haemoglobin may be preferable.

2.5.3.2 Non-obstetric conditions
PCOS affects ~5% of all women in their fertile years. PCOS has been associated with an increased risk for future development of CVD, but larger studies have produced conflicting results. The risk of developing hypertension is probably somewhat increased, but again the data are conflicting. PCOS does seem to be associated with a higher risk of developing DM (RR 2–4), suggesting that periodic screening for DM is appropriate.

Premature menopause, better defined as primary ovarian insufficiency, occurs in roughly 1% in women ≤40 years of age. It has been reported to be associated with an increased risk of CVD (RR ~1.5), but studies are sparse. There are insufficient data to draw conclusions on a possible increased risk of hypertension or DM.

Gaps in evidence
- The degree to which increased CVD risk associated with several of the female-specific conditions occurs independent of conventional CVD risk factors is unknown.
- Information on whether female-specific conditions improve risk classification in women is unknown.

2.5.4 Ethnic minorities
Key messages
- CVD risk varies considerably between immigrant groups. South Asians and sub-Saharan Africans have a higher risk, while Chinese and South Americans have a lower risk.
- South Asians are characterized by a high prevalence and inadequate management of DM.
- Current risk estimation equations do not provide adequate estimations of CVD risk in ethnic minorities.

Recommendation for ethnic minorities

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>Class*</th>
<th>Levelb</th>
<th>Refc</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ethnicity should be considered in CVD risk assessment.</td>
<td>Ha</td>
<td>A</td>
<td>207, 208</td>
</tr>
</tbody>
</table>

CVD = cardiovascular disease.
*Class of recommendation.
*bLevel of evidence.
*cReference(s) supporting recommendations.
Based on available mortality and prospective data, the following correction factors could be applied when assessing CVD risk using SCORE among first-generation immigrants only.

- Southern Asia: multiply the risk by 1.4
- Sub-Saharan Africa and the Caribbean: multiply the risk by 1.3
- Western Asia: multiply the risk by 1.2
- Northern Africa: multiply the risk by 0.9
- Eastern Asia or South America: multiply the risk by 0.7

These values reflect the best estimations from available data and should be interpreted with caution, but can be used to guide CV risk management.

Gaps in evidence

- Studies focusing on CVD risk and the prevalence of CVD risk factors among minorities in Europe are needed.
- Validation of the SCORE risk estimation among ethnic minorities is needed.
- Ethnicity-specific thresholds to define high risk (based on the SCORE evaluation) should be identified. Alternatively, ethnicity-specific CVD risk equations should be developed.

3a. How to intervene at the individual level: risk factor intervention

3a.1 Behaviour change

Key message

- Cognitive behavioural methods are effective in supporting persons in adopting a healthy lifestyle.

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Class*</th>
<th>Levelb</th>
<th>Refc</th>
</tr>
</thead>
<tbody>
<tr>
<td>Established cognitive-behavioural strategies (e.g. motivational interviewing) to facilitate lifestyle change are recommended.</td>
<td>I</td>
<td>A</td>
<td>231</td>
</tr>
<tr>
<td>Involvement of multidisciplinary healthcare professionals (e.g. nurses, dieticians, psychologists) is recommended.</td>
<td>I</td>
<td>A</td>
<td>232, 233</td>
</tr>
<tr>
<td>In individuals at very high CVD risk, multimodal interventions integrating medical resources with education on healthy lifestyle, physical activity, stress management and counselling on psychosocial risk factors, are recommended.</td>
<td>I</td>
<td>A</td>
<td>233, 234</td>
</tr>
</tbody>
</table>

CVD = cardiovascular disease.

*Class of recommendation.

*Level of evidence.

*Reference(s) supporting recommendations.

‘Lifestyle’ is usually based on long-standing behavioural patterns that are maintained by social environment. Individual and environmental factors impede the ability to adopt a healthy lifestyle, as does complex or confusing advice from caregivers. Friendly and positive interaction enhances an individual’s ability to cope with illness and adhere to recommended lifestyle changes (‘empowerment’). It is important to explore each patient’s experiences, thoughts, worries, previous knowledge and circumstances of everyday life. Individualized counselling is the basis for motivation and commitment. Decision-making should be shared between the caregiver and patient (including also the individual’s spouse and family). Use of the principles of effective communication will facilitate treatment and prevention of CVD.

In addition, caregivers can build on cognitive behavioural strategies to assess the individual’s thoughts, attitudes and beliefs concerning the perceived ability to change behaviour, as well as the environmental context. Behavioural interventions such as ‘motivational interviewing’ increase motivation and self-efficacy.

Previous unsuccessful attempts often affect self-efficacy for future change. A crucial step is to help set realistic goals combined with self-monitoring of the chosen behaviour. Moving forward in small, consecutive steps is key to changing long-term behaviour. Communication training is important for health professionals. The ‘ten strategic steps’ listed in Table 9 can enhance counselling of behavioural change.

Combining the knowledge and skills of caregivers (such as physicians, nurses, psychologists, experts in nutrition, cardiac

<table>
<thead>
<tr>
<th>Table 8 Principles of effective communication to facilitate behavioural change</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Spend enough time with the individual to create a therapeutic relationship – even a few more minutes can make a difference.</td>
</tr>
<tr>
<td>• Acknowledge the individual’s personal view of his/her disease and contributing factors.</td>
</tr>
<tr>
<td>• Encourage expression of worries and anxieties, concerns and self-evaluation of motivation for behaviour change and chances of success.</td>
</tr>
<tr>
<td>• Speak to the individual in his/her own language and be supportive of every improvement in lifestyle.</td>
</tr>
<tr>
<td>• Ask questions to check that the individual has understood the advice and has any support he or she requires to follow it.</td>
</tr>
<tr>
<td>• Acknowledge that changing life-long habits can be difficult and that sustained gradual change is often more permanent than a rapid change.</td>
</tr>
<tr>
<td>• Accept that individuals may need support for a long time and that repeated efforts to encourage and maintain lifestyle change may be necessary in many individuals.</td>
</tr>
<tr>
<td>• Make sure that all health professionals involved provide consistent information.</td>
</tr>
</tbody>
</table>

Downloaded from http://eurheartj.oxfordjournals.org/ by guest on January 22, 2017
rehabilitation and sports medicine) into multimodal behavioural interventions can optimize preventive efforts.\(^{232-234}\) Multimodal behavioural interventions are especially recommended for individuals at very high risk.\(^{232-234}\) These interventions include promoting a healthy lifestyle through behaviour changes, including nutrition, PA, relaxation training, weight management and smoking cessation programmes for resistant smokers.\(^{233,234}\) They enhance coping with illness and improve adherence and CV outcome.\(^{238,239}\)

Psychosocial risk factors (stress, social isolation, and negative emotions) that may act as barriers against behaviour change should be addressed in tailored individual or group counselling sessions.\(^{233,234}\)

There is evidence that more extensive/longer interventions lead to better long-term results with respect to behaviour change and prognosis.\(^{232-234}\) Individuals of low socio-economic status, older age or female sex may need tailored programmes in order to meet their specific needs regarding information and emotional support.\(^{232,240,241}\)

**Gap in evidence**
- There is limited evidence to determine which interventions are most effective in specific groups (e.g., young—old, male—female, high vs. low socio-economic status).

### 3a.2 Psychosocial factors

**Key messages**
- Treatment of psychosocial risk factors can counteract psychosocial stress, depression and anxiety, thus facilitating behaviour change and improving quality of life and prognosis.
- The caregiver–patient interaction should follow the principles of patient-centred communication. Age- and sex-specific psychosocial aspects should be considered.

#### Recommendations for psychosocial factors

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Class*</th>
<th>Levelb</th>
<th>Refc</th>
</tr>
</thead>
<tbody>
<tr>
<td>Multimodal behavioural interventions, integrating health education, physical exercise and psychological therapy, for psychosocial risk factors and coping with illness are recommended in patients with established CVD and psychosocial symptoms in order to improve psychosocial health.</td>
<td>I</td>
<td>A</td>
<td>242</td>
</tr>
<tr>
<td>Referral for psychotherapy, medication or collaborative care should be considered in the case of clinically significant symptoms of depression, anxiety or hostility.</td>
<td>IIa</td>
<td>A</td>
<td>243, 244</td>
</tr>
<tr>
<td>Treatment of psychosocial risk factors with the aim of preventing CAD should be considered when the risk factor itself is a diagnosable disorder (e.g., depression) or when the factor worsens classical risk factors.</td>
<td>IIa</td>
<td>B</td>
<td>245, 246</td>
</tr>
</tbody>
</table>

**CAD** = coronary artery disease; **CVD** = cardiovascular disease.

*Class of recommendation.

*Level of evidence.

*Reference(s) supporting recommendations.

Caregivers in clinical practice are in a unique position to directly support their patients regarding psychosocial risk factors in individuals with high CV risk or with established disease. Empathic, patient-centred communication helps to establish and maintain a trustful relationship and is a powerful source of emotional support and professional guidance in coping with psychosocial stressors, depression, anxiety, CV risk factors and CVD.\(^{247,248}\) The principles of a supportive caregiver–patient interaction are\(^{247,248}\)

- Spend enough time with the patient, listen carefully and repeat essential keywords.
- Consider age- and sex-specific psychosocial aspects.
- Encourage expression of emotions, do not trivialize psychosocial burdens and worries.
- Explain essential medical facts in the patient’s own language, convey hope and relief from feelings of guilt and reinforce adaptive thoughts and actions.
- In the case of severe mental symptoms, obtain treatment preferences and perform shared decision-making regarding further diagnostic and therapeutic steps.
- Summarize important aspects of the consultation to confirm that the patient has been understood.
- Offer regular follow-up contacts.

---

**Table 9 Ten strategic steps to facilitate behaviour change**

<table>
<thead>
<tr>
<th>Step</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Develop a therapeutic alliance.</td>
</tr>
<tr>
<td>2.</td>
<td>Counsel all individuals at risk of or with manifest cardiovascular disease.</td>
</tr>
<tr>
<td>3.</td>
<td>Assist individuals to understand the relationship between their behaviour and health.</td>
</tr>
<tr>
<td>4.</td>
<td>Help individuals assess the barriers to behaviour change.</td>
</tr>
<tr>
<td>5.</td>
<td>Gain commitments from individuals to own their behaviour change.</td>
</tr>
<tr>
<td>6.</td>
<td>Involve individuals in identifying and selecting the risk factors to change.</td>
</tr>
<tr>
<td>7.</td>
<td>Use a combination of strategies including reinforcement of the individual's capacity for change.</td>
</tr>
<tr>
<td>8.</td>
<td>Design a lifestyle-modification plan.</td>
</tr>
<tr>
<td>9.</td>
<td>Involve other healthcare staff whenever possible.</td>
</tr>
<tr>
<td>10.</td>
<td>Monitor progress through follow-up contact.</td>
</tr>
</tbody>
</table>
Specialized psychological interventions have additional beneficial effects on distress, depressiveness and anxiousness, even when added to standard rehabilitation.242 These interventions include individual or group counselling on psychosocial risk factors and coping with illness, stress management programmes, meditation, autogenic training, biofeedback, breathing, yoga and/or muscular relaxation.

Large and consistent effects on depression have been shown in ‘collaborative care’, which may involve a systematic assessment of depression, a (non-physician) care manager to perform longitudinal symptom monitoring, treatment interventions and care coordination and specialist-provided stepped care recommendations and treatment.249 Collaborative care for depression resulted in a 48% lower risk for developing first CAD events 8 years after treatment compared with usual care [RR 0.52 (95% CI 0.31, 0.86)].245 Internet-delivered cognitive behavioural therapy in depressed patients with high CVD risk produced small, but robust, improvement of depressive symptoms, adherence and some health behaviours.246 In patients with established CAD, mental health treatments for depression (psychotherapy and/or medication) have moderate efficacy for reducing cardiac events (NNT 34), but do not reduce total mortality.243 Collaborative care is especially effective on depressive symptoms and partially effective on cardiac prognosis.249,250 Furthermore, there is evidence that PA can effectively improve depression in patients with CAD.251

In addition to the treatment of mood symptoms, there are several other approaches to psychosocial intervention that have proved useful. Two RCTs252,253 have shown the favourable impact of stress management and social support groups on the prognosis of clinical CAD. Nurse-led interventions reveal beneficial effects on anxiety, depression and general well-being in CAD patients.254,255 In hostile CAD patients, a group-based hostility-control intervention may lead not only to decreases in behaviourally assessed hostility levels, but also to decreased levels of depression, resting heart rate (HR) and CV reactivity to mental stress, as well as to increased social support and satisfaction with life.256 Work reorganizations aimed at improving autonomy and increasing control at work may result in improved social support and a reduction in physiological stress responses. Hence, a reduction of work stress in managers and supervisors may have beneficial health effects on the target individuals and may also improve perceived social support in their subordinates.257

**Gap in evidence**
- Evidence that treatment of clinically significant depression and anxiety alone will prevent CVD and improve outcomes is inconclusive.

**3a.3 Sedentary behaviour and physical activity**

**Key messages**
- Regular PA is a mainstay of CV prevention; participation decreases all-cause and CV mortality.
- PA increases fitness and improves mental health.
- Sedentary subjects should be encouraged to start light-intensity aerobic PA.

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Class</th>
<th>Level</th>
<th>Ref</th>
</tr>
</thead>
<tbody>
<tr>
<td>It is recommended for healthy adults of all ages to perform at least 150 minutes a week of moderate intensity or 75 minutes a week of vigorous intensity aerobic PA, or an equivalent combination thereof.</td>
<td>I</td>
<td>A</td>
<td>258–261</td>
</tr>
<tr>
<td>For additional benefits in healthy adults, a gradual increase in aerobic PA to 300 minutes a week of moderate intensity, or 150 minutes a week of vigorous intensity aerobic PA, or an equivalent combination thereof is recommended.</td>
<td>I</td>
<td>A</td>
<td>259, 260</td>
</tr>
<tr>
<td>Regular assessment and counselling on PA is recommended to promote the engagement and, if necessary, to support an increase in PA volume over time.</td>
<td>I</td>
<td>B</td>
<td>262–264</td>
</tr>
<tr>
<td>PA is recommended in low-risk individuals without further assessment.</td>
<td>I</td>
<td>C</td>
<td>265, 266</td>
</tr>
<tr>
<td>Multiple sessions of PA should be considered, each lasting 20 minutes and evenly spread throughout the week, i.e. on 4–5 days a week and preferably every day of the week.</td>
<td>IIa</td>
<td>B</td>
<td>267, 268</td>
</tr>
<tr>
<td>Clinical evaluation, including exercise testing, should be considered for sedentary people with CV risk factors who intend to engage in vigorous PAs or sports.</td>
<td>IIa</td>
<td>C</td>
<td>265</td>
</tr>
</tbody>
</table>

CV = cardiovascular; PA = physical activity.

- Class of recommendation.
- Level of evidence.
- Reference(s) supporting recommendations.
- Volume is the total weekly dose of PA.

**3a.3.1 Introduction**

Regular PA reduces the risk of many adverse health outcomes over a wide age range: all-cause and CVD mortality are reduced in healthy individuals by 20–30% in a dose–response fashion,258–260,267,269 in subjects with coronary risk factors269 and in cardiac patients.270 PA has a positive effect on many risk factors, including hypertension, low-density lipoprotein cholesterol (LDL-C) and non-HDL-C, body weight and type 2 DM.265 This applies to both men and women and across a broad range of ages from childhood to the very elderly. A sedentary lifestyle is one of the major risk factors for CVD independent of participation in PA.271
3a.3.2 Physical activity prescription

Health providers should assess the PA level in any subject (how many days and minutes per day are spent on average doing PA at moderate or vigorous intensity). They should warn against inactivity and help add PA to daily life. Subjects should be advised on appropriate types of activities and ways of progressing and should be helped to set personal goals to achieve and maintain the benefits. To this end, individuals should be encouraged to find some activity they either enjoy and/or that they can include in their daily routines, as such activities are more likely to be sustainable. For a more effective behaviour change, clinicians should explore practical ways to overcome barriers to exercise. For this reason, the link between primary care and local community-based structures for activity, recreation and sport is crucial.262 The amount of time spent being sedentary should be minimized by active travelling (cycling or walking), taking breaks from extended periods of sitting and reducing screen time.272 Brief exercises are more cost effective than supervised gym-based exercise classes or instructor-led walking programmes.264

3a.3.2.1 Aerobic physical activity

Aerobic PA, the most studied and recommended modality, with a beneficial dose—response effect on prognosis,259,260,268 consists of movements of large muscle mass in a rhythmic manner for a sustained period. It includes everyday activity, including active travel (cycling or walking), heavy household work, gardening, occupational activity and leisure time activity or exercise such as brisk walking, Nordic walking, hiking, jogging or running, cycling, cross-country skiing, aerobic dancing, skating, rowing or swimming.

Similar to all other interventions, its prescription can be adjusted in terms of frequency, duration and intensity. However, practising PA below the lowest recommended levels should be encouraged in individuals unable to meet the minimum or in those sedentary individuals who have just started, with a gradual increase in activity level.

Moderate or vigorous aerobic exercise should be recommended. This can be expressed either in absolute or relative terms.

Absolute intensity is the amount of energy expended per minute of activity, assessed by oxygen uptake per unit of time (mL/min or L/min) or by metabolic equivalent (MET), which is estimated as the rate of energy expenditure while sitting at rest. By convention this corresponds to 3.5 mL O2/kg/min.273 A list of PA intensities in MET values is available.271 An absolute measure does not take into account individual factors such as body weight, sex, and fitness level: older persons exercising at a vigorous intensity of 6 METs may be exercising at their maximum intensity, while a younger person working at the same absolute intensity may be exercising moderately.

Relative intensity is the level of effort required to perform an activity. Less fit individuals generally require a higher level of effort than fitter people to perform the same activity. It is determined relative to an individual’s level of cardiorespiratory fitness (V\text{O}_2\text{max}) or as a percentage of a person’s measured or estimated maximum HR (\%HR\text{max}), which is 220 — age. It also can be expressed as an index of individual rate of effort (how hard the person feels he/she is exercising), that is, the rating of perceived exertion (RPE) or by frequency of breathing (the so-called Talk Test). For individuals on medication, it is important to consider possible modification of HR response and to refer to other relative intensity parameters. Especially for older and deconditioned individuals, a relative measure of intensity is more appropriate. Classification for both absolute and relative intensity and examples are presented in Table 10.

PA should occur at a frequency of at least three to five sessions per week, but preferably every day.

It is recommended that individuals accumulate at least 30 min/day, 5 days/week of moderate intensity PA (i.e. 150 min/week) or 15 min/day, 5 days/week of vigorous intensity PA (75 min/week), or a combination of both, performed in sessions with a duration of at least 10 min. Shorter exercise sessions (i.e. < 10 min) may also be appropriate, especially in very deconditioned individuals.267,276,277 For lipid control or body weight management, longer durations of exercise, 40 and 60—90 min/day, respectively, have been proposed.278

Aerobic interval training and high-intensity interval training cannot yet be broadly recommended until further data on safety and efficacy are available.246

3a.3.2.2 Muscle strength/resistance physical activity

Isotonic PA stimulates bone formation and reduces bone loss; it preserves and enhances muscle mass, strength, power and functional

<table>
<thead>
<tr>
<th>Intensity</th>
<th>Absolute intensity</th>
<th>Examples</th>
<th>Relative intensity</th>
<th>%HR\text{max}</th>
<th>RPE (Borg scale score)</th>
<th>Talk Test</th>
</tr>
</thead>
<tbody>
<tr>
<td>Light</td>
<td>1.1–2.9</td>
<td>Walking &lt;4.7 km/h, light household work.</td>
<td>50–63</td>
<td>10–11</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Moderate</td>
<td>3–5.9</td>
<td>Walking briskly (4.8–6.5 km/h), slow cycling (15 km/h), painting/decorating, vacuuming, gardening (mowing lawn), golf (pulling clubs in trolley), tennis (doubles), ballroom dancing, water aerobics.</td>
<td>64–76</td>
<td>12–13</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vigorous</td>
<td>≥ 6.0</td>
<td>Race-walking, jogging or running, bicycling &gt;15 km/h, heavy gardening (continuous digging or hoeing), swimming laps, tennis (single).</td>
<td>77–93</td>
<td>14–16</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

MET (metabolic equivalent) is estimated as the energy cost of a given activity divided by resting energy expenditure: 1 MET = 3.5 mL O2 kg⁻¹ min⁻¹ oxygen consumption (VO2). RPE, rating of perceived exertion (20 value Borg score).

\%HR\text{max}, percentage of measured or estimated maximum heart rate (220—age).

Modified from Howley.275
ability, with some evidence of benefit in lipid and BP control and insulin sensitivity, especially in combination with aerobic exercise. It should target the major muscle groups (agonist and antagonist) and include multijoint or compound movements through the full range of motion of the joints, such as working with resistance bands, calisthenics using body weight for resistance, carrying heavy loads and heavy gardening. For each exercise session, the suggested prescription is two to three sets of 8–12 repetitions at the intensity of 60–80% of the individual’s 1 repetition maximum (1 RM, the maximum load that can be lifted one time) at a frequency of at least 2 days a week. For older adults or very deconditioned individuals, it is suggested to start with one set of 10–15 repetitions at 60–70% of 1 RM.

3a.3.2.3 Neuromotor physical activity
For older adults at risk of falls, neuromotor exercise helps to maintain and improve balance and motor skills (balance, agility, coordination and gait). This includes multifaceted activities such as tai chi and yoga, and recreational activities using paddles or sport balls to challenge hand–eye coordination. The optimal volume is not known.

3a.3.2.4 Phases and progression of physical activity
PA sessions should include the following phases: warm-up, conditioning (aerobic, muscle strength/resistance and neuromotor exercise), cool-down and stretching/flexibility. Progressive warm-up before and cool-down after exercise may prevent injuries and adverse cardiac events. Inactive adults should start gradually, at light or moderate intensity for short periods of time (even <10 min), with sessions spread throughout the week. With the improvement in exercise tolerance, each subject progresses in the level of PA, but increases in any components (i.e. frequency, duration and intensity) should be gradual, to minimize risks of muscle soreness, injury, fatigue and the long-term risk of overtraining. Following any adjustments, the individual should check for adverse effects (e.g. excessive shortness of breath) and if there are any such effects, downward adjustments should be made.

3a.3.3 Risk assessment
The risk of an adverse CV response during PA is extremely low for apparently healthy adults (5–17 sudden deaths/million population/year). The risk of participation is outweighed by the substantial health benefits conferred by PA. Risk during light- or moderate-intensity exercise is lower than during vigorous activity, thus in healthy individuals who wish to undertake moderate PA, such as a walking programme, a preliminary medical evaluation is not needed.

Before starting more intensive leisure time activities (i.e. structured or competitive activity, amateur sports, exercise and fitness training), a risk assessment should be tailored to the individual’s clinical (i.e. metabolic, musculoskeletal condition/disease) and cardiac risk profile, the current level of habitual PA and the intended level of PA. Individuals who exercise only occasionally seem to have an increased risk of acute coronary events and sudden cardiac death during or after exercise. Sedentary subjects and those with CV risk factors should start aerobic PA at low-intensity activity and progress gradually. Clinical evaluation, including exercise testing, may be considered for sedentary people with CV risk factors who intend to engage in vigorous PA and sports. The information gathered from exercise tests may be useful in establishing a safe and effective exercise prescription. Validated self-assessment questionnaires have been proposed for sedentary individuals entering low-intensity leisure time sports activity or starting moderate-intensity activities (see Table B in web addenda).

Gaps in evidence
- The lower and upper limit of aerobic PA intensity, duration and frequency to exert a beneficial effect is unknown.
- The effectiveness of PA monitoring vs. simple counselling to optimize the motivation of patients to adhere to active lifestyle is unknown.
- The role and sustainability of modern technology (such as wearable technology, ‘exergaming’ and smartphone apps) for motivating people to undertake more PA has not been established.

3a.4 Smoking intervention
Key messages
- Stopping smoking is the most cost-effective strategy for CVD prevention.
- There is a strong evidence base for brief interventions with advice to stop smoking, all types of nicotine replacement therapy (NRT), bupropion, varenicline and greater effectiveness of drugs in combination, except for NRT plus varenicline. The most effective are brief interventions plus assistance with stopping using drug therapy and follow-up support.
- Electronic cigarettes (e-cigarettes) may help in smoking cessation but should be covered by the same marketing restrictions as cigarettes.
- Passive secondary smoking carries significant risk, with the need to protect non-smokers.

### Recommendations for smoking intervention strategies

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Class α</th>
<th>Level β</th>
<th>Ref c</th>
</tr>
</thead>
<tbody>
<tr>
<td>It is recommended to identify smokers and provide repeated advice on stopping with offers to help, by the use of follow up support, nicotine replacement therapies, varenicline, and bupropion individually or in combination.</td>
<td>I</td>
<td>A</td>
<td>283–286</td>
</tr>
<tr>
<td>It is recommended to stop all smoking of tobacco or herbal products, as this is strongly and independently causal of CVD.</td>
<td>I</td>
<td>B</td>
<td>287–291</td>
</tr>
<tr>
<td>It is recommended to avoid passive smoking.</td>
<td>I</td>
<td>B</td>
<td>292, 293</td>
</tr>
</tbody>
</table>

CVD = cardiovascular disease.

αClass of recommendation.
βLevel of evidence.
γReference(s) supporting recommendations.
years of life, contrasting with <3 years with severe hypertension and <1 year with mild hypertension. Smoking is an established cause of a plethora of diseases and is responsible for 50% of all avoidable deaths in smokers, half of these due to CVD. The 10-year fatal CVD risk is approximately doubled in smokers. The RR in smokers <50 years of age is five-fold higher than in non-smokers.

Slightly less than half of lifetime smokers will continue smoking until death. Approximately 70% of UK smokers want to stop smoking at some time in the future, with ~43% trying to stop in the past year; however, only 2–3% of the population succeed in stopping. Even modest and low levels of smoking confer vascular risk.

Although the rate of smoking is declining in Europe, it remains very common and is increasing in women, adolescents and the socially disadvantaged. Widening education-related inequalities in smoking cessation rates have been observed in many European countries. In the EUROASPIRE IV survey among CAD patients, 16% smoked after a mean follow-up time of 16 months, and nearly half of the participants who smoked at the time of their coronary event were persistent smokers. The survey also found that evidence-based treatment for smoking cessation was underused.

### 3a.4.2 Dosage and type

The risks associated with smoking show a dose–response relationship with no lower limit for deleterious effects. Duration also plays a role, and while cigarette smoking is the most common, all types of smoked tobacco, including low-tar (“mild” or “light”) cigarettes, filtered cigarettes, cigars and pipes, are harmful. Smoking is deleterious regardless of how it is done, including by water pipe. Tobacco smoke is more harmful when inhaled, but smokers who claim not to inhale the smoke (e.g., pipe smokers) are also at increased risk of CVD. Smokeless tobacco is also associated with a small but statistically significant increased risk of MI and stroke.

### 3a.4.3 Passive smoking

Passive smoking increases the risk of CAD. A smoking spouse or workplace exposure increases CVD risk by an estimated 30%. Major health benefits result from reduced environmental tobacco smoke, with public smoking bans in various different geographical locations leading to significant decreases in MI rates (see section 3c.4).

### 3a.4.4 Mechanisms by which tobacco smoking increases risk

Smoking enhances the development of both atherosclerosis and superimposed thrombotic phenomena. Smoking affects endothelial function, oxidative processes, platelet function, fibrinolysis, inflammation, lipid oxidation and vasomotor function. In experimental studies, several of these effects are fully or partly reversible within a very short time. Plaque formation is not thought to be fully reversible and thus smokers would never be expected to reach the risk level of never smokers concerning CVD. Nicotine replacement shows no adverse effect on outcomes in patients with cardiac disease.

### 3a.4.5 Smoking cessation

The benefits of smoking cessation have a large evidence base. Some advantages are almost immediate; others take more time. CVD risk in former smokers is in between that of current and never smokers.

Stopping smoking after an MI is potentially the most effective of all preventive measures: a systematic review and meta-analysis showed reductions in MIs and in the composite endpoints of death/MI (RR 0.57 and 0.74, respectively) compared with continued smoking. The benefit is consistent over gender, duration of follow-up, study site and time period. Significant morbidity reductions occur within the first 6 months. Randomized trials also support smoking cessation, with the risk of CVD approaching (but never equalling) the risk of never smokers within 10–15 years.

Smoking reduction has not been shown to increase the probability of future smoking cessation, but some advocate nicotine-assisted smoking reduction in smokers unable or unwilling to quit. Quitting must be encouraged in all smokers (Table 11). There is no age limit to the benefits of smoking cessation. Passive smoking should also be avoided.

Professional support can increase the odds of stopping [RR 1.66 (95% CI 1.42, 1.94)]. An impetus for smoking cessation occurs at the time of diagnosing or (invasive) treatment of CVD. Prompting a person to try to quit, brief reiteration of CV and other health hazards and agreeing on a specific plan with a follow-up arrangement are evidence-based interventions (see Figure K in web addenda).

Smoking cessation programmes initiated during hospital admission should continue for a prolonged period after discharge. A smoking history including daily tobacco consumption and degree of addiction (most commonly assessed by the Fagerström test) may guide the degree of support and pharmacological aids. Smokers should be advised about expected weight gain, on average, 5 kg and that the health benefits of tobacco cessation far outweigh the risks from weight gain.

### 3a.4.6 Evidence-based drug interventions

Following the failure of advice, encouragement and motivational interventions, or in addition to them, NRT, varenicline or bupropion should be offered to assist cessation. All forms of NRT (chewing gum, transdermal nicotine patches, nasal spray, inhaler, sublingual tablets) are effective: in a systematic review, the RR for abstinence by 50–70% compared with NRTs increase the rate of quitting by 50–70%, regardless of setting.

The antidepressant bupropion aids long-term smoking cessation with a similar efficacy to NRT. A meta-analysis of 44 trials

<table>
<thead>
<tr>
<th>Table 11</th>
<th>The “Five As” for a smoking cessation strategy for routine practice</th>
</tr>
</thead>
<tbody>
<tr>
<td>A-ASK:</td>
<td>Systematically inquire about smoking status at every opportunity.</td>
</tr>
<tr>
<td>A-ADVISE:</td>
<td>Unequivocally urge all smokers to quit.</td>
</tr>
<tr>
<td>A-ASSESS:</td>
<td>Determine the person’s degree of addiction and readiness to quit.</td>
</tr>
<tr>
<td>A-ASSIST:</td>
<td>Agree on a smoking cessation strategy, including setting a quit date, behavioural counselling, and pharmacological support.</td>
</tr>
<tr>
<td>A-ARRANGE:</td>
<td>Arrange a schedule of follow-up.</td>
</tr>
</tbody>
</table>
comparing long-term cessation rates using bupropion vs. control yielded a relative success rate of 1.62.283 Bupropion carries a known risk of seizures (reported as ~1/1000 users),286 without increased risks of neuropsychiatric or heart and circulatory problems. Overall, NRT and bupropion help ~80% more people to quit than placebo; this means that for every 10 people who quit with placebo, ~18 could be expected to quit with NRT or with bupropion.285

The partial nicotine receptor agonist varenicline at the standard dose increases the chances of quitting more than two-fold compared with placebo (14 trials, 6166 people).283 The number of people stopping smoking with varenicline is higher than with bupropion (three trials, 1622 people). Varenicline more than doubles the chances of quitting compared with placebo, so that for every 10 who quit with placebo, ~28 could be expected to quit with varenicline. Varenicline helps ~50% more people to quit than nicotine patch and ‘other’ NRTs (tablets, sprays, lozenges and inhalers) and ~70% more people than nicotine gum. So for every 10 people who quit with an NRT patch or with ‘other’ NRTs, ~15 would be expected to quit with varenicline, and for every 10 who quit with NRT gum, ~17 would be expected to quit with varenicline.285

Low-dose varenicline (four trials, 1272 people) roughly doubles the chances of quitting and reduces the number and severity of side effects. The main side effect of varenicline is nausea, but this is mostly mild or moderate and usually subsides over time.285 Although concerns have been raised, retrospective cohort studies and an RCT indicate no severe adverse events with varenicline in the setting of ACS patients, with the large EVITA trial in ACS ongoing.

Clonidine has helped people to quit, but causes side effects and is therefore a second-line agent. It is not clear whether mecamylamine used with NRT helps people to quit. Other treatments did not seem to help. So far, nicotine vaccines are not licensed for use anywhere in the world.285

Combining two types of NRT is as effective as using varenicline, and helps more people to quit than a single type of NRT.285

### 3a.4.7 Electronic cigarettes

Electronic cigarettes (e-cigarettes) are battery-operated devices that simulate combustible cigarettes by heating nicotine and other chemicals into a vapour that is inhaled. Electronic cigarettes deliver the addictive nicotine without the vast majority of tobacco chemicals, and are probably less harmful than tobacco.305

Evidence on the effectiveness of e-cigarettes is limited due to the small number of trials, low event rates and wide confidence intervals.306 Data from some observational studies and a randomized trial suggest that the efficacy of first-generation e-cigarettes is similar to that of transdermal NRT patches or NRT inhalers.307 The benefit may come from low nicotine delivery or just the non-nicotine behavioural components of e-cigarette use. About 6% of former smokers who used e-cigarettes daily relapsed to smoking after 1 month and 6% after 1 year, and nearly half of dual users of both tobacco and e-cigarettes stopped smoking after 1 year, indicating that e-cigarette use might be effective in relapse prevention and smoking cessation.309 These studies and real-world data indicate that e-cigarettes are moderately effective as smoking cessation and harm reduction aids, but that a significant component of that effect is due to changes in behaviour rather than in nicotine delivery. Recent evidence indicates that e-cigarettes, as currently being used, are associated with significantly less quitting among smokers.310 Although no safety issues have been observed in the short term (2 years), determining the long-term health effects of e-cigarettes (and in particular dual use with cigarettes) will require more research.305

### 3a.4.8 Other smoking cessation interventions

Both individual and group behavioural interventions are effective in helping smokers quit. Support from the individual’s partner and family is important. There are no reliable data that acupuncture, acupressure, laser therapy, hypnotherapy or electrostimulation are effective for smoking cessation.

#### Gap in evidence

- More efficient, safe and cost-effective smoking cessation aids are required.

### 3a.5 Nutrition

#### Key messages

- Dietary habits influence the risk of CVD and other chronic diseases such as cancer.
- Energy intake should be limited to the amount of energy needed to maintain (or obtain) a healthy weight, that is, a BMI >20.0 but <25.0 kg/m².
- In general, when following the rules for a healthy diet, no dietary supplements are needed.

### Recommendation on nutrition

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>Class</th>
<th>Level</th>
<th>Ref</th>
</tr>
</thead>
<tbody>
<tr>
<td>A healthy diet is recommended as a cornerstone of CVD prevention in all individuals.</td>
<td>I</td>
<td>B</td>
<td>311</td>
</tr>
</tbody>
</table>

CVD = cardiovascular disease.

Class of recommendation.

Level of evidence.

Reference(s) supporting recommendations.

#### 3a.5.1 Introduction

Dietary habits influence CV risk, either through an effect on risk factors such as cholesterol, BP, body weight and DM, or through other effects.311 Table 12 summarizes the characteristics of a healthy diet.

Most evidence on the relation between nutrition and CVD is based on observational studies; randomized clinical trials estimating the impact of diet on endpoints are scarce. The impact of diet is studied on three levels: specific nutrients, specific foods/food groups and specific dietary patterns, of which the Mediterranean diet is the most studied.

The nutrients of interest with respect to CVD are fatty acids (which mainly affect lipoprotein levels), minerals (which mainly affect BP), vitamins and fibre.

#### 3a.5.2 Fatty acids

For prevention of CVD, the types of fatty acids consumed are more important than the total fat content.
The risk of CAD is reduced by 2–3% when 1% of energy intake from saturated fatty acids is replaced by polyunsaturated fatty acids. The same has not been clearly shown for replacement with carbohydrates and monounsaturated fatty acids (MUFAs). Saturated fatty acid intake should be reduced to a maximum of 10% of energy intake by replacing it with polyunsaturated fatty acids.

MUFAs have a favourable effect on HDL-C levels when they replace saturated fatty acids or carbohydrates, but there is little evidence that MUFAs lower CAD risk. Polyunsaturated fatty acids lower LDL-C levels, and to a lesser extent HDL-C levels, when they replace saturated fatty acids. The polyunsaturated fatty acids can be divided into two subgroups: omega-6 fatty acids, mainly from plant foods, and omega-3 fatty acids, mainly from fish oils and fats. Within the subclass of omega-3 fatty acids, eicosapentaenoic acid and docosahexaenoic acid (EPA/DHA) are especially important. They do not change serum cholesterol, but their intake and consumption must be discouraged.

### Table 12 Healthy diet characteristics

<table>
<thead>
<tr>
<th>Diet characteristic</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturated fatty acids to account for &lt;10% of total energy intake, through replacement by polyunsaturated fatty acids.</td>
<td></td>
</tr>
<tr>
<td>Trans unsaturated fatty acids: as little as possible, preferably no intake from processed food, and &lt;1% of total energy intake from natural origin.</td>
<td></td>
</tr>
<tr>
<td>&lt;5 g of salt per day.</td>
<td></td>
</tr>
<tr>
<td>30–45 g of fibre per day, preferably from wholegrain products.</td>
<td></td>
</tr>
<tr>
<td>≥200 g of fruit per day (2–3 servings).</td>
<td></td>
</tr>
<tr>
<td>≥200 g of vegetables per day (2–3 servings).</td>
<td></td>
</tr>
<tr>
<td>Fish 1–2 times per week, one of which to be oily fish.</td>
<td></td>
</tr>
<tr>
<td>30 gms unsalted nuts per day.</td>
<td></td>
</tr>
<tr>
<td>Consumption of alcoholic beverages should be limited to 2 glasses per day (20 g/d of alcohol) for men and 1 glass per day (10 g/d of alcohol) for women.</td>
<td></td>
</tr>
<tr>
<td>Sugar-sweetened soft drinks and alcoholic beverages consumption must be discouraged.</td>
<td></td>
</tr>
</tbody>
</table>

The impact of dietary cholesterol on serum cholesterol levels is weak compared with that of the fatty acid composition of the diet. When guidelines are followed to lower saturated fat intake, this usually also leads to a reduction in dietary cholesterol intake. Therefore, some guidelines (including this one) on healthy diet do not give specific guidelines on the intake of dietary cholesterol; others recommend a limited intake of < 300 mg/day.

### 3a.5.3 Minerals

A meta-analysis estimated that even a modest reduction in sodium intake of 1 g/day reduces SBP by 3.1 mmHg in hypertensive patients and 1.6 mmHg in normotensive patients. The Dietary Approaches to Stop Hypertension (DASH) trial showed a dose–response relation between sodium reduction and BP reduction. In most western countries, salt intake is high (~ 9–10 g/day), whereas the recommended maximum intake is 5 g/day. Optimal intake levels might be as low as ~ 3 g/day. Although the relation between salt intake and BP remains controversial, the totality of evidence warrants salt reduction as an important way to prevent CAD and stroke. On average, 80% of salt intake comes from processed foods, while only 20% is added later on. Salt reduction can be achieved by making different dietary choices (fewer processed foods, more basic foods) and the reformulation of foods (lowering salt content) (see Chapter 3c.2).

Potassium has favourable effects on BP. The main sources of potassium are fruits and vegetables. An inverse statistically significant association exists between potassium intake and the risk of incident stroke [RR 0.76 (95% CI 0.66, 0.89)]. Apart from reducing sodium intake, increasing potassium intake contributes to the lowering of BP.

### 3a.5.4 Vitamins

Many case–control and prospective observational studies have observed inverse associations between levels of vitamin A and E and the risk of CVD. However, intervention trials have failed to confirm these observational studies. Also, for the B vitamins (B6, folic acid and B12) and vitamin C, trials have shown no beneficial effects.

In the bottom tertile of serum levels of vitamin D, CV and total mortality is 35% higher [RR 1.35 (95% CI 1.13, 1.61)] than in the highest tertile. A 41% higher risk of CV mortality [RR 1.41 (95% CI 1.18, 1.68)] and 57% higher risk of all-cause mortality [RR 1.57 (95% CI 1.36, 1.81)] has been reported in the lowest vs. highest quintile. A much smaller effect was observed in RCTs: an 11% risk reduction in all-cause mortality was observed for vitamin D3 supplementation [RR 0.89 (95% CI 0.80, 0.99)], but not for vitamin D2 supplementation. Due to a lack of power, it was not possible to look at CV mortality specifically. Therefore, conclusions about vitamin D supplementation [type of supplement (D2 or D3), dosage and duration] for CV prevention cannot yet be drawn.

### 3a.5.5. Fibre

Recent meta-analyses of prospective cohort studies show that a 7 g/day higher intake of total fibre is associated with a 9% lower risk of CAD [RR 0.91 (95% CI 0.87, 0.94)] and a 10 g/day higher fibre intake is associated with a 16% lower risk of stroke [RR 0.84 (95% CI 0.75, 0.94)] and a 6% lower risk of type 2 DM [RR 0.94 (95% CI 0.91, 0.97)]. There is no evidence yet for a similar association with fibre from fruits and vegetables. Although the mechanism has not been elucidated completely, it is known that a high fibre intake reduces postprandial glucose responses after carbohydrate-rich meals and lowers total cholesterol and LDL-C levels.
3a.5.6 Foods and food groups
3a.5.6.1 Fruits and vegetables
Prospective cohort studies have shown a protective effect of the consumption of fruits and vegetables on CVD, but RCTs are scarce. A meta-analysis reported a decrease of 4% [RR 0.96 (95% CI 0.92, 0.99)] in CV mortality for each additional serving of fruits (equivalent to 77 g) and vegetables (equivalent to 80 g) per day, while all-cause mortality did not reduce further with intakes of more than five servings. A meta-analysis reported a risk reduction for stroke of 11% [RR 0.89 (95% CI 0.83, 0.97)] for three to five daily servings of fruits and vegetables and of 26% [RR 0.74 (95% CI 0.69, 0.79)] for more than five servings compared with less than three servings. A meta-analysis on CAD reported a 4% decrease in CAD risk [RR 0.96 (95% CI 0.93, 0.99)] for each additional serving of fruits and vegetables per day.

3a.5.6.2 Nuts
A meta-analysis of prospective cohort studies has shown that daily consumption of 30 g of nuts reduces the risk of CVD by ~30% [RR 0.71 (95% CI 0.59, 0.85)]. It must be noted that the energy density of nuts is high.

3a.5.6.3 Fish
The protective effect of fish on CVD is attributed to the n-3 fatty acid content. Pooled risk estimates from prospective cohort studies show that eating fish at least once a week results in a 16% reduction in the risk of CAD [RR 0.85 (95% CI 0.75, 0.95)] compared with eating less fish. A recent meta-analysis showed that eating fish two to four times a week reduces the risk of stroke by 6% [RR 0.94 (95% CI 0.90, 0.98)] compared with eating fish less than once a week. The relation between fish intake and CV risk is not linear. Especially in the range of no or very low intake, risk is increased. The public health impact of a small increase in fish consumption in the general population is therefore potentially large.

For fish oil, three randomized controlled prevention trials have been published. All three trials, in post-AMI or CAD patients who received an extra amount of 400–1000 g EPA/DHA daily, did not observe a reduction in CV events in the intervention group. A recent meta-analysis of 20 trials, mostly prevention of recurrent CV events and mostly using fish oil supplements, showed no benefit of fish oil supplementation on CV outcomes.

3a.5.6.4 Alcoholic beverages
Drinking three or more alcoholic beverages per day is associated with elevated CV risk. Results from epidemiological studies suggest a lower risk of CV occurring with moderate (one to two units per day) alcohol consumption compared with non-drinkers. This association appears not to be explained by special characteristics of abstainers, although the potential for residual confounding and reverse causality cannot be fully excluded. Moreover, a recent Mendelian randomization study including analyses from 59 epidemiological studies has shed doubt on any beneficial effect of moderate alcohol consumption, suggesting that the lowest risks for CV outcomes were in abstainers and that any amount of alcohol is associated with elevated BP and BMI.

3a.5.6.5 Soft drinks and sugar
Sugar-sweetened soft drinks are the largest single food source of calories in the US diet and are important in Europe. In children and adolescents, beverages may now even account for 10–15% of the calories consumed. Regular consumption of soft drinks has been associated with overweight, metabolic syndrome and type 2 DM. Substitution of sugar-sweetened soft drinks with artificially sweetened drinks resulted in less weight gain in children over an 18-month period. Sugar-sweetened beverages also cause weight gain in adults. Regular consumption of sugar-sweetened beverages (i.e. two servings per day compared with one serving per month) was associated with a 35% higher risk of CAD in women, even after other unhealthy lifestyle and dietary factors were accounted for, whereas artificially sweetened beverages were not associated with CAD. The WHO guideline recommends a maximum intake of 10% of energy from sugar (mono- and disaccharides), which includes added sugars as well as sugars present in fruits and fruit juices.

3a.5.7 Functional foods
Functional foods containing phytosterols (plant sterols and stanols) are effective in lowering LDL-C levels by an average of 10% when consumed in amounts of 2 g/day. The cholesterol-lowering effect is in addition to that obtained with a low-fat diet or use of statins. Further cholesterol reduction can be obtained with higher doses of phytosterols. No studies with clinical endpoints have been performed yet.

3a.5.8 Dietary patterns
Studying the impact of a total dietary pattern theoretically shows the full preventive potential of diet since it yields a combined estimate of the impact of several favourable dietary habits. The Mediterranean diet comprises many of the nutrients and foods that have been discussed previously: high intake of fruits, vegetables, legumes, wholegrain products, fish and unsaturated fatty acids (especially olive oil); moderate consumption of alcohol (mostly wine, preferably consumed with meals) and low consumption of (red) meat, dairy products and saturated fatty acids. A meta-analysis of prospective cohort studies has demonstrated that greater adherence to a Mediterranean diet is associated with a 10% reduction in CV incidence or mortality [pooled RR 0.90 (95% CI 0.87, 0.93)] and an 8% reduction in all-cause mortality [pooled RR 0.92 (95% CI 0.90, 0.94)]. An RCT in high-risk individuals suggested that following a Mediterranean diet over a 5 year period, compared with a control diet, was related to a 29% lower risk of CV [RR 0.71 (95% CI 0.56, 0.90)].

Gaps in evidence
- The biggest challenge in dietary prevention of CVD is to develop more effective strategies to make people change their diet (both quantitatively and qualitatively) and to maintain that healthy diet and a normal weight.
- Research into the substances in foods that underlie the protective effects is ongoing.

3a.6 Body weight
Key messages
- Both overweight and obesity are associated with an increased risk of CVD death and all-cause mortality. All-cause mortality is lowest with a BMI of 20–25 kg/m² (in those < 60 years of age); further weight reduction cannot be considered protective against CVD.
Healthy weight in the elderly is higher than in the young and middle-aged. Achieving and maintaining a healthy weight has a favourable effect on metabolic risk factors (BP, blood lipids, glucose tolerance) and lower CV risk.

Recommendation for body weight

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>Class</th>
<th>Level</th>
<th>Ref</th>
</tr>
</thead>
<tbody>
<tr>
<td>It is recommended that subjects with healthy weight maintain their weight. It is recommended that overweight and obese people achieve a healthy weight (or aim for a reduction in weight) in order to reduce BP, dyslipidaemia and risk of developing type 2 DM, and thus improve the CV risk profile.</td>
<td>I</td>
<td>A</td>
<td>338, 339</td>
</tr>
</tbody>
</table>

BP = blood pressure; CVD = cardiovascular disease; DM = diabetes mellitus.

3a.6.1 Introduction

In many countries, favourable trends in major risk factors such as blood cholesterol, BP and smoking prevalence have been observed, translating into reduced CV mortality. However, BMI has greatly increased in all countries over recent decades, resulting in a concomitant increase in the prevalence of type 2 DM. In the USA, it has been projected that if obesity trends from 2005 to 2020 continue, obesity will increasingly offset the positive effects of declining smoking rates. The main clinical complications of increasing body weight are increases in BP, dyslipidaemia, insulin resistance, systemic inflammation and prothrombotic state and albuminuria and the development of DM and CV events (HF, CAD, AF, stroke).

3a.6.2 Which index of obesity is the best predictor of cardiovascular risk?

BMI (weight [kg]/height [m²]) can be measured easily and is used extensively to define categories of body weight (see Table C in the web addenda). In addition to the amount of body fat, its distribution is important. Body fat stored in the abdomen (intra-abdominal fat) carries a higher risk than subcutaneous fat. Several measures of body fatness are available (see Table D in the web addenda). Most data are available for BMI, waist:hip circumference ratio and simple waist circumference. The optimal level for measurement of waist circumference is midway from the lower rib margin to the anterior superior iliac crest, in the standing position. The WHO thresholds for waist circumference are the most widely accepted in Europe. Based on these thresholds, two action levels are recommended:

(i) waist circumference ≥ 94 cm in men and ≥ 80 cm in women represents the threshold at which further weight should be gained and

(ii) waist circumference ≥ 102 cm in men and ≥ 88 cm in women represents the threshold at which weight reduction should be advised.

These thresholds have been calculated based on Caucasians, and it is apparent that different cut-offs for anthropometric measurements are required in different races and ethnicities. A meta-analysis concluded that both BMI and waist circumference are similarly strong and continuously associated with CVD and type 2 DM. Therefore, BMI generally suffices in routine practice.

3a.6.3 Does ‘metabolically healthy obesity’ exist?

The phenotype of ‘metabolically healthy obesity’ (MHO), defined by the presence of obesity in the absence of metabolic risk factors, has gained a lot of interest. Some studies argue that a specific subgroup of obese individuals is resistant to metabolic complications such as arterial hypertension and insulin resistance. However, MHO individuals present a higher all-cause mortality compared with normal weight metabolically healthy individuals. Long-term results from the Whitehall study support the notion that MHO is a transient phase moving towards glucometabolic abnormalities rather than a specific ‘state’.

3a.6.4 The obesity paradox in established heart disease

At the population level, obesity is associated with CVD risk. However, among those with established CAD, the evidence is contradictory. Systematic reviews of patients with CAD or undergoing percutaneous coronary intervention have suggested an ‘obesity paradox’ whereby obesity appears protective. This is also the case for HF patients. However, this evidence should not be misinterpreted to recommend higher target BMIs for those with established CVD since reverse causality may be operating. Cardio-respiratory fitness might influence relationships between adiposity and clinical prognosis in the obesity paradox. Normal weight unfit individuals have a higher risk of mortality than fit individuals, regardless of their BMI. Overweight and obese fit individuals have mortality risks similar to normal weight fit individuals. Furthermore, the results of the EPIC study suggest that the influence of physical inactivity on mortality appears to be greater than that of high BMI.

3a.6.5 Treatment goals and modalities

CVD risk has a continuous positive relationship with BMI and other measures of body fat. Because all-cause mortality appears to increase at BMI levels < 20, we do not recommend such low BMI levels as treatment goals. Although diet, exercise and behaviour modifications are the mainstay therapies for overweight and obesity, they are often unsuccessful for long-term treatment. Medical therapy with orlistat and/or bariatric surgery are additional options. A recent meta-analysis indicates that patients undergoing bariatric surgery have a reduced risk of MI, stroke, CV events and mortality compared with non-surgical controls.

Gaps in evidence

- Knowledge and implementation of effective strategies to achieve weight loss and maintain a long-term healthy weight.
- Identification of the relative roles of diet, exercise and behaviour modification in the management of overweight and obese people.
- The optimal level of BMI over the life course (at older ages and after a CV event).
3a.7 Lipid control

Key messages
- Elevated levels of plasma LDL-C are causal to atherosclerosis.
- Reduction of LDL-C decreases CV events.
- Low HDL-C is associated with increased CV risk, but manoeuvres to increase HDL-C have not been associated with a decreased CV risk.
- Lifestyle and dietary changes are recommended for all.
- Total CV risk should guide the intensity of the intervention.
- Total cholesterol and HDL-C are adequately measured on non-fasting samples, thus allowing non-HDL-C to be derived.

3a.7.2 Total and low-density lipoprotein cholesterol

Most cholesterol is normally carried in LDL-C. Over a wide range of plasma cholesterol concentrations, there is a strong and graded positive association between total as well as LDL-C and risk of CVD. This association applies to men and women, and to those without CVD as well as with established CVD.

The evidence that reducing plasma LDL-C reduces CVD risk is unequivocal; the results of epidemiological studies and trials with and without statins using angiographic or clinical endpoints confirm that the reduction of LDL-C is of prime concern in the prevention of CVD.

Meta-analyses of many statin trials show a dose-dependent relative reduction in CVD with LDL-C lowering. Every 1.0 mmol/L reduction in LDL-C is associated with a corresponding 20–25% reduction in CVD mortality and non-fatal MI.

3a.7.3 Apolipoprotein B

Apolipoprotein B (apoB; the main apoprotein of atherogenic lipoproteins) levels have also been measured in outcome studies in parallel with LDL-C. Based on the available evidence, it appears that apoB is a similar risk marker to LDL-C. Also, there appears to be less laboratory error in the determination of apoB than LDL-C, particularly in patients with marked hypertriglyceridaemia. ApoB > 3.4 mmol/L (400 mg/dL), but there is no evidence that apoB is a better predictor of CVD than LDL-C.

3a.7.4 Triglycerides

Hypertriglyceridaemia is a significant independent CVD risk factor, but the association is far weaker than for hypercholesterolaemia. The risk is associated more strongly with moderate than with very severe hypertriglyceridaemia (> 10 mmol/L (> 900 mg/dL)), which is a risk factor for pancreatitis. There are, however, no randomized trials to provide sufficient evidence to derive target levels for triglycerides. Meta-analyses suggest that targeting triglycerides may reduce CVD in specific subgroups with high triglycerides and low HDL-C. At present, fasting triglycerides > 1.7 mmol/L (> 150 mg/dL) continue to be considered a marker of increased risk, but concentrations ≤ 1.7 mmol/L are not evidence-based target levels for therapy.

3a.7.5 High-density lipoprotein cholesterol

Low HDL-C is independently associated with higher CVD risk. Low HDL-C may even rival hypercholesterolaemia (due to high concentrations of LDL-C) as a risk factor for CAD. The combination of moderately elevated triglycerides and low concentrations of HDL-C is very common in patients with type 2 DM, abdominal obesity and insulin resistance and in those who are physically inactive. This lipid pattern is also characterized by the presence of small, dense, atherogenic LDL particles. An HDL-C level < 1.0 mmol/L (< 40 mg/dL) in men and < 1.2 mmol/L (< 45 mg/dL) in women may be regarded as a marker of increased risk. Recent Mendelian randomization studies, however, cast doubt on the causal role of HDL-C in CVD. Physical activity and other lifestyle factors, rather than drug treatment, remain important means of increasing HDL-C levels.
3a.7.6 Lipoprotein(a)
Lipoprotein(a) [Lp(a)] is a low-density lipoprotein to which an additional protein called apolipoprotein(a) is attached. High concentrations of Lp(a) are associated with increased risk of CAD and ischaemic stroke and Mendelian randomization studies support a causal role in CVD for Lp(a). There is no randomized intervention study showing that reducing Lp(a) decreases CVD risk. However, there is insufficient evidence to support this variable as a treatment goal. Since the measurement of apolipoproteins is not available to all physicians in Europe, it is more costly than currently used lipid variables and only adds moderately to the information derived from currently applied lipid parameters, its use is not recommended.

3a.7.7 Apolipoprotein B/apolipoprotein A1 ratio
Apolipoprotein A1 (apoA1) is the major apoprotein of high-density lipoprotein. It is beyond doubt that the apoB/apoA1 ratio is one of the strongest risk markers. However, there is insufficient evidence to validate this variable as a treatment goal. Since the measurement of apolipoproteins is not available to all physicians in Europe, it is more costly than currently used lipid variables and only adds moderately to the information derived from currently applied lipid parameters, its use is not recommended.

3a.7.8 Calculated lipoprotein variables

3a.7.8.1 Low-density lipoprotein cholesterol
LDL-C can be measured directly, but in most studies and in many laboratories LDL-C is calculated using the Friedewald formula:363

\[ LDL-C = \text{total cholesterol} - \text{HDL-C} - (0.45 \times \text{triglycerides}) \]

\[ LDL-C = \text{total cholesterol} - \text{HDL-C} - (0.2 \times \text{triglycerides}) \]

The calculation is valid only when the concentration of triglycerides is \(<4.5 \text{ mmol/L (}< ~400 \text{ mg/dL)}\). Similar problems may be faced when LDL-C is low [\(< ~1.3 \text{ mmol/L (<50 mg/dL)}\)]. Direct methods may be less sensitive to plasma triglyceride levels. However, recent data show that the direct methods may also be biased when triglyceride levels are high. Also, the values obtained with the different direct methods are not necessarily identical, especially for low and high LDL-C values.

3a.7.8.2 Non-high-density lipoprotein cholesterol
(accurate in non-fasting samples)
Non-HDL-C comprises the cholesterol in low-density lipoprotein, intermediate-density lipoprotein, remnant and VLDL, thus capturing all the information regarding pro-atherogenic lipoproteins. Non-HDL-C predicts CVD risk even better than LDL-C. LDL-C limits may be transferred to non-HDL-C limits by adding 0.8 mmol/L (30 mg/dL). Calculated by simply subtracting HDL-C from total cholesterol, non-HDL-C, unlike LDL-C, does not require the triglyceride concentration to be \(<4.5 \text{ mmol/L (<400 mg/dL)}\). Therefore, it is certainly a better measure than calculated LDL-C for patients with increased plasma triglyceride concentrations, but also has an additional advantage of not requiring patients to fast before blood sampling. There is evidence for a role of non-HDL-C as a treatment target. Since non-HDL-C is capturing the information regarding all the atherogenic apoB-containing lipoproteins, we suggest that it is a reasonable alternative treatment goal while acknowledging that it has not been an endpoint in therapeutic trials.

3a.7.8.3 Remnant cholesterol
Recently the remnant cholesterol [total cholesterol - (HDL-C + LDL-C)] has been shown to be causally related to atherosclerosis in Mendelian randomization studies. This parameter, however, is not suggested as a predictor or main target for therapy and further population data and clinical studies are awaited.

3a.7.9 Exclusion of secondary and familial dyslipidaemia
The presence of dyslipidaemias secondary to other conditions must be excluded before beginning treatment, as treatment of underlying disease improves hyperlipidaemia without requiring antilipidaemic therapy. This is particularly true for hypothyroidism. Secondary dyslipidaemias can also be caused by alcohol abuse, DM, Cushing’s syndrome, diseases of the liver and kidneys and several drugs (e.g. corticosteroids). Patients who could have genetic dyslipidaemias, such as FH, can be identified by extreme lipid abnormalities and/or family history. If possible, these patients should be referred for specialist evaluation. The treatment recommendations in this guideline may not apply to these specific patients, who are dealt with in detail in the ESC/European Atherosclerosis Society guidelines on dyslipidaemias. An LDL-C >5.1 mmol/L (>200 mg/dL) in therapy-naive patients requires careful evaluation for possible FH. However, in the presence of premature CVD or family history, possible FH should be considered at lower LDL-C levels.

3a.7.10 Who should be treated and what are the goals?
In general, RCTs are the ideal evidence base for decisional thresholds and treatment goals. For treatment goals, this requires RCTs randomly allocating subjects to different lipid goal levels. However, most evidence in terms of treatment goals is derived from observational studies and from post hoc analyses of RCTs (and meta-regression analyses thereof) randomly allocating different treatment strategies (and not treatment goals). Hence, recommendations reflect consensus based on large-scale epidemiological data and RCTs comparing treatment regimens, not on RCTs comparing different lipid goal levels.

In the past, an LDL-C of 2.6 mmol/L (100 mg/dL) has been considered a treatment threshold and goal. This goal remains reasonable for most patients who have an indication for LDL-C-lowering therapy based on calculation of the CV risk (see section 2). Evidence from trials has suggested that lowering LDL-C to \(<1.8 \text{ mmol/L (<70 mg/dL)}\) is associated with a lower risk of recurrent CVD events. Therefore, an LDL-C level of 1.8 mmol/L (70 mg/dL) appears to be a reasonable goal for prevention of recurrent CV events and in other very-high-risk subjects. A treatment goal of an LDL-C reduction of at least 50% is also recommended if the baseline LDL-C level is 1.8–3.5 mmol/L (70–135 mg/dL).

Non-HDL-C target values may be an alternate target if non-fasting samples are obtained, and goals should be \(<2.6, <3.3 \text{ and } <3.8 \text{ mmol/L (<100, <130 and <145 mg/dL)}\) with very high, high and low to moderate CV risk, respectively. In addition, this is a secondary goal in people with elevated triglycerides. In the same subjects, although not generally recommended, apoB levels at \(<80 \text{ and } <100 \text{ mg/dL can be reasonable goals for subjects with very high and high CV risk, respectively.}

The benefit of cholesterol-lowering therapy depends on initial levels of risk: the higher the risk, the greater the benefit in absolute risk reduction (Table 13). There are no differences in the relative reduction between men and women and between younger and older age or between those with and without DM.
3a.7.11 Patients with kidney disease
CKD can be characterized by mixed dyslipidaemia (high triglycerides, high LDL-C and low HDL-C). Statin therapy has a beneficial effect on CVD outcomes in CKD and in some studies slows the rate of kidney function loss. Similar data have been observed for combination therapy of a statin with ezetimibe, but not for ezetimibe alone. For patients with end-stage renal disease, we recommend that hypolipidaemic therapy should not be initiated. If patients with CKD already on a hypolipidaemic therapy enter end-stage renal disease, the therapy may be maintained.

3a.7.12 Drugs
The currently available lipid-lowering drugs include inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (statins), fibrates, bile acid sequestrants (anion exchange resins), niacin (nicotinic acid), selective cholesterol absorption inhibitors (e.g. ezetimibe) and, more recently, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. Response to all therapy varies widely among individuals and therefore monitoring the effect on LDL-C levels is recommended.

Statins, by decreasing LDL-C, reduce CV morbidity and mortality as well as the need for coronary artery interventions.

3a.7.13 Drugs and concomitant therapy
Increased levels of liver enzymes in plasma occur occasionally during statin therapy, and in most cases are reversible. Routine monitoring of liver enzyme values is not indicated. In addition, 5–10% of patients receiving statins complain of myalgia, but rhabdomyolysis is extremely rare. The risk of myopathy (severe muscular symptoms) can be minimized by identifying vulnerable patients and/or by avoiding statin interactions with specific drugs (see Table E in web addenda). Because statins are prescribed on a long-term basis, possible interactions with other drugs deserve particular and continuous attention, as many patients will receive pharmacological therapy for concomitant hyperlipidaemia.

Data indicate that combination therapy with ezetimibe also brings a benefit that is in line with the Cholesterol Treatment Trialist’s (CTT) Collaboration meta-analysis supporting the notion that LDL-C reduction is key to the achieved benefit independent of the approach used. Statins at doses that effectively reduce LDL-C by at least 50% also seem to halt progression or even contribute to regression of coronary atherosclerosis. Statins also lower triglycerides, and meta-analysis evidence shows statins may also lower pancreatitis risk. Therefore, they should be used as the drugs of first choice in patients with hypercholesterolaemia or combined hyperlipidaemia.

Table 13 Possible intervention strategies as a function of total cardiovascular risk and low-density lipoprotein cholesterol level

<table>
<thead>
<tr>
<th>Total CV risk (SCORE)</th>
<th>LDL-C levels</th>
<th>Classa/Levelb</th>
<th>Classa/Levelb</th>
<th>Classa/Levelb</th>
<th>Classa/Levelb</th>
</tr>
</thead>
<tbody>
<tr>
<td>%</td>
<td>&lt;70 mg/dL</td>
<td>70 to &lt;100 mg/dL</td>
<td>100 to &lt;155 mg/dL</td>
<td>155 to &lt;190 mg/dL</td>
<td>≥190 mg/dL</td>
</tr>
<tr>
<td>&lt;1</td>
<td>Lifestyle advice</td>
<td>Lifestyle advice</td>
<td>Lifestyle advice</td>
<td>Lifestyle advice</td>
<td>Lifestyle advice, consider drug if uncontrolled</td>
</tr>
<tr>
<td>≥1 to &lt;5</td>
<td>Lifestyle advice</td>
<td>Lifestyle advice</td>
<td>Lifestyle advice, consider drug if uncontrolled</td>
<td>Lifestyle advice, consider drug if uncontrolled</td>
<td>Lifestyle advice, consider drug if uncontrolled</td>
</tr>
<tr>
<td>≥5 to &lt;10, or high-risk</td>
<td>Lifestyle advice</td>
<td>Lifestyle advice, consider drug if uncontrolled</td>
<td>Lifestyle advice and drug treatment for most</td>
<td>Lifestyle advice and drug treatment</td>
<td>Lifestyle advice and drug treatment</td>
</tr>
<tr>
<td>≥10 or very high-risk</td>
<td>Lifestyle advice, consider drug</td>
<td>Lifestyle advice and concomitant drug treatment</td>
<td>Lifestyle advice and concomitant drug treatment</td>
<td>Lifestyle advice and concomitant drug treatment</td>
<td>Lifestyle advice and concomitant drug treatment</td>
</tr>
</tbody>
</table>

CV = cardiovascular; LDL-C = low-density lipoprotein cholesterol; SCORE = Systematic Coronary Risk Estimation.

aClass of recommendation.
bLevel of evidence.

Guidance on the use of drug treatment must be interpreted in the light of the physician’s judgement and knowledge with regards to his or her individual patient. Note that risk stratification is not applicable in familial hypercholesterolaemia, where drug treatment is recommended, and that, in this table, drug treatment may be considered at risks lower than the generic treatment thresholds indicated in paragraph 2.3.5. Thus treatment may occasionally be considered in moderate risk (1–5%) individuals, provided that patients are well-informed of the limited absolute risk reduction, and high numbers needed to treat. In higher risk (5–10%), drug therapy is associated with somewhat larger absolute benefits, and should at least be considered. Drug therapy is strongly advised in those at very high risk (≥10%). If baseline LDL-C in this category is already below the target level of 1.8 mmol/L, benefit of statin therapy initiation is less certain, but may still be present.
Lifestyle management to aid weight control by sustainable dietary changes and increased PA levels should be central in the management of patients with type 2 DM.

- Intensive treatment of BP in DM, with a target of 140 mmHg systolic for the majority, reduces the risk of macrovascular and microvascular outcomes. A lower SBP target of 130 mmHg further lessens the risks for stroke, retinopathy and albuminuria and should be applied to selected patients.

- Lipid lowering is a key mechanism to lower CVD risk in both type 2 and type 1 DM. All patients >40 years of age and selected younger patients at elevated risk are recommended for statin therapy.

- In DM patients with existing CVD, the use of a sodium-glucose co-transporter-2 (SGLT2) inhibitor substantially lessened CVD and total mortality and HF hospitalisation without major adverse effects. SGLT2 inhibitors should be considered early in the course of DM management in such patients.

- Recent evidence points to sizeable reductions in CVD mortality in DM patients via improvements in risk factor management, although the increasing worldwide DM prevalence will create major challenges. More should be done to prevent DM.
Recommendations for management of diabetes

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Class*</th>
<th>Level†</th>
<th>Ref⁵</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lifestyle changes including smoking cessation, low fat diet, high fibre diet, aerobic physical activity, and strength training are recommended.</td>
<td>I</td>
<td>A</td>
<td>387</td>
</tr>
<tr>
<td>Reduction in energy intake is recommended to patients to help achieve lower weight or prevent weight gain.</td>
<td>I</td>
<td>B</td>
<td>387</td>
</tr>
<tr>
<td>A target HbA1c for the reduction in risk of CVD and microvascular complications in DM of &lt;7.0% (&lt;53 mmol/mol) is recommended for the majority of non-pregnant adults with either type 1 or type 2 DM.</td>
<td>I</td>
<td>A</td>
<td>388, 389</td>
</tr>
<tr>
<td>For patients with a long duration of DM, the elderly, frail, or those with existing CVD, a relaxing of the HbA1c targets (i.e. less stringent) should be considered.</td>
<td>IIa</td>
<td>B</td>
<td>389</td>
</tr>
<tr>
<td>A target HbA1c of ≤6.5% (≤48 mmol/mol) should be considered at diagnosis or early in the course of type 2 DM in patients, who are not frail and do not have CVD.</td>
<td>IIa</td>
<td>B</td>
<td>389</td>
</tr>
<tr>
<td>When screening for DM in individuals with or without CVD, assessment of HbA1c (which can be done non-fasting) or fasting blood glucose should be considered. An oral glucose tolerance test can be offered when there is still doubt.</td>
<td>IIa</td>
<td>A</td>
<td>390</td>
</tr>
<tr>
<td>Metformin is recommended as first-line therapy if tolerated and not contra-indicated, following evaluation of renal function.</td>
<td>I</td>
<td>B</td>
<td>391</td>
</tr>
<tr>
<td>Avoidance of hypoglycaemia and excessive weight gain should be considered and individual approaches (with respect to both treatment targets and drug choices) should be considered in patients with advanced disease.</td>
<td>IIA</td>
<td>B</td>
<td>389, 392, 393</td>
</tr>
<tr>
<td>In patients with type 2 DM and CVD, the use of an SGLT2 inhibitor should be considered early in the course of the disease to reduce CV and total mortality.</td>
<td>IIA</td>
<td>B</td>
<td>394</td>
</tr>
<tr>
<td>Lipid lowering agents (principally statins) are recommended to reduce CV risk in all patients with type 2 or type 1 DM above the age of 40 years.</td>
<td>I</td>
<td>A</td>
<td>371, 372</td>
</tr>
<tr>
<td>Lipid lowering agents (principally statins) may be considered also in individuals below 40 years of age if at significantly elevated risk, based on the presence of micro-vascular complications or other major CV risk factors.</td>
<td>IIb</td>
<td>A</td>
<td>371, 372</td>
</tr>
<tr>
<td>In DM patients at very high-risk (see table 5), a LDL-C target &lt;1.8 mmol/L (&lt;70 mg/dL), or a reduction of at least 50% if the baseline LDL-C is between 1.8 and 3.5 mmol/L (70 and 135 mg/dL), is recommended.⁴ In DM patients with high-risk (see table 5), LDL-C target &lt;2.6 mmol/L (&lt;100mg/dL) or a reduction of at least 50% if the baseline LDL-C is between 2.6 and 5.1 mmol/L (100 and 200 mg/dL) is recommended.⁴</td>
<td>I</td>
<td>B</td>
<td>395</td>
</tr>
<tr>
<td>BP targets in type 2 DM are generally recommended to be &lt;140/85 mmHg, but a lower target of &lt;130/80 mmHg is recommended in selected patients (e.g. younger patients at elevated risk for specific complications) for additional gains on stroke, retinopathy and albuminuria risk. Renin-angiotensin-aldosterone system blocker is recommended in the treatment of hypertension in DM, particularly in the presence of proteinuria or micro-albuminuria. Recommended BP target in patients with type 1 DM is &lt;130/80 mmHg.</td>
<td>I</td>
<td>B</td>
<td>396, 397</td>
</tr>
<tr>
<td>The use of drugs that increase HDL-C to prevent CVD in type 2 DM is not recommended.</td>
<td>III</td>
<td>A</td>
<td>386</td>
</tr>
<tr>
<td>Antithrombotic therapy (e.g. with aspirin) is not recommended for people with DM who do not have CVD.</td>
<td>III</td>
<td>A</td>
<td>398</td>
</tr>
</tbody>
</table>

BP = blood pressure; CV = cardiovascular; DM = diabetes mellitus; HbA1c = glycated haemoglobin; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol; SGLT2 = Sodium-glucose co-transporter-2.

*Class of recommendation.
†Level of evidence.
‡Reference(s) supporting recommendations.
§Non-HDL-C is a reasonable and practical alternative target because it does not require fasting. Non-HDL-C secondary targets of <2.6 and <3.3 mmol/L (<100 and <130 mg/dL) are recommended for very high, and high-risk subjects, respectively. See section 3a.7.10 for more details.

People with DM are on average at double the risk of CVD.⁴⁹⁹ A simple DM risk questionnaire can guide which patients without CVD should be tested for DM.⁴⁰⁰

Keeping close to the recommended targets for BP, lipid control, glycaemia and HbA1c is important for the prevention of CVD. Clear reductions have occurred in CVD death rates in DM consistent with better management of risk factors, although the increasing prevalence of DM continues to create pressures on all health care systems.

The targets, especially the glycaemic and in some cases lipids, should be less stringently implemented in older people with DM, those with a longer duration of DM, those with evidence of CVD and the frail.⁴⁰¹ There is mounting evidence for a very high relative risk in younger individuals with type 2 DM (age <40 years),⁴⁰² and additional guidance on care is needed.

Except for glucose management, prevention of CVD follows the same general principles as for people without DM. Achieving low BP levels and low LDL-C and total cholesterol concentrations is particularly important. Many treatment targets are more stringent for patients with DM. Typically, patients with type 2 DM have multiple CVD risk factors, each requiring treatment according to existing guidelines.

3a.8.1 Lifestyle intervention

The ESC and European Association for the Study of Diabetes scientific statements advocate lifestyle management as a first
measure for the prevention and management of DM. Most patients with DM are obese, so weight control is a central component. Several dietary patterns can be adopted where the predominance of fruits, vegetables, wholegrain cereals and low-fat protein sources is more important than the precise proportions of total energy provided by the major macronutrients. Salt intake should be restricted. Specific dietary recommendations include limiting saturated and trans fats and alcohol intake, monitoring carbohydrate consumption and increasing dietary fibre. A Mediterranean-type diet is acceptable, where fat sources are derived primarily from monounsaturated oils.

A combination of aerobic and resistance exercise training is effective in the prevention of the progression of DM and for the control of glycaemia. Little is known about how to promote and sustain PA; however, reinforcement by health care providers to patients to find sustainable ways to increase PA is crucial. Smoking increases the risk of DM, CVD and premature death and should be strongly discouraged (see section 3a.4.5). Lifestyle intervention can also prevent DM development in those at elevated risk and, in turn, lowers future microvascular and macrovascular risks.

3a.8.2 Cardiovascular risk
At diagnosis or in those with a short duration of disease, DM is not a CAD risk equivalent state. In general, risk levels approach CAD risk equivalence after about a decade or in those with proteinuria or low eGFR. Emerging data suggest that patients who develop DM at a younger age have a high complication burden. People with DM and with existing CAD have a vascular risk well in excess of those with CAD but without DM and a substantially lower life expectancy.

Statins are recommended for all those newly diagnosed with type 2 DM beyond a certain age (>40 years is currently recommended). This recommendation reflects greater lifetime vascular risk trajectories in these individuals. However, a proportion of DM patients at 40–50 years of age may have a low 10 year risk of CVD due to the reduction in newly diagnosed patients with DM but not treated with modern BP- or lipid-lowering therapies, with the best evidence to support metformin, leading to its position as first-line therapy.

3a.8.3 Glucose control
The UK Prospective Diabetes Study (UKPDS) established the importance of intensive glucose lowering with respect to CVD risk reduction in newly diagnosed patients with DM but not treated with modern BP- or lipid-lowering therapies, with the best evidence to support metformin, leading to its position as first-line therapy. Three trials were conducted to see if CV events could be reduced further with more intensive glycaemia treatment and lower target HbA1c levels. However, the results were surprising, with unexpected increases in total and CVD deaths in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial and a trend towards an increase in CVD death in the Veterans Affairs Diabetes Trial (VADT). The results prompted concerns about the safety of intensive glucose lowering and the appropriateness of pursuing tight glucose control, particularly in older people with DM and in those with existing CVD. Subsequent meta-analyses of intensive glucose control, including data from UKPDS, Prospective Pioglitazone Clinical Trial in Macrovascular Events (PROactive), ACCORD, Action in Diabetes and Vascular disease: PreterAx and DiaMicon MR Controlled Evaluation (ADVANCE) and VADT, showed significant reductions in non-fatal AMI and CAD events, but no effect on stroke or total mortality. The additional analyses of these trials suggested that CVD benefits for an average HbA1c reduction of ~0.9% over 5 years were far less than via usual reductions in cholesterol and BP seen with statins and available BP-lowering agents. Four recent trials of newer DM therapies (DPP-4 and GLP-1) from patients with DM and existing CVD or at high risk demonstrated non-inferiority (i.e. safety) but not superiority with respect to CVD risk. There was, however, an increase in the rate of hospitalization for HF with saxagliptin in the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus – Trombolyis in Myocardial Infarction (SAVOR-TIMI 53) trial.

Very recently, the SGLT2 inhibitor empagliflozin demonstrated substantial reductions in CVD death (by 38%) and all-cause mortality (by 32%), as well as in hospitalisation for HF (by 35%), as compared with standard care, suggesting use of an SGLT2 inhibitor should come very early in the course of management of patients with DM and CVD. The pattern of trial results whereby non-fatal MI and stroke were not reduced by active treatment, as well as the rapid separation of mortality curves, suggest that the mechanism of benefit was likely to relate more to cardio-renal haemodynamic effects than to atherothrombotic actions or effects of glucose lowering per se. More research on understanding the trial results is needed.

3a.8.4 Blood pressure
In people with type 2 DM, apart from lifestyle interventions, the reduction of BP (along with cholesterol) should be targeted as strictly as targeting glucose/HbA1c levels. BP targets should be considered regardless of overall CV risk score in patients with type 2 DM.

Hypertension is more common in patients with type 2 DM compared with the general population. A recent systematic review and meta-analysis of randomized trials of BP-lowering agents in >100,000 patients with type 2 DM confirmed that lowering BP reduces the risk of all-cause mortality, CV events, CAD events, stroke, HF, retinopathy, new or worsening albuminuria and renal failure. The results were similar when trials with low risk of bias were selected. Furthermore, a systolic target <140 mmHg lessens the risk of total mortality and most separate outcomes. Further reductions in the risk for albuminuria, retinopathy and stroke, but not in overall survival or aggregate clinical endpoints, were achieved with a systolic target <130 mmHg. In people >80 years of age, targets should be set higher, aiming for <150/90 mmHg, unless renal impairment is present.

Combination treatment is commonly needed to lower BP effectively in DM. An ACE-I or an angiotensin receptor blocker (ARB), where tolerated, should always be included as first-line therapy because of the evidence of superior protective effects against initiation or progression of nephropathy.

3a.8.5 Lipid-lowering therapy
The Heart Protection Study (HPS) demonstrated that treatment with simvastatin 40 mg reduced the risk of CAD and stroke in people with DM and individuals without DM who had no prior AMI or angina pectoris. Further robust support for statin benefit came from the Collaborative Atorvastatin Diabetes Study (CARDS), which compared 10 mg atorvastatin with placebo and from the
CTT meta-analysis in DM patients. There is also trial evidence to show greater CVD risk reduction with more intense statin therapy in DM patients. More recent trial evidence shows a clear CVD benefit of lowering LDL-C with ezetimibe on top of a statin in patients with type 2 DM. Emerging evidence also shows that PCSK9 inhibitors are equally efficacious in lowering LDL-C in type 2 DM patients, although results of CV outcome trials are awaited. Lower treatment targets should be pursued in patients with type 2 DM who have overt CVD or CKD.

While the most common lipid abnormality in type 2 DM is elevated triglyceride and low HDL-C, trials examining possible CVD benefits of lipid (mainly triglyceride) lowering with fibrates in DM have not been positive. The US Food and Drug Administration (FDA) states that the current evidence base is insufficient to support fibrates for CVD protection and that more trial evidence is needed.

Prescribing of lipid-lowering agents in older people with DM (>85 years) requires special consideration because exposure to higher doses (or higher potency) may not increase life expectancy, but may increase the risk of adverse effects.

3a.8.6 Antithrombotic therapy

Patients with type 1 or type 2 DM have an increased tendency to develop thrombotic phenomena. The Antiplatelet Trialists’ Collaboration meta-analysis demonstrated the benefits of antithrombotic therapy (mainly aspirin) in patients with DM with clinically established CAD, cerebrovascular disease or other forms of thrombotic disease, with a 25% reduction in risk of CV events.

The role of aspirin in patients without CVD remains unproven. A meta-analysis of six RCTs found no statistically significant reduction in the risk of major CV events or all-cause mortality when aspirin was compared with placebo or no aspirin in people with DM and no pre-existing CVD. Further trials are ongoing.

3a.8.7 Microalbuminuria

Microalbuminuria (urinary albumin excretion from 30 to 300 mg/24 h) predicts the development of overt nephropathy in patients with type 1 or type 2 DM, while the presence of overt proteinuria (300 mg/24 h) generally indicates established renal parenchymal damage. In patients with DM and hypertension, microalbuminuria—even below the current threshold values—predicts CV events, and a continuous relationship between CV as well as non-CV mortality and urinary protein/creatinine ratios has been reported. Microalbuminuria can be measured from spot urine samples (due to inaccuracy in sampling, 24 h or night-time urine collection is discouraged) by indexing the urinary albumin concentration to the urinary creatinine concentration (2.5/3.5–25/35 mg/mmol). Patients with DM and microalbuminuria or proteinuria should be treated with an ACE-I or ARB regardless of baseline BP.

Gaps in evidence

- There is a need to examine whether a type 2 DM CV risk score based on either 10 year or lifetime risk helps to improve targeting of preventative therapies and leads to a reduction in CV risk or a gain in lifetime years free from disease.
- Further trial data are needed to establish if the empagliflozin outcome findings hold for other classes of SGLT2 inhibitors and to better understand the mechanisms of benefit. It would also be useful to know if SGLT2 inhibitors lessen CV mortality and HF risks in patients with DM but without CVD.
- More research on the benefits of glucagon-like peptide 1 (GLP-1) receptor agonists on CVD risk is needed and trials are due to be reported in subsequent years. Early evidence suggests no CVD benefit with short-term use of dipeptidyl peptidase 4 (DPP-4) inhibitors in people at high risk for CVD, as reviewed.

3a.8.8 Type 1 diabetes

Key messages

- CVD and mortality risks have decreased in type 1 DM patients but remain unacceptably elevated in those with very poor glycaemic control or any evidence of kidney disease.
- Intensive management of hyperglycaemia in DM reduces the risk of macrovascular complications and premature mortality; a target of 6.5–7.5% (48–58 mmol/mol) HbA1c is recommended.
- The recommended BP target in the majority of patients with type 1 DM is 130/80 mmHg.
- Lipid-lowering agents targeting LDL-C reduction should be recommended to the majority of patients >40 years of age and to those younger than this with evidence of nephropathy or with multiple risk factors.

Type 1 DM is the result of a lack of insulin production in the pancreas, confirmed by absent or virtually absent C-peptide levels. The average age of onset is ~14 years, although persons of any age can develop type 1 DM. Type 1 DM should be suspected in any patient who progresses to insulin within the first year of diagnosis. A large contemporary study in Scotland observed a relative risk for CVD events of 2.3 in men and 3 in women with type 1 DM compared with the general population, suggesting CVD risks may have declined over time, commensurate with improvements in life expectancy. Another report from Sweden demonstrated CVD mortality rates in type 1 DM to be twice the rates of the general population in those with HbA1c levels <6.6% (52 mmol/mol), whereas risk was especially high (10-fold) in those with very poor control (≥9.7% ≥83 mmol/mol). In the majority of studies, the risk of CVD events or mortality was highest among those with diabetic nephropathy, microalbuminuria or CKD. The presence of proliferative retinopathy and autonomic neuropathy also signalled an elevated CVD risk.

The Diabetes Control and Complications Trial (DCCT) established the importance of tight glucose control to lessen the risks of both microvascular and macrovascular disease. A 27 year follow-up of this trial showed that 6.5 years of initial intensive DM therapy in type 1 DM was associated with a modestly lower all-cause mortality rate when compared with conventional therapy. A glycaemic target for HbA1c of 6.5–7.5% (48–58 mmol/mol) appears to be a balanced approach for long-term care of patients with type 1 DM. The use of insulin analogues, insulin pumps and continuous glucose monitoring to improve glycaemic control while minimizing hypoglycaemia is the subject of intense research, as is the use of agents (e.g. metformin, GLP-1 agonists) commonly used in type 2 DM.

The CTT suggested lipid lowering with statins is as equally effective in type 1 patients as in type 2. All patients >40 years of age
with type 1 DM should be recommended for statins unless they have a short duration of DM and no other risk factors. Younger patients with multiple risk factors or evidence of end organ damage (albuminuria, low eGFR, proliferative retinopathy or neuropathy) should be considered for statin therapy.

A target BP of 130/80 mmHg is accepted practice in type 1 DM, with evidence of specific benefits of ACE-I or ARBs on the early development and later progression of microvascular disease in younger type 1 DM patients. A lower target BP of 120/75–80 mmHg may be helpful in younger type 1 DM patients (<40 years of age) with persistent microalbuminuria. Studies supporting improved CVD outcome in type 1 DM through BP reduction are lacking. As more patients with type 1 DM are living to older age, SBP targets may need to be relaxed (140 mmHg) in some to avoid side effects.

Current evidence suggests many patients with type 1 DM > 40 years of age continue to smoke, are still not receiving statins and, perhaps most importantly, have very poor glucose control. Further efforts to target these established risk factors are needed.

### Gaps in evidence
- Further studies are needed on metformin and GLP-1 receptor agonists in (subgroups of) patients with type 1 DM to determine whether they improve glycaemic control, aid in weight reduction and improve clinical outcomes.
- There is a need for a CVD risk score in type 1 DM to better guide initiation of preventative therapies in younger patients.

### 3a.9 Hypertension

#### Key messages
- Elevated BP is a major risk factor for CAD, HF, cerebrovascular disease, PAD, CKD and AF.
- The decision to start BP-lowering treatment depends on the BP level and total CV risk.
- Benefits of treatment are mainly driven by BP reduction per se, not by drug type.
- Combination treatment is needed to control BP in most patients.

### Recommendations for management of hypertension

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Classa</th>
<th>Levelb</th>
<th>Refc</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lifestyle measures (weight control, increased physical activity, alcohol moderation, sodium restriction, and increased consumption of fruits, vegetables, and low-fat dairy products) are recommended in all patients with hypertension and in individuals with high normal BP.</td>
<td>I</td>
<td>A</td>
<td>337, 428-430</td>
</tr>
<tr>
<td>All major BP lowering drug classes (i.e. diuretics, ACE-I, calcium antagonists, ARBs, and β-blockers) do not differ significantly in their BP-lowering efficacy and thus are recommended as BP lowering treatment.</td>
<td>I</td>
<td>A</td>
<td>431, 432</td>
</tr>
<tr>
<td>In asymptomatic subjects with hypertension but free of CVD, CKD, and DM, total CV risk stratification using the SCORE model is recommended.</td>
<td>I</td>
<td>B</td>
<td>30</td>
</tr>
<tr>
<td>Drug treatment is recommended in patients with grade 3 hypertension irrespective of CV risk, as well as in patients with grade 1 or 2 hypertension who are at very high CV risk.</td>
<td>I</td>
<td>B</td>
<td>433</td>
</tr>
<tr>
<td>Drug treatment should be considered in patients with grade 1 or 2 hypertension who are at high CV risk.</td>
<td>IIa</td>
<td>B</td>
<td>433</td>
</tr>
<tr>
<td>In patients at low to moderate total CV risk and with grade 1 or 2 hypertension, lifestyle measures are recommended.</td>
<td>I</td>
<td>B</td>
<td>433</td>
</tr>
<tr>
<td>In patients at low to moderate total CV risk and with grade 1 or 2 hypertension, if lifestyle measures fail to reduce BP, drug treatment may be considered.</td>
<td>IIb</td>
<td>B</td>
<td>433</td>
</tr>
<tr>
<td>SBP &lt;140 mmHg and DBP &lt;90 mmHg are recommended in all treated hypertensive patients &lt;60 years old.</td>
<td>I</td>
<td>B</td>
<td>433</td>
</tr>
<tr>
<td>In patients &gt;60 years old with SBP ≥160 mmHg, it is recommended to reduce SBP to between 150 and 140 mmHg.</td>
<td>I</td>
<td>B</td>
<td>434</td>
</tr>
<tr>
<td>In fit patients &lt;80 years old, a target SBP &lt;140 mmHg may be considered if treatment is well tolerated. In some of these patients a target SBP &lt;120 mmHg may be considered if at (very) high-risk and tolerate multiple BP lowering drugs.</td>
<td>IIb</td>
<td>B</td>
<td>434, 435</td>
</tr>
<tr>
<td>In individuals &gt;80 years and with initial SBP ≥160 mmHg, it is recommended to reduce SBP to between 150 and 140 mmHg, provided they are in good physical and mental conditions.</td>
<td>I</td>
<td>B</td>
<td>434</td>
</tr>
<tr>
<td>In frail elderly patients, a careful treatment intensity (e.g. number of BP lowering drugs) and BP targets should be considered, and clinical effects of treatment should be carefully monitored.</td>
<td>IIa</td>
<td>B</td>
<td>436</td>
</tr>
<tr>
<td>Initiation of BP lowering therapy with a two-drug combination may be considered in patients with markedly elevated baseline BP or at high CV risk. Combination of two drugs at fixed doses in a single pill may be considered because of improved adherence.</td>
<td>IIb</td>
<td>C</td>
<td>437</td>
</tr>
<tr>
<td>β-blockers and thiazide diuretics are not recommended in hypertensive patients with multiple metabolic risk factors, due to the increased risk of DM.</td>
<td>III</td>
<td>B</td>
<td>438</td>
</tr>
</tbody>
</table>

ACE-I = angiotensin-converting enzyme inhibitor; ARBs = angiotensin receptor blockers; BP = blood pressure; CKD = chronic kidney disease; CV = cardiovascular; CVD = cardiovascular disease; DBP = diastolic blood pressure; SBP = systolic blood pressure; SCORE = Systematic Coronary Risk Estimation.

aClass of recommendation.

bLevel of evidence.

cReference(s) supporting recommendations.

dOverweight, obesity, dyslipidaemia, impaired glucose tolerance.
3a.9.1. Introduction

High BP is a leading risk factor for disease burden globally, accounting for 9.4 million deaths and 7.0% of global disability-adjusted life-years (DALYs) in 2010. Compared with 1990, the impact of high BP has increased by ≏2.1 million deaths. Overall, the prevalence of hypertension is ≏30–45% in adult persons ≥18 years of age, with a steep increase with ageing.

Elevated BP is a risk factor for CAD, HF, cerebrovascular disease, PAD, CKD and AF. The risk of death from either CAD or stroke increases progressively and linearly from BP levels as low as 115 mmHg systolic and 75 mmHg diastolic upwards, although for absolute risk the curves flatten in the lower BP ranges.

3a.9.2 Definition and classifications of hypertension

The definition and classifications of hypertension are shown in Table 14.

3a.9.3 Blood pressure measurement

Office BP is recommended for screening and diagnosis of hypertension, which should be based on at least two BP measurements per visit and on at least two visits. If the BP is only slightly elevated, repeated measurements should be made over a period of several months to achieve an acceptable definition of the individual’s ‘usual’ BP and to decide about initiating drug treatment. If BP is more markedly elevated or accompanied by target organ damage, other CV factors or established CV or renal disease, repeated BP measurements are required within a shorter period in order to make treatment decisions.

3a.9.4 Office or clinic blood pressure measurement

Auscultatory or oscillometric semi-automatic sphygmomanometers should be validated and checked periodically. Measurement of BP at the upper arm is preferred, and cuff and bladder dimensions should be adapted to the arm circumference. If feasible, automated recording of multiple BP readings in the office, with the patient seated in an isolated room, might be considered as a means of improving reproducibility and matching office BP values closer to those provided by daytime ambulatory BP monitoring (ABPM) or home BP measurements (HBPMs).

3a.9.5 Out-of-office blood pressure monitoring

Out-of-office BP is commonly assessed by ABPM or HBPM, usually by self-measurement; it is usually lower than the office BP and the difference increases as office BP increases (Table 15).

The following general principles and remarks should be taken into account: (i) the procedure should be adequately explained to the patient, with verbal and written instructions; (ii) interpretation of the results should take into account that the reproducibility of out-of-office BP measurements is reasonably good for 24 h, day and night BP averages, but less so for shorter periods; (iii) ABPM and HBPM provide somewhat different information on the subject’s BP status and risk, and the two methods should thus be regarded as complementary rather than competitive; (iv) devices should be validated and regularly calibrated, at least every 6 months.

Both ABPM and HBPM values are closely related to diagnosis. Night-time BP seems to be a stronger predictor than daytime BP. Out-of-office measurement may be useful not only in untreated subjects, but also in treated patients, with the aim of monitoring the effects of treatment and increasing compliance with drug therapy.

3a.9.6 Diagnostic evaluation in hypertensive patients

Laboratory tests should include haemoglobin, fasting plasma glucose (HbA1c if not fasting) and serum tests for total cholesterol, HDL-C, triglycerides, potassium, uric acid, creatinine (and calculated renal function) and thyrotropin (in postmenopausal women). Urinalysis should include albumin:creatinine ratio, dipstick test, sediment and quantitative proteinuria if the dipstick test is positive. Echocardiography and fundoscopy can be considered. The routine measurement of additional biomarkers and/or the use of vascular imaging methods is not recommended.

Table 14. Definition and classification of blood pressure levels\(^a\)

<table>
<thead>
<tr>
<th>Category</th>
<th>Systolic BP (mmHg)</th>
<th>Diastolic BP (mmHg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Optimal</td>
<td>&lt;120</td>
<td>&lt;80</td>
</tr>
<tr>
<td>Normal</td>
<td>120–129</td>
<td>80–84</td>
</tr>
<tr>
<td>High-normal</td>
<td>130–139</td>
<td>85–89</td>
</tr>
<tr>
<td>Grade 1 hypertension</td>
<td>140–159</td>
<td>90–99</td>
</tr>
<tr>
<td>Grade 2 hypertension</td>
<td>160–179</td>
<td>100–109</td>
</tr>
<tr>
<td>Grade 3 hypertension</td>
<td>≥180</td>
<td>≥110</td>
</tr>
<tr>
<td>Isolated systolic hypertension</td>
<td>≥140</td>
<td>&lt;90</td>
</tr>
</tbody>
</table>

BP = blood pressure.
\(^a\)BP levels in untreated individuals.

Table 15. Blood pressure thresholds for definition of hypertension with different types of BP measurement

<table>
<thead>
<tr>
<th></th>
<th>SBP (mmHg)</th>
<th>DBP (mmHg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Office or clinic</td>
<td>140</td>
<td>90</td>
</tr>
<tr>
<td>24-hour</td>
<td>125–130</td>
<td>80</td>
</tr>
<tr>
<td>Day</td>
<td>130–135</td>
<td>85</td>
</tr>
<tr>
<td>Night</td>
<td>120</td>
<td>70</td>
</tr>
<tr>
<td>Home</td>
<td>130–135</td>
<td>85</td>
</tr>
</tbody>
</table>

DPB = diastolic blood pressure; SBP = systolic blood pressure.
### 3a.9.7 Risk stratification in hypertension

The decision to start pharmacological treatment depends not only on the BP level but also on total CV risk, outlined in section 2. However, even subclinical hypertensive organ damage predicts CV death independently of SCORE, and the combination may improve risk prediction, especially in subjects at moderate risk (SCORE 1–4%).[](#445)[](#446) Echocardiography is more sensitive than ECG in diagnosing LVH and in predicting CV risk, and may help in more precise stratification of the overall risk and in directing therapy.[](#447) An albumin:creatinine ratio > 30 mg/g in urine is also a marker of subclinical damage in hypertensive patients.

### 3a.9.8 Who to treat, and when to initiate antihypertensive treatment

The decision to start antihypertensive treatment depends on the BP level and total CV risk. Lifestyle changes are recommended in all patients with suboptimal BP, including masked hypertension. Prompt initiation of drug treatment is recommended in individuals with grade 3 hypertension with any level of CV risk.[](#431) Lowering BP with drugs is more frequently required when the total CV risk is very high and should also be considered when the risk is high (section 2.3.5).[](#435) Initiation of BP-lowering drug treatment may also be considered in grade 1 or 2 hypertensive patients at low to moderate risk when BP is within this range at several repeated visits or elevated by ambulatory BP criteria and remains within this range despite a reasonable period of time with lifestyle changes.[](#447) However, the NNT in this patient category is very high, and patients should be informed and their preference must be considered.

Lifestyle changes only with close BP monitoring should be the recommendation in young individuals with isolated moderate elevation of brachial SBP[](#446) and in individuals with high-normal BP who are at low or moderate risk.[](#447) Also, in white coat hypertensive patients without additional risk factors, therapeutic intervention should be limited to lifestyle changes, accompanied by close follow-up. Drug treatment may also be considered in white coat hypertensive patients with a higher CV risk because of metabolic derangements or in the presence of organ damage.

### 3a.9.9 How to treat

#### 3a.9.9.1 Lifestyle changes

Lifestyle interventions, weight control and regular PA alone may be sufficient for patients with high-normal and grade 1 hypertension, and should always be advised for patients receiving BP-lowering drugs, as these may reduce the dosage of BP-lowering drugs needed to achieve BP control. The lifestyle intervention specific to hypertension is salt restriction. At the individual level, effective salt reduction is by no means easy to achieve. As a minimum, advice should be given to avoid added salt and high-salt food. As the BP-lowering effect of increased potassium has been well documented in the DASH diet (rich in fruits, vegetables and low-fat dairy products with a reduced content of dietary cholesterol as well as saturated and total fat), patients with hypertension should generally be advised to eat more fruits and vegetables and to reduce their intake of saturated fat and cholesterol.[](#447)

#### 3a.9.9.2 Blood pressure-lowering drugs

The large number of randomized trials of BP-lowering therapy, both those comparing active treatment vs. placebo and those comparing different compounds, confirm that (i) the main benefits of BP-lowering treatment are due to lowering of BP per se, and are largely independent of the drugs employed; and (ii) thiazide and thiazide-like diuretics (chlorothalidone and indapamide), β-blockers, calcium antagonists, ACE-Is and ARBs can adequately lower BP and reduce the risk of CV death and morbidity.[](#331)[](#432) Thus these drugs are all recommended for initiation and maintenance of BP control, either as monotherapy or in combination. Some aspects should be considered for each of the BP-lowering drug groups.

The position of β-blockers as first-choice BP-lowering drugs has been questioned. A meta-analysis of 147 randomized trials[](#437) reports only a slight inferiority of β-blockers in preventing stroke (17% reduction rather than 29% reduction with other agents), but a similar effect in preventing CAD and HF, and higher efficacy in patients with a recent coronary event. However, since β-blockers induce weight gain, have adverse effects on lipid metabolism and increase (compared with other drugs) the incidence of DM, they are not preferred in hypertensive patients with multiple metabolic risk factors and conditions that increase the risk of new-onset DM (such as obesity, impaired fasting glucose). However, this may not apply to vasodilating β-blockers such as carvedilol and nebivolol, which have less or no dysmetabolic action, as well as a reduced incidence of new-onset DM compared with conventional β-blockers.

Thiazide diuretics also have dyslipidaemic and diabetogenic effects, particularly when used in high doses. Thiazides have often been administered together with β-blockers in trials showing a relative excess of new-onset DM.

ACE-Is and ARBs are particularly effective in reducing LVH, reducing microalbuminuria and proteinuria, preserving renal function and delaying end-stage renal disease.
Evidence concerning the benefits of other classes of agents is much more limited. The α₁ blockers, centrally acting agents (α₂ adrenergic receptor antagonists and imidazoline-receptor agonists), aldosterone drugs and the renin inhibitor aliskiren effectively lower BP in hypertension, but there are no data documenting their ability to improve CV outcome. All of these agents have frequently been used as added drugs in trials documenting CV protection and can thus be used for combination treatment in addition to the recommended combinations (see below).

Drugs with 24 h efficacy are preferred. Simplification of treatment improves adherence to therapy, and effective 24 h BP control is prognostically important in addition to office BP control. Long-acting drugs also minimize BP variability, which may offer protection against progression of organ damage and the risk of CV events.

Any all-purpose ranking of drugs for general BP lowering is infeasible and no evidence is available that different choices should be made based on age or sex (except for caution in using ACE-Is and ARBs in women of childbearing age because of possible teratogenic effects). Some agents should be considered as the preferred choice in specific conditions because they have been used in trials that included patients with those conditions or because of greater effectiveness in specific types of organ damage (Table 17).

**Table 17 Drugs to be preferred in specific conditions**

<table>
<thead>
<tr>
<th>Condition</th>
<th>Drug</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asymptomatic organ damage</td>
<td></td>
</tr>
<tr>
<td>LVH</td>
<td>ACE-I, calcium antagonist, ARB</td>
</tr>
<tr>
<td>Asymptomatic atherosclerosis</td>
<td>Calcium antagonist, ACE-I</td>
</tr>
<tr>
<td>Microalbuminuria</td>
<td>ACE-I, ARB</td>
</tr>
<tr>
<td>Renal dysfunction</td>
<td>ACE-I, ARB</td>
</tr>
<tr>
<td>Clinical CV event</td>
<td></td>
</tr>
<tr>
<td>Previous stroke</td>
<td>Any agent effectively lowering BP</td>
</tr>
<tr>
<td>Previous MI</td>
<td>β-blockers, ACE-I, ARB</td>
</tr>
<tr>
<td>Angina pectoris</td>
<td>β-blockers, calcium antagonist</td>
</tr>
<tr>
<td>Heart failure</td>
<td>Diuretic, β-blockers, ACE-I, ARB, mineralocorticoid receptor antagonist</td>
</tr>
<tr>
<td>Aortic aneurysm</td>
<td>β-blockers</td>
</tr>
<tr>
<td>Atrial fibrillation: prevention</td>
<td>Consider ARB, ACE-I, β-blockers or mineralocorticoid receptor antagonist</td>
</tr>
<tr>
<td>Atrial fibrillation: rate control</td>
<td>β-blockers, non-dihydropyridine calcium antagonist</td>
</tr>
<tr>
<td>ESRD/proteinuria</td>
<td>ACE-I, ARB</td>
</tr>
<tr>
<td>Peripheral artery disease</td>
<td>ACE-I, calcium antagonist</td>
</tr>
<tr>
<td>Other</td>
<td></td>
</tr>
<tr>
<td>ISH (elderly)</td>
<td>Diuretic, calcium antagonist</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>ACE-I, ARB</td>
</tr>
<tr>
<td>Pregnancy</td>
<td>Metyldopa, β-blockers, calcium antagonist</td>
</tr>
<tr>
<td>Black people</td>
<td>Diuretic, calcium antagonist</td>
</tr>
</tbody>
</table>

There is sufficient evidence to recommend that SBP be lowered to <140 mmHg and DBP to <90 mmHg in all non-elderly hypertensive patients. Evidence is missing in the elderly hypertensive patient, in whom the benefit of lowering SBP to <140 mmHg has not been tested in randomized trials.

A DBP target <90 mmHg is always recommended, except in patients with DM, in whom values <85 mmHg are recommended. Nevertheless, it should be considered that DBP values between 80 and 85 mmHg are generally safe and well tolerated.

Post hoc analyses of large-scale trials (e.g. ONTARGET, INVEST and VALUE), although suffering from the limitation posed by comparisons of non-randomized groups, suggest that, at least in high-risk hypertensive patients, there may be no advantage in lowering SBP to <130 mmHg, except perhaps for risk of stroke. A J-curve phenomenon for achieved SBP <130 mmHg cannot be excluded, mainly in patients with advanced atherosclerotic diseases and/or frailty.
The publication of the primary results of the Systolic Blood Pressure Intervention Trial (SPRINT), which compared the benefit of treatment of SBP to a target of <120 mmHg with treatment to a target of <140 mmHg, challenged the above goal recommendations in high-risk patients without DM.\textsuperscript{453} Frail elderly were under-represented in this trial. Targeting an SBP <120 mmHg compared with <140 mmHg (average values 121 mmHg and 136 mmHg, respectively, at the first year) resulted in lower rates of a combined outcome of fatal and non-fatal major CV events and death from any cause. However, significantly higher rates of serious adverse events, hypotension, syncope, electrolyte abnormalities and acute kidney injury or failure, but not injurious falls, were observed in the intensive-treatment group. The fact that the study was open label in a strategy close to usual care with frequent visits may have helped to adjust the antihypertensive treatment if serious side effects occurred and thus minimized the risk of events. Generalizability of the findings of SPRINT to patients with DM and to frail elderly is problematic.

Based on current data, it may still be prudent to recommend lowering SBP/DBP to values within the range 130–139/80–85 mmHg, and possibly close to the lower values in this range, in all hypertensive patients.

3a.9.11 Hypertension in special groups

3a.9.11.1 Diabetes mellitus

See section 3a.8.4.

3a.9.11.2 Elderly

Large meta-analyses confirm that treatment is highly beneficial in the elderly hypertensive patient. The proportional benefit in patients >60 years of age is no less than that for younger patients.

In patients >60 years of age with SBP ≥160 mmHg, there is solid evidence to recommend reducing SBP to 140–150 mmHg. However, in fit patients <80 years of age, BP-lowering treatment may be considered at SBP values ≥140 mmHg, with a target SBP <140 mmHg if treatment is well tolerated.

Evidence is now available from an outcome trial that BP-lowering treatment also has benefits in patients >80 years of age. Because patients in the Hypertension in the Very Elderly Trial (HYVET) were generally in good condition, the extent to which HYVET data can be extrapolated to more frail octogenarians is uncertain. In individuals >80 years of age with an initial SBP ≥160 mmHg, it is recommended to reduce SBP to 140–150 mmHg, provided the individual is in good physical and mental condition.\textsuperscript{436} The decision to treat should be made on an individual basis, and patients should always be carefully monitored during treatment, with BP also measured in the standing position. In frail elderly patients, it is recommended to be careful and reach a decision based on monitoring of the clinical effects of treatment.

3a.9.12 Resistant hypertension

The definition of hypertension resistant to treatment is when a therapeutic strategy that includes appropriate lifestyle measures plus a diuretic and two other BP-lowering drugs belonging to different classes at adequate doses (but not necessarily including a mineralocorticoid receptor antagonist) fails to lower SBP and DBP values to <140 mmHg and <90 mmHg, respectively. Depending on the population examined and the level of medical screening, the prevalence of resistant hypertension has been reported to range from 5 to 30% of the overall hypertensive population, with figures <10% probably representing the true prevalence. Resistant hypertension is associated with a high risk of CV and renal events.\textsuperscript{451} Before a patient is considered treatment resistant, consideration should be given to a lack of treatment adherence, white coat syndrome or high salt or alcohol intake, as well as drug intake with a potential pressor effect, the use of recreational drugs or secondary hypertension. In these patients, physicians should check whether the drugs included in the existing multiple drug regimen have any BP-lowering effect and withdraw them if their effect is absent or minimal. Anti-aldosterone drugs, amiloride or the α1 blocker doxazosin should be considered as the fourth or fifth drug, if no contra-indication exists (eGFR <45 mL/min/m² and/or serum potassium >4.5 mmol/L for mineralocorticoid receptor antagonists).

In the case of drug treatment ineffectiveness (i.e. resistant hypertension), specialist referral should be considered. Any invasive approach in these patients should be considered only for truly resistant hypertensive patients, with clinic values ≥160 mmHg SBP or ≥110 mmHg DBP and with BP elevation confirmed by ABPM.

3a.9.13 Duration of treatment and follow-up

Generally, BP-lowering therapy should be maintained indefinitely. Cessation of therapy in hypertensive patients is mostly followed by the return of BP to pretreatment levels. In some patients, in whom treatment is accompanied by effective BP control for an extended period, it may be possible to reduce the number and/or dosage of drugs. This may be particularly the case if BP control is accompanied by healthy lifestyle changes. A reduction of medications should be made gradually and the patient should be checked frequently because of the risk of reappearance of hypertension.

Patient follow-up should be carried out by the health care team, which should include physicians, nurses and pharmacists in a concerted activity, although wide variations exist in the organization of health care systems across Europe. In some countries, the task relies more on physicians, while in others, specially educated and trained nurses play a more prominent role. Once the target is reached, a visit interval of a few months is reasonable; there is no difference in BP control between 3 and 6 month intervals. The regression of asymptomatic organ damage occurring during treatment reflects the treatment-induced reduction of morbidity and fatal CV events;\textsuperscript{454} however, a cost-effectiveness analysis in which signs of organ damage should best be assessed in the follow-up has never been done.\textsuperscript{447}

Gaps in evidence

- Drug treatment in white coat hypertension.
- If and when drug treatment should be started in the high-normal BP range.
- The optimal office BP values (i.e. the most protective and safe) for patients to achieve by treatment in different demographic and clinical conditions.
• The optimal out-of-office (home and ambulatory) BP targets and whether the treatment strategies based on control of out-of-office BP provide an advantage over strategies based on conventional (office) BP control.

3a.10 Antiplatelet therapy

Key messages
• Antiplatelet therapy is not recommended in individuals free from CVD, due to the increased risk of major bleeding.

### Recommendations for antiplatelet therapy

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Class</th>
<th>Level</th>
<th>Ref</th>
</tr>
</thead>
<tbody>
<tr>
<td>In acute coronary syndromes, a P2Y12 inhibitor for 12 months is recommended in addition to aspirin, unless there are contra-indications such as excessive risk of bleeding.</td>
<td>I</td>
<td>A</td>
<td>455–457</td>
</tr>
<tr>
<td>P2Y12 inhibitor administration for a shorter duration of 3–6 months after DES implantation may be considered in patients deemed at high bleeding risk.</td>
<td>IIb</td>
<td>A</td>
<td>458–461</td>
</tr>
<tr>
<td>P2Y12 inhibitor administration in addition to aspirin beyond 1 year may be considered after careful assessment of ischaemic and bleeding risks of the patient.</td>
<td>IIb</td>
<td>A</td>
<td>462, 463</td>
</tr>
<tr>
<td>In the chronic phase (&gt;12 months) after MI, aspirin is recommended.</td>
<td>I</td>
<td>A</td>
<td>464</td>
</tr>
<tr>
<td>In patients with non-cardioembolic ischaemic stroke or TIA, prevention with aspirin only, or dipyridamole plus aspirin or clopidogrel alone is recommended.</td>
<td>I</td>
<td>A</td>
<td>465–467</td>
</tr>
<tr>
<td>Prasugrel is not recommended in patients with stable CAD. Ticagrelor is not recommended in patients with stable CAD without a previous ACS.</td>
<td>III</td>
<td>C</td>
<td>463</td>
</tr>
<tr>
<td>In patients with non-cardioembolic cerebral ischaemic events, anticoagulation is not recommended.</td>
<td>III</td>
<td>B</td>
<td>468, 469</td>
</tr>
<tr>
<td>Antiplatelet therapy is not recommended in individuals without CVD due to the increased risk of major bleeding.</td>
<td>III</td>
<td>B</td>
<td>464</td>
</tr>
</tbody>
</table>

ACS = acute coronary syndrome; CAD = coronary artery disease; DES = drug-eluting stent; MI = myocardial infarction; TIA = transient ischaemic attack.

### 3a.10.1 Antiplatelet therapy in individuals without cardiovascular disease

Prevention in individuals without overt CV or cerebrovascular disease was investigated using long-term aspirin vs. control in a systematic review of six trials including 95 000 individuals. A risk reduction from 0.57% to 0.51%/year of serious vascular events was found by the Antithrombotic Trialists’ Collaboration.464 Major gastrointestinal and extracranial bleeds increased by 0.03%/year. The risk of vascular mortality was not changed by treatment with aspirin. In a recent Japanese study,470 patients 60–85 years of age presenting with hypertension, dyslipidaemia or DM were randomized to treatment with 100 mg aspirin or placebo. The 5 year cumulative primary outcome event rate (death from CV causes) was not significantly different between the groups, but treatment with aspirin significantly increased the risk of extracranial haemorrhage requiring transfusion or hospitalization (P = 0.004). In individuals with multiple risk factors, clopidogrel in combination with aspirin vs. aspirin alone was tested in the Clopidogrel for High Atherothrombotic Risk and Ischaemic Stabilisation, Management, and Avoidance (CHARISMA) trial and was not of significant benefit.471 The results of the four major ongoing primary prevention trials—two in DM patients,472,473 one in individuals of advanced age,474 and one in individuals with moderate CV risk—are expected to become available over the next 5 years.

### 3a.10.2 Antiplatelet therapy in individuals with cardiovascular or cerebrovascular disease

In the acute state of cerebral ischaemia, aspirin reduced the risk of new vascular events within 2–4 weeks by preventing four recurrent strokes and five vascular deaths per 1000 patients treated.476

Following an episode of ACS, dual antiplatelet therapy given for a period of 12 months is a standard treatment based on results from the CURE,455 TRITON456 and PLATO457 studies, whereas no clinical studies support the use of prasugrel and ticagrelor in patients with stable CAD.

In long-term prevention after MI, stroke or PAD, aspirin is the most studied drug. In a meta-analysis of 16 trials comprising 17 000 individuals, the Antithrombotic Trialists’ Collaboration,464 aspirin treatment was associated with serious vascular events in 6.7%/patients/year vs. 8.2%/ of controls. The risk of total stroke was 2.08%/year vs. 2.59% (P = 0.002) and coronary events was 4.3%/year vs. 5.3% (P = 0.0001). Aspirin was associated with a 10% reduction in total mortality, with a significant excess of major bleeds; nevertheless, the benefits of aspirin exceeded the bleeding hazards.

In patients with prior MI, stroke or PAD, clopidogrel showed a slight superiority with respect to aspirin; the rate of serious vascular events was 5.32%/year with clopidogrel vs. 5.83%
with aspirin ($P = 0.043$). There were slightly more bleeds with aspirin.477

Adding aspirin to clopidogrel in high-risk patients with recent ischaemic stroke or transient ischaemic attack (TIA) was associated with a non-significant difference in reducing major vascular events. However, the risk of life-threatening or major bleeding was significantly increased by the addition of aspirin.478

On the other hand, the Clopidogrel in High-risk patients with Acute Non-disabling Cerebrovascular Events (CHANCE) trial showed that the combined treatment of clopidogrel and aspirin decreased the 90 day risk of stroke without increasing haemorrhage compared with aspirin alone in 5170 Chinese patients randomized within 24 h after symptom onset of minor stroke or TIA to clopidogrel–aspirin or to aspirin alone.479

In patients with prior non-cardioembolic ischaemic stroke, dual antiplatelet therapy with dipyridamole plus aspirin showed superiority over aspirin.465 In such patients, oral vitamin K antagonists are not superior to aspirin and are associated with a higher bleeding risk.468,469

In patients with ischaemic stroke, a direct comparison of dipyridamole plus aspirin vs. clopidogrel alone466 showed similar rates of recurrent stroke, including haemorrhagic stroke. There was a higher frequency of major haemorrhagic events with dipyridamole plus aspirin (4.1% vs. 3.6%).

Vorapaxar is a novel antiplatelet agent that selectively inhibits the cellular actions of thrombin through antagonism of PAR-1. In 26 449 patients who had a history of MI, ischaemic stroke or PAD, the primary composite endpoint—CV death, MI or stroke—was significantly reduced with vorapaxar in addition to standard antiplatelet therapy, but with increased risk of moderate or severe bleeding.480 Vorapaxar cannot be recommended systematically in patients with stable atherosclerotic disease.

Gap in evidence

- Experience with the new antiplatelet drugs in patients with stable CAD is still limited and so is their use in combination with anti-coagulant treatment.

3a.11 Adherence to medication

Key messages

- Adherence to medication in individuals at high risk and in patients with CVD is low.
- Several types of interventions are effective in improving medication adherence.
- The polypill may increase adherence to treatment and improve CV risk factor control.

Adherence to medication in individuals at high risk and in patients with CVD is low, resulting in worse outcomes and higher health care costs.487 One month after AMI, 25–30% of patients stop at least one drug, with a progressive decline in adherence over time. After 1 year, only 50% of patients report persistent use of statins, β-blockers or BP-lowering therapy.483,484 The reasons for poor adherence are multifactorial (Table F in web addenda).483

Cost-related non-adherence is a relevant problem in many health care systems. For example, in American veterans, adherence to lipid-lowering medication decreased as co-payments increased.488 Depression also independently doubles the risk for non-adherence.489 Reasons for non-adherence tend to cluster; for example, complex medication regimens may be important in individuals with chronic disease or multiple risk factors. This places high demands on caregivers to provide clear advice and continuous care.484 Physicians often fail to communicate critical elements of medication use (e.g. possible adverse effects, how long to take the medication and the frequency or timing of dosing).490 Thus there is a need to train physicians to identify risk factors for non-adherence and promote adherence to medication.

Several interventions are effective in improving adherence in chronic conditions.481 Solely reducing dosage demands resulted in strong effects, but other interventions such as repetitive monitoring and feedback, multisession information and combined behavioural interventions have shown effects ranging from minor to strong.481 Collaboration with pharmacists or pharmacist-directed care was
superior to standard care with respect to BP, total cholesterol and LDL-C levels.\textsuperscript{991} Knowledge of one’s CAC score may increase risk perception and adherence to medication.\textsuperscript{992}

In clinical practice, physicians should assess adherence to medication, identify reasons for possible non-adherence and promote adherence according to the following established principles:

- Provide clear advice regarding the benefits and possible adverse effects of the medication and the duration and timing of dosing.
- Consider patients’ habits and preferences (shared decision-making).
- Simplify the treatment regimen to the lowest feasible level.
- Ask patients in a non-judgmental way how the medication works for them and discuss possible reasons for non-adherence (e.g. side effects, worries).
- Implement repetitive monitoring and feedback.
- Introduce physician assistants and/or trained nurses or pharmacists whenever it is necessary and feasible.
- In case of persistent non-adherence, offer multisession or combined behavioural interventions [e.g. for patients after myocardial revascularization in a cardiac rehabilitation (CR) setting].

\section{3a.11.1 Polypill}

More than a decade ago, Wald and Law quantified the efficacy and adverse effects of a fixed dose combination (FDC) from published trials and proposed that an FDC consisting of a statin, BP-lowering agents, aspirin and folate could potentially reduce CVD by 80% in individuals >55 years of age.\textsuperscript{993}

A recent systematic review and meta-analysis\textsuperscript{485} summarizes nine randomized trials (\(n = 7047\)) on FDCs, largely conducted in higher-risk populations and primarily designed to evaluate changes in CV risk factors and adherence. However, FDCs included in the analysis were single pills of diverse composition and doses (although all contained a statin and at least one BP-lowering agent) and had a range of comparators (placebo, single-drug active component ‘usual care’). No convincing evidence of either benefit or risk for FDCs in terms of all-cause mortality or CV events was found. FDC therapy improved adherence (only one trial) compared with a multidrug strategy by 33% (95% CI 26%, 41%) compared with usual care.

In another international study, not included in the previous meta-analysis, 695 CAD patients were randomized to test the effect of an FDC polypill containing aspirin, simvastatin and ramipril, or the three drugs separately. The study showed that FDC improved adherence compared with separate medications after 9 months of follow-up (adherence 63% vs. 52%; \(P = 0.006\)).\textsuperscript{986}

The polypill should not be considered in isolation, but as an integral part of a comprehensive CVD prevention strategy that includes efforts to reduce tobacco use, increase PA and increase consumption of a heart-healthy diet.\textsuperscript{494} However, potential adverse effects of a single drug component of the FDC cannot be specifically corrected and therefore may also affect treatment adherence to the other components. Until we have the results of ongoing trials with major CVD as the endpoint, the polypill cannot be recommended for prevention of CVD and cannot be prescribed to all individuals.

\section*{Gaps in evidence}

- There is limited evidence about which interventions for improving adherence to medication are the most effective and in whom (e.g. young–old, male–female, high vs. low socio-economic status).
- The effect of the polypill as a global strategy to reduce CVD remains uncertain.

\section{3b. How to intervene at the individual level: disease-specific intervention—atrial fibrillation, coronary artery disease, chronic heart failure, cerebrovascular disease, peripheral artery disease (web addenda)}

\section{3c. How to intervene at the population level}

\subsection*{3c.1 Introduction (healthy lifestyle promotion)}

The population level approach follows the Geoffrey Rose paradigm: small shifts in the risk of disease (or risk factor) across a whole population consistently lead to greater reductions in disease burden than a large shift in high-risk individuals only. This population-wide approach has further advantages: it addresses CV health over the entire life course and reduces health inequalities.

Individual behaviour is enacted in an environment with hierarchical levels, which encompass individual choice, family influence, cultural and ethnic grouping, workplace, health care and policy at the state and global levels (e.g. EU policies and international trade agreements). The aim of this section is to provide stakeholders with evidence-based suggestions for the most effective interventions to improve CVD risk that can be implemented at a group, community, regional, national or global level. Health care professionals play an important role in advocating evidence-based population-level interventions.

Strategies such as ‘nudging’ (to push mildly) and ‘default’ have been proposed as tools. By changing the context to make healthy decisions the default, the individual is nudged in the healthy direction. The task for both national and local authorities is to create social environments that provide healthier defaults.

The evidence presented here builds on recent comprehensive reviews\textsuperscript{311,495–497} and individual studies and summarizes the ‘totality of evidence’. It is rarely feasible to use an RCT to evaluate population-level interventions (in contrast to individual-level interventions). The guidelines committee has chosen to follow the definition of ‘level of evidence’ for population-level approaches. Thus consistent findings from several high-quality studies were considered sufficient to merit strong recommendations.
3c.2 Population-based approaches to diet

Key messages
- Structural measures such as product reformulation, limitations on marketing and taxes on unhealthy foods, subsidizing the costs of healthier foods and consumer-friendly nutrition labelling will improve healthy food choices.
- Healthy environments in the community, at schools and in workplaces will stimulate a healthy lifestyle.

Many EU countries recognize the health benefits of reducing the energy density and salt and sugar content as well as replacement of trans and saturated fat by unsaturated fat in foods and drinks.\(^{311,495,498}\) These have led to successful reductions in trans fats\(^{316}\) and salt,\(^{495,499-501}\) the latter likely leading to decreases in BP.\(^{501}\) Mandatory upper limits harmonized across the EU will ensure that all EU consumers are equally protected.\(^{498}\)

Governments can facilitate nationwide cooperation between (local) governments, non-governmental organizations (NGOs), the food industry, retail, catering, schools, workplaces and other stakeholders. The French Ensemble Prévenons l’Obésité des Enfants (EPODE) project is an example of a multistakeholder cooperation that can help decrease childhood obesity.\(^{502}\)

### Recommendations for population-based approaches to diet

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Class(^a)</th>
<th>Level(^b)</th>
<th>Ref(^c)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Legislation on composition of foods to reduce energy density, salt and saturated fat, and (added) sugar content of foods and beverages, and to limit portion sizes is recommended.</td>
<td>I</td>
<td>B</td>
<td>311, 495, 496, 498-501</td>
</tr>
<tr>
<td>Elimination of industrially produced trans fats is recommended.</td>
<td>I</td>
<td>A</td>
<td>316</td>
</tr>
<tr>
<td>Facilitating an integrated and coherent policy and activities of the (local) governments, non-governmental organizations, food industry, retail, catering, schools, workplaces and other stakeholders to promote a healthy diet and to prevent overweight is recommended.</td>
<td>I</td>
<td>C</td>
<td>498, 502</td>
</tr>
<tr>
<td>Legislation restricting marketing aimed at children of foods that are high in fats, sugar and/or salt, less healthy options, junk foods, drinks with alcohol and non-alcoholic beverages rich in sugar (e.g. on TV, internet, social media and on food packages) is recommended.</td>
<td>I</td>
<td>C</td>
<td>311, 495, 503, 504</td>
</tr>
<tr>
<td>Reformulation of foods accompanied by educational information campaigns should be considered to create awareness on the nutrition quality of foods among consumers.</td>
<td>IIa</td>
<td>C</td>
<td>505, 506</td>
</tr>
<tr>
<td>Mandatory and harmonized simplified front-of-pack nutrition labelling is recommended.</td>
<td>I</td>
<td>C</td>
<td>311, 496, 506</td>
</tr>
<tr>
<td>Independently and coherently formulated criteria for nutrient profiles should be considered in support of health and nutrition claims and front-of-pack logos (e.g. traffic lights, healthy choices, key-holes).</td>
<td>IIa</td>
<td>C</td>
<td>311</td>
</tr>
<tr>
<td>Mandatory nutrition labelling for non-pre-packaged foods, including in restaurants hospitals and workplaces, should be considered.</td>
<td>IIa</td>
<td>C</td>
<td>311, 506</td>
</tr>
<tr>
<td>Pricing and subsidy strategies are recommended to promote healthier food and beverage choices.</td>
<td>I</td>
<td>B</td>
<td>311, 495, 507, 508</td>
</tr>
<tr>
<td>Taxes on foods and beverages rich in sugar and saturated fat, and on alcoholic drinks are recommended.</td>
<td>I</td>
<td>B</td>
<td>311, 495, 507, 508</td>
</tr>
<tr>
<td>At all schools, pre-schools and daycare centres a multi-component, comprehensive and coherent policy is recommended to promote a healthy diet.</td>
<td>I</td>
<td>B</td>
<td>311, 495, 502, 504</td>
</tr>
<tr>
<td>Availability of fresh drinking water and healthy foods in schools, and in vending machines is recommended.</td>
<td>I</td>
<td>B</td>
<td>311, 495, 504, 505</td>
</tr>
<tr>
<td>At all companies a coherent and comprehensive health policy and nutritional education are recommended to stimulate the health awareness of employees.</td>
<td>I</td>
<td>B</td>
<td>311, 495, 496, 509</td>
</tr>
<tr>
<td>Increased availability of fresh drinking water and improved nutritional quality of food served and/or sold in the workplace, and in vending machines should be considered.</td>
<td>IIa</td>
<td>C</td>
<td>311, 496</td>
</tr>
<tr>
<td>Regulation of location and density of fast food and alcohol purchasing outlets and other catering establishments should be considered.</td>
<td>IIa</td>
<td>C</td>
<td>495-497</td>
</tr>
</tbody>
</table>

\(^a\)Class of recommendation.
\(^b\)Level of evidence.
\(^c\)Reference(s) supporting recommendations.

Diet is a powerful determinant of obesity, hypertension, dyslipidaemia, DM and CV health. Rapid reductions in CV events can be seen after changes in diet at the population level.\(^{497,510}\) Stakeholders, including health care professionals, have a shared responsibility for population-based approaches and can help to promote healthy diets and environments.\(^{495,498}\) (Figure I in web addenda).
projects are in place in Belgium, Spain, The Netherlands, Greece and Australia.

Educational tools and intervention in the media may lead to a reduction in childhood obesity (e.g. limiting children’s exposure to advertising of unhealthy foods). In 2013, the European Heart Network (EHN) published a report summarizing recent developments in relation to the marketing of unhealthy foods to children. Accompanying consumer awareness campaigns on healthy foods and nutrition labelling can be effective. Consumers understand different systems of labelling and their use has a positive impact on sales. The EHN is calling for a simplified, colour-coded, front-of-pack scheme indicating high, medium and low levels of nutrients. This scheme can be applied to all foods and could be expanded to certain restaurants. Labelling also stimulates the reformulation of foods and thus it has the potential to improve dietary intake and reduce diet-related chronic diseases.

Pricing strategies can lead to a decline in the sales of unhealthy foods and an increase in the sales of fruits and vegetables. Modelling studies have demonstrated that food taxes could improve energy and nutrient intake, BMI and health. An increasing number of countries have introduced taxes on unhealthy foods and drinks (e.g. the fat tax in Denmark (caused a 10–15% decrease in consumption; now repealed) and the junk food tax in Hungary (sales declined by 27%)).

Consideration should be given to balanced economic incentives: subsidies and taxes to counteract any unbalanced effect on the socially disadvantaged.

To tackle obesity, every school and workplace should have a policy to promote a healthy environment and provide healthy foods and meals. Ideally, health education should be part of the school curriculum. Workplace dietary modification interventions alone and in combination with nutrition education or environmental changes have shown improvements in the consumption of fruits and vegetables and/or fats.

In the community, planning the location and density of fast food outlets and good access to supermarkets is needed, especially in deprived areas.

Gaps in evidence

- Scientific evidence of the impact of food and nutrition policy instruments on outcome measures such as food intake and CV health is largely lacking.
- Cost-effectiveness studies of the impact of different policy options are also limited.

### 3c.3 Population-based approaches to physical activity

**Key messages**

- A sedentary lifestyle and physical inactivity affects more than half of the population worldwide.
- Regular PA is recommended for all men and women as a lifelong part of lifestyle, with at least 150 min/week of moderate activity or at least 75 min/week of vigorous activity or an equivalent combination thereof. Any activity is better than none and more activity is better than some.
- Population-based interventions are effective in promoting PA.
- Early childhood education in PA and movement should start at preschool/kindergarten.
- Daily PA at school should be at least 30 minutes, and preferably 60 minutes.
- Good neighbourhoods and a safe environment enhances and encourages PA in everyday life.

---

**Recommendations for population-based approaches to physical activity**

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Class*</th>
<th>Levelb</th>
<th>Ref c</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Governmental restrictions and mandates</strong></td>
<td>Consideration of PA when planning new landscaping/buildings or towns is recommended.</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td><strong>Media and education</strong> See also section 3c.2 for multi-component interventions</td>
<td>Sustained, focused, media and educational campaigns, using multiple media modes (e.g. apps, posters, flyers and signage) may be considered to promote PA.</td>
<td>IIb</td>
<td>C</td>
</tr>
<tr>
<td>Short term community-based educational programmes and wearable devices promoting healthy behaviours, such as walking should be considered.</td>
<td>IIa</td>
<td>C</td>
<td>514–516</td>
</tr>
<tr>
<td><strong>Labelling and information</strong></td>
<td>Point-of-decision prompts should be considered to encourage use of stairs.</td>
<td>IIa</td>
<td>B</td>
</tr>
<tr>
<td>Exercise prescription for health promotion by physicians, especially GPs, similar to drug prescription should be considered.</td>
<td>IIa</td>
<td>C</td>
<td>517, 518</td>
</tr>
<tr>
<td><strong>Economic incentives</strong></td>
<td>Increased fuel (gasoline) taxes should be considered to increase active transport/commuting.</td>
<td>IIa</td>
<td>C</td>
</tr>
<tr>
<td>Tax reduction incentives for individuals to purchase exercise equipment or health club/fitness memberships may be considered.</td>
<td>IIb</td>
<td>C</td>
<td>512, 518</td>
</tr>
<tr>
<td>Sustained individual financial incentives may be considered for increased activity/fitness or weight loss.</td>
<td>IIb</td>
<td>C</td>
<td>512, 513, 518</td>
</tr>
<tr>
<td>Tax reduction incentives to employers to offer comprehensive worksite wellness programmes with nutrition, PA, and tobacco cessation/prevention components may be considered.</td>
<td>IIb</td>
<td>C</td>
<td>512, 518</td>
</tr>
</tbody>
</table>

---

*Class: I: Strong recommendation, IIa: Moderate recommendation, IIb: Weak recommendation.*

*Level: C: Good evidence.*

*Ref: References.*
In most countries, the majority of adults and children do not achieve the minimum activity levels recommended by health organizations: every person should engage in moderate exercise for at least 150 min/week and/or vigorous activity for at least 75 min/week or an equivalent thereof.258,520 For population-based prevention, the statement of ‘seven best investments’512 gives the universal and comprehensive advice to promote PA.512 Specific national guidelines developed for PA include frequency, intensity, time (duration) and type of activity (FITT), which can influence legislative initiatives, such as ‘active cities’ with bicycle lanes and walking paths and reallocation of road space.

Focused media and educational campaigns can initiate physical activities.519 Recent campaigns from sports medicine societies have endorsed PA prescriptions from GPs (http://www.efsma.net). The PA should be assessed at every medical encounter.

A simple strategy for increasing daily exercise is to encourage the use of stairs rather than the elevator or escalator, along with signage directing people to the stairs and health promotion materials endorsing the positive effects of stair climbing.516

Interestingly, an increase in fuel prices may reduce car driving and increase active commuting for those who live within reasonable walking or biking distances, with the exception of diseased or disabled persons.96

PA education should be started in preschool/kindergarten and continue for all levels of primary and secondary education. For school education, a multicomponent intervention should focus on improving lifelong PA by trained teachers. At least 3 h/week, and preferably 60 min/day, of sports or PA should be performed during school time.511 Regular activity also improves cognitive competence for learning.513,521 This activity can be supplemented with active commuting to school and supervised walking routes to and from school, with less reliance on buses.514

Workplaces can offer different opportunities for PA promotion. Some larger companies offer a fitness centre on company grounds without fees for employees. Workplace-based interventions may increase regular physical exercise for employees, but results demonstrate that a high proportion of workers do not participate.522 Therefore, supervisors and managers should endorse workplace interventions by encouraging employees to undertake PA.

Improved accessibility to recreation and exercise facilities with increased operating hours and utilizing community resources such as school playgrounds may increase regular PA in all age groups and reduce socio-economic inequality of access.517

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Classa</th>
<th>Levelb</th>
<th>Refc</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Schools</strong> See also section 3c.2 for multi-component interventions</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Increased availability and types of school playground spaces and equipment for exercise activity and sports are recommended.</td>
<td>Ia</td>
<td>B</td>
<td>512, 519</td>
</tr>
<tr>
<td>Regular classroom PA breaks during academic lessons should be considered.</td>
<td>Ia</td>
<td>B</td>
<td>511</td>
</tr>
<tr>
<td>Increasing active commuting to school should be considered e.g. a walking school bus programme with supervised walking routes to and from school for safety.</td>
<td>Ia</td>
<td>C</td>
<td>512, 514</td>
</tr>
<tr>
<td>Increased number and duration of PA classes, with revised PA curricula to implement at least moderate activity and trained teachers in exercise and sports may be considered.</td>
<td>Ib</td>
<td>B</td>
<td>511, 513</td>
</tr>
<tr>
<td><strong>Workplaces</strong> See also section 3c.2 for multi-component interventions</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Comprehensive worksite wellness programmes should be considered with nutrition and PA components.</td>
<td>Ia</td>
<td>B</td>
<td>512, 520–522</td>
</tr>
<tr>
<td>Structured worksite programmes that encourage PA and provide a set time for PA during work hours should be considered. Improving stairway access and appeal, potentially in combination with “skip-stop” elevators that skip some floors should be considered.</td>
<td>Ia</td>
<td>C</td>
<td>512, 514</td>
</tr>
<tr>
<td>Promoting worksite fitness centres should be considered.</td>
<td>Ia</td>
<td>C</td>
<td>517</td>
</tr>
<tr>
<td><strong>Community setting</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Health care providers should consider inquiring about PA in every medical encounter and adding it to the record. In addition, they should consider to motivate the individual and promote PA.</td>
<td>Ia</td>
<td>C</td>
<td>512, 520</td>
</tr>
<tr>
<td>Improved accessibility of recreation and PA spaces and facilities (e.g. building of parks and playgrounds, increasing operating hours, use of school facilities during non-school hours), improved walkability should be considered.</td>
<td>Ia</td>
<td>C</td>
<td>512, 520</td>
</tr>
<tr>
<td>Improved neighbourhood aesthetics (to increase activity in adults) should be considered.</td>
<td>Ia</td>
<td>C</td>
<td>512, 520</td>
</tr>
</tbody>
</table>

GPs = general practitioners; PA = physical activity.

*aClass of recommendation.

*bLevel of evidence.

*cReference(s) supporting recommendations.

Gap in evidence
- Sustainability and long-term outcomes of population-based actions to promote PA.
### 3c.4 Population-based approaches to smoking and other tobacco use

#### Key messages
- Adolescence is the most vulnerable period for uptake of smoking, with lifelong consequences.
- High taxes on all tobacco products is the most effective policy measure to reduce smoking uptake by the young.
- Restrictions on smokeless tobacco due to strong evidence of harm.
- Restrictions on e-cigarettes due to uncertainty regarding safety and effect.
- Plain packaging is effective in reducing tobacco consumption.
- Restrictions on advertising, promotion and sponsorship by the tobacco industry.
- A goal would be to make a common European decision to achieve a smoking-free Europe by 2030.

#### Recommendations for population-based approaches to smoking and other tobacco use

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Class</th>
<th>Level</th>
<th>Ref</th>
</tr>
</thead>
<tbody>
<tr>
<td>Banning smoking in public places is recommended to prevent smoking and to promote smoking cessation.</td>
<td>I</td>
<td>A</td>
<td>495</td>
</tr>
<tr>
<td>Banning smoking in public places, outside public entrances, workplaces, in restaurants and bars is recommended to protect people from passive smoking.</td>
<td>I</td>
<td>A</td>
<td>496, 523</td>
</tr>
<tr>
<td>Prohibit sales of tobacco products to adolescents are recommended.</td>
<td>I</td>
<td>A</td>
<td>495</td>
</tr>
<tr>
<td>Banning of tobacco vending machines is recommended.</td>
<td>I</td>
<td>A</td>
<td>495</td>
</tr>
<tr>
<td>Restrictions on advertising, marketing and sale of smokeless tobacco are recommended.</td>
<td>I</td>
<td>A</td>
<td>524-527</td>
</tr>
<tr>
<td>Complete ban on advertising and promotion of tobacco products are recommended.</td>
<td>I</td>
<td>B</td>
<td>496</td>
</tr>
<tr>
<td>Reduced density of retail tobacco outlets in residential areas, schools and hospitals is recommended.</td>
<td>I</td>
<td>B</td>
<td>496</td>
</tr>
<tr>
<td>Harmonization of border sales and tax free sales of all tobacco products is recommended.</td>
<td>I</td>
<td>B</td>
<td>495</td>
</tr>
<tr>
<td>Restrictions on advertising, marketing and sale of electronic cigarettes should be considered.</td>
<td>IIa</td>
<td>A</td>
<td>305, 528</td>
</tr>
<tr>
<td>Telephone and internet based lines for cessation counselling and support services are recommended.</td>
<td>I</td>
<td>A</td>
<td>496</td>
</tr>
<tr>
<td>Media and educational campaigns as part of multicomponent strategies to reduce smoking and increase quit rates, reduce passive smoking and use of smokeless tobacco are recommended.</td>
<td>I</td>
<td>A</td>
<td>496</td>
</tr>
<tr>
<td>Media and educational campaigns concentrating solely on reducing smoking, increasing quit rates, reducing passive smoking and the use of smokeless tobacco should be considered.</td>
<td>IIa</td>
<td>B</td>
<td>495, 496</td>
</tr>
<tr>
<td>Cigarette package pictorial and text warnings are recommended.</td>
<td>I</td>
<td>B</td>
<td>495, 496</td>
</tr>
<tr>
<td>Plain packaging is recommended.</td>
<td>I</td>
<td>B</td>
<td>495, 496</td>
</tr>
<tr>
<td>Higher taxes and prices on all tobacco products are recommended.</td>
<td>I</td>
<td>A</td>
<td>495, 496</td>
</tr>
<tr>
<td>Banning smoking in schools, pre-schools and child care to protect from passive smoking is recommended.</td>
<td>I</td>
<td>A</td>
<td>495</td>
</tr>
<tr>
<td>Promotion and teaching of a healthy lifestyle including tobacco-free life should be considered in all schools.</td>
<td>IIa</td>
<td>B</td>
<td>495</td>
</tr>
<tr>
<td>Workplace specific bans on smoking to reduce passive smoking and increase quit rates are recommended.</td>
<td>I</td>
<td>A</td>
<td>495, 496</td>
</tr>
<tr>
<td>Workplace policy on healthy choices including tobacco cessation/prevention is recommended.</td>
<td>I</td>
<td>A</td>
<td>496</td>
</tr>
<tr>
<td>It is recommended that health personnel, caregivers and school personnel set an example by not smoking or using tobacco products at work.</td>
<td>I</td>
<td>A</td>
<td>495, 496</td>
</tr>
<tr>
<td>It is recommended to advise pregnant women to be tobacco-free during pregnancy.</td>
<td>I</td>
<td>A</td>
<td>524</td>
</tr>
<tr>
<td>It is recommended to advise parents to be tobacco-free when children are present.</td>
<td>I</td>
<td>A</td>
<td>495, 496</td>
</tr>
<tr>
<td>It is recommended to advise parents to never smoke in cars and private homes.</td>
<td>I</td>
<td>A</td>
<td>495, 496</td>
</tr>
<tr>
<td>Residence-specific restrictions on smoking should be considered.</td>
<td>IIa</td>
<td>B</td>
<td>496</td>
</tr>
</tbody>
</table>

*Class of recommendation.

*Level of evidence.

*Reference(s) supporting recommendations.
The WHO Framework Convention on Tobacco Control recommends smoke-free laws: protecting people from tobacco smoke and banning smoke in public places, warning about the dangers of tobacco, raising taxes on tobacco and enforcing advertising bans.\textsuperscript{523} Children and low socio-economic groups are sensitive to population-based tobacco intervention. Passive smoking increases CVD risk,\textsuperscript{495,496} more so in women than in men.\textsuperscript{529} All smoking, including smoking a water pipe, is deleterious. Smokeless tobacco (in Europe usually snus, a moist powder tobacco placed under the upper lip) increases the risk of fatal pipe, is deleterious. Smokeless tobacco (in Europe usually snus, a moist powder tobacco placed under the upper lip) increases the risk of fatal CVD events,\textsuperscript{526–527} and the use of snus during pregnancy increases the risk of stillbirth.\textsuperscript{530} There is no evidence that snus increases smoking cessation more than nicotine replacement products or medication. Many smokers use e-cigarettes to quit. There are many unanswered questions about their safety, efficacy for harm reduction and cessation and impact on public health. International legislation should be harmonized to prevent a new tobacco epidemic.\textsuperscript{495} Multicomponent strategies are best. Advertising bans reduce tobacco consumption, and mass media campaigns reduce smoking uptake by teenagers and increase adult quitting.\textsuperscript{495} Media and educational campaigns in schools reduce smoking and promote smoking cessation. Editors should increase the coverage of tobacco and health in the media.\textsuperscript{531} Telephone or Internet-based cessation support reduces tobacco use.\textsuperscript{496}

Packs with pictorial and text warnings raise awareness of tobacco dangers.\textsuperscript{495} Plain and standardized packaging without brand labels enhances the effectiveness. Higher taxes reduce tobacco consumption and encourage quitting, particularly among young and lower socio-economic groups.\textsuperscript{495,496} School-based smoking bans should be implemented.\textsuperscript{496} Smoking bans at workplaces reduce exposure to passive smoking, decrease smoking and increase quitting rates.\textsuperscript{497} Tobacco outlet density near homes, hospitals and schools should be reduced. Pregnant women should avoid tobacco, and parents should be tobacco free when children are present. Health personnel, caregivers and teachers must set an example by not using tobacco products at work.

### Gaps in evidence

- Effect of school-based smoking restrictions.
- Health harm of e-cigarettes.
- More evidence on environmental smoking is needed, as smoke particles may remain in rooms for many years.

#### 3c.5 Alcohol abuse protection

### Key messages

- Excessive alcohol intake is associated with increased CV mortality, and alcohol ranks as the second-leading cause of DALYs lost in high-income countries.
- The interventions for addressing the harmful use of alcohol are cost effective, with good return (i.e. increasing alcoholic beverage excise taxes, restricting access to alcoholic beverages and implementing comprehensive restrictions and bans on advertising and promotion of alcoholic beverages).

### Recommendations for protecting against alcohol abuse

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Class\textsuperscript{a}</th>
<th>Level\textsuperscript{b}</th>
<th>Ref\textsuperscript{c}</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Governmental restrictions and mandates</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Regulating physical availability of alcoholic beverages is recommended, including minimum legal purchase age, restrictions on outlet density and time and place of sales, public health oriented licensing systems, and governmental monopolies of retail sales.</td>
<td>I</td>
<td>B</td>
<td>532–536</td>
</tr>
<tr>
<td>Drink-driving countermeasures are recommended such as lowered blood alcohol concentration limits and “zero tolerance”, random breath testing and sobriety check points.</td>
<td>I</td>
<td>B</td>
<td>534, 537</td>
</tr>
<tr>
<td>Implementing comprehensive restrictions and bans on advertising and promotion of alcoholic beverages is recommended.</td>
<td>I</td>
<td>C</td>
<td>532</td>
</tr>
<tr>
<td><strong>Media and education</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Educational information campaigns may be considered to create awareness on the hazardous effects of alcohol.</td>
<td>IIB</td>
<td>B</td>
<td>532, 538</td>
</tr>
<tr>
<td><strong>Labelling and information</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Labelling alcohol with information on caloric content and health warning messages of the harmful effects of alcohol may be considered.</td>
<td>IIB</td>
<td>B</td>
<td>532, 538</td>
</tr>
<tr>
<td><strong>Economic incentives</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Taxes on alcoholic beverages are recommended.</td>
<td>I</td>
<td>B</td>
<td>533</td>
</tr>
<tr>
<td><strong>Schools</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>At every school, pre-school and day care a multi-component, comprehensive and coherent education may be considered to prevent alcohol abuse.</td>
<td>IIB</td>
<td>B</td>
<td>532, 538</td>
</tr>
<tr>
<td><strong>Workplaces</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>At every company a coherent and comprehensive health policy and nutritional education on stimulating the health of employees, including limiting excessive alcohol intake, are recommended.</td>
<td>I</td>
<td>B</td>
<td>495</td>
</tr>
<tr>
<td><strong>Community setting</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Measures to support and empower primary care to adopt effective approaches to prevent and reduce harmful use of alcohol are recommended.</td>
<td>I</td>
<td>B</td>
<td>539</td>
</tr>
<tr>
<td>Enacting management policies relating to responsible serving of alcoholic beverages should be considered to reduce the negative consequences of drinking.</td>
<td>IIA</td>
<td>B</td>
<td>534, 538</td>
</tr>
<tr>
<td>Planning of location and density of alcohol purchasing outlets and other catering establishments should be considered.</td>
<td>IIA</td>
<td>C</td>
<td></td>
</tr>
</tbody>
</table>

\textsuperscript{a}Class of recommendation.  
\textsuperscript{b}Level of evidence.  
\textsuperscript{c}Reference(s) supporting recommendations.
At the population level, alcohol consumption is associated with multiple health risks that clearly outweigh any potential benefits. In 2012, ~3.3 million deaths (5.9% of all global deaths) and 139 million DALYs (5.1% of the global burden of disease and injury) were attributable to alcohol consumption. The highest numbers of deaths are from CVDs, with 33.3% of the alcohol-attributable deaths due to CVD.\(^{495}\) Ischaemic heart disease mortality is 65% higher in male heavy drinkers and more than double in female heavy drinkers.\(^{540}\)

The relationship between alcohol consumption and CAD and cerebrovascular diseases is complex. It depends on both the level and pattern of alcohol consumption. Low alcohol consumption, ranging from one to three alcohol units per day (a unit equates to about 80 mL of wine, 250 mL of normal strength beer or 30–50 mL of spirits) in some segments of the population is associated with the lowest all-cause mortality, largely due to lower coronary mortality.\(^{541}\)

SBP and DBP levels increase as alcohol consumption increases to \(>3\) units/day, as does the risk of cardiac arrhythmias, cardiomyopathy, sudden death and haemorrhagic stroke.\(^{542}\) The pattern of alcohol use has an effect on CVD risk; binge drinking is associated with a higher risk of sudden death and stroke.\(^{543}\)

The following strategies and interventions have the highest level of effectiveness to prevent the harmful use of alcohol: age limits for sale and serving;\(^{535}\) drink-driving strategies;\(^{537}\) government retail monopolies on the sale of alcohol and reducing the hours of sale;\(^{536}\) banning alcohol advertising, promotion and sponsorship of events;\(^{532}\) and an increase in retail prices.\(^{533,538}\)

In the absence of other population-level measures, such as taxation and advertising restrictions, labelling alcohol with information on caloric content and health warning messages of the harmful effects of alcohol has been shown to have a limited effect.\(^{538}\)

Alcohol regulations in the policies of workplaces, educational centres and schools are effective.\(^{532}\)

Brief intervention in primary care to prevent alcohol abuse has been shown to be effective.\(^{539}\)

In the community, excessive alcohol intake can be limited by restrictions in the number and opening hours of outlets and by increasing the minimum age for sales and servings.\(^{495}\)

**Gap in evidence**

- Better quality evidence is needed with regard to potential confounding in studies on the effects of alcohol consumption.

## 3c.6 Healthy environment

Air pollution contributes to the risk of respiratory and CV diseases.\(^{544}\)

Important sources of fine particles in the EU are motorized road traffic, power plants and industrial and residential heating using oil, coal or wood. Up to a third of Europeans living in urban areas are exposed to levels exceeding EU air quality standards. In particular, young and old individuals and subjects with a high risk of CVD are more prone to the detrimental effects of air pollution on the circulation and the heart.

The EU Commission released a policy package to be implemented by the year 2030 with measures to reduce harmful emissions from traffic, energy plants and agriculture. Further efforts to reduce air pollution should be encouraged and taken up by national governments (e.g. through appropriate and effective legislation). Patient organizations and health professionals have an important role to play in supporting education and policy initiatives and provide a strong voice in the call for action at the governmental level.\(^{544}\)

The media can inform the population on air quality (e.g. by apps) and by providing smog alerts. Information on patients’ behaviour during smog is needed. Economic incentives such as reduced taxes on electric and hybrid cars can contribute to the improvement of air quality. New houses and schools can be built in areas remote from highways and polluting industries.

## 4a. Where to intervene at the individual level

The question of ‘where’ prevention should take place requires only a simple answer: everywhere! Prevention of CVD should be valued and implemented at all levels of society and in all health care settings. This should include increased spending on prevention in health care and on actions that make communities healthier. All clinicians should consider prevention and promotion of healthy lifestyles a professional responsibility with individual patients and should support policies that promote healthier lifestyles. Patients should also be empowered and have the knowledge and support to make informed decisions and to demand robust prevention efforts from health care groups and society.

### 4a.1 Clinical settings and stakeholders

#### 4a.1.1 Cardiovascular disease prevention in primary care

**Key messages**

- The prevention of CVD should be delivered in all health care settings, including primary care.
- Where appropriate, all health professionals should assess CV risk factors to determine the individual’s total CV risk score.
- GPs and nurses should work together as a team to provide the most effective multidisciplinary care.

**Recommendation for cardiovascular disease prevention in primary care**

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>Class</th>
<th>Level</th>
</tr>
</thead>
<tbody>
<tr>
<td>It is recommended that GPs, nurses and allied health professionals within primary care deliver CVD prevention for high-risk patients.</td>
<td>I</td>
<td>C</td>
</tr>
</tbody>
</table>

*Class of recommendation.

Level of evidence.

The physician in general practice is the key person to initiate, coordinate and provide long-term follow-up for CVD prevention. In most countries, GPs deliver >90% of consultations and provide most public health medicine, including preventive care and chronic disease monitoring. In the case of CVD prevention, they have a unique role in identifying individuals at risk of CVD and assessing their eligibility for intervention based on their risk profile. How to maximize attendance rates and adherence, particularly in those who are at highest risk, remains an issue.

As mentioned in section 2.2, a systematic approach is recommended to risk assessment, giving priority to persons with a priori higher risk (such as family history of premature CVD, presence of hypertension, etc.); opportunistic screening of persons <40 years of age without CV risk factors is not recommended.

Intensive and structured intervention in general practice contributes to the prevention of recurrent CV events and reduces hospital admissions in CAD patients.\(^{545}\)
The successful implementation of CVD prevention guidelines relies heavily on GPs providing risk factor evaluation, intervention and patient education. However, CV targets in general practice are often not achieved. The EUROASPIRE III survey (primary prevention arm) showed that the lifestyle of people being treated as high CV risk—defined as patients treated with BP- and lipid-lowering drugs as well as anti-diabetes drugs—showed much persistent smoking and a high prevalence of both obesity and central obesity. BP, lipid and glucose control is poor, with most patients not achieving the targets defined in the prevention guidelines.5

Surveys done among GPs and physicians in several European regions found that most were aware of the European guidelines on CVD prevention, but that only 36–57% were using the guidelines in practice, and less than half performed comprehensive risk assessments. The main barrier was time, but GPs also cited that there were too many guidelines, unrealistic targets for risk factor control, a preference for using their own experience and a lack of knowledge regarding comprehensive risk assessment.546–549 Online resources, mobile apps, pocket guidelines and summary cards may contribute as a means to overcome the implementation challenge.

Evidence for an effective role for nurses in primary care exists. A study of nurse-coordinated preventive cardiology programmes for primary prevention of CVD compared with routine practice conducted in a matched, paired-cluster RCT in six pairs of general practices in six European countries showed more high-risk patients achieved the lifestyle and risk factor targets in the nurse-coordinated arm compared with usual care.550

In 2009, a randomized trial in The Netherlands on CVD risk management and preventive care found that practice nurses achieved results equal to GPs after 1 year of follow-up.551 A clinical trial (n = 525) in the USA also showed that advanced practice nurses working with community health workers can achieve significant improvements in CV risk factors (BP, cholesterol, DM control) in underserved inner-city populations compared with enhanced usual care, and it was cost-effective.552

Gap in evidence
- Further research is needed in order to explore what is the best strategy to improve implementation of CVD prevention guidelines in general practice, taking into account the heterogeneity among countries in terms of health systems and local resources.

4a.1.2 Acute hospital admission setting

**Recommendation for CVD prevention strategies in the acute hospital admission setting**

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>Class&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Level&lt;sup&gt;b&lt;/sup&gt;</th>
<th>Ref&lt;sup&gt;c&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>It is recommended to implement strategies for prevention in CVD patients, including lifestyle changes, risk factor management and pharmacological optimization, after an acute event before hospital discharge to lower risk of mortality and morbidity.</td>
<td>I</td>
<td>A</td>
<td>300, 553</td>
</tr>
</tbody>
</table>

<sup>a</sup>Class of recommendation.  
<sup>b</sup>Level of evidence.  
<sup>c</sup>Reference(s) supporting recommendations.

The importance of starting appropriate prevention before hospital discharge cannot be overemphasized, as prevention treatment tends to decrease rather than increase post-hospitalization, with proportions of patients on appropriate therapy declining over time and patients not reaching risk factor targets.595,554

The acute care team should emphasize the importance of the preventive measures directly to the patient, because failure to do so may suggest that these measure are valueless; and they interact with other health professionals (e.g. physicians, nurses) to ensure that prevention strategies initiated during hospitalization are sustained and supported in other settings.

Thus patients, while in acute care, should receive appropriate interventions to optimize prevention strategies. These include full clinical assessment to guide optimization of medical therapy, individualized behavioural education for risk factor modification and referral to exercise-based CR.

Education should be person-centred with full participation of patients and caregivers, providing explanations for each intervention, while early mobilization and physical conditioning programmes should vary according to the individual’s clinical status.

### 4a.1.3 Specialized prevention programmes

#### Recommendations for specialized prevention programmes

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Class&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Level&lt;sup&gt;b&lt;/sup&gt;</th>
<th>Ref&lt;sup&gt;c&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Participation in a CR programme for patients hospitalized for an acute coronary event or revascularization, and for patients with HF, is recommended to improve patient outcomes.</td>
<td>I</td>
<td>A</td>
<td>555, 556</td>
</tr>
<tr>
<td>Preventive programmes for therapy optimization, adherence and risk factor management are recommended for stable patients with CVD to reduce disease recurrence.</td>
<td>I</td>
<td>B</td>
<td>557–560</td>
</tr>
<tr>
<td>Methods to increase referral to and uptake of CR should be considered such as electronic prompts or automatic referrals, referral and liaison visits, structured follow-up by physicians, nurses or therapists, and early starts to programmes after discharge.</td>
<td>IIa</td>
<td>B</td>
<td>557, 558</td>
</tr>
<tr>
<td>Nurses and allied health professional led programmes should be considered to deliver CVD prevention across healthcare settings.</td>
<td>IIa</td>
<td>B</td>
<td>550–552, 561</td>
</tr>
</tbody>
</table>

CR = cardiac rehabilitation; CVD = cardiovascular disease; HF = heart failure.

<sup>a</sup>Class of recommendation.  
<sup>b</sup>Level of evidence.  
<sup>c</sup>Reference(s) supporting recommendations.

Specialized prevention programmes are delivered as CR or other prevention programmes for all patients with CVD or at high risk for CVD. The core components and goals of CR have been standardized,562 but the structure, length and type of programme offered
differs widely by country, affected by national guidelines and standards, legislation and payment factors.\textsuperscript{563}

CR is a comprehensive programme involving exercise training, risk factor modification, education and psychological support. An overview of six Cochrane systematic reviews of CR (148 RCTs with 98,093 subjects) concluded that for low- to moderate-risk patients with HF, or who are post-MI or revascularization, exercise-based CR decreased hospital admissions and improved health-related quality of life (HRQoL) compared with usual care, and may reduce mortality longer term.\textsuperscript{555} A limitation of current reviews is the inclusion of trials prior to modern treatment, differing patients groups and heterogeneous programmes of CR. Thus more research is needed to determine the optimal intervention. A number of recent controlled cohort studies have found a survival benefit for patients receiving CR compared with no CR. An ongoing meta-analysis of CR in the modern era may provide more definitive results regarding patient programmes and outcomes. At present, the benefit of CR appears to be through direct physiological effects of exercise training and through CR’s effects on risk factors, behaviour and mood.\textsuperscript{555} CR also provides an opportunity for social support and to screen patients for psychosocial risk factors.

Referral and participation in CR varies widely across countries: many CR programmes do not include unstable patients or patients with HF, devices or PAD, and referral and retention of women and older, higher-risk patients remains suboptimal.\textsuperscript{563,564} Referrals to CR can be increased through electronic prompts or automatic referrals, while patient uptake may be improved with structured follow-up by nurses or therapists and early starts to programmes after discharge.\textsuperscript{557,558,565}

Nurse-led programmes can also deliver effective preventive programmes in patients with CVD. The EUROACTION trial used a 16 week family-centred approach that led to healthier lifestyle changes in activity and diet and more effective control of risk factors in patients and their partners compared with usual care.\textsuperscript{550} The Randomised Evaluation of Secondary Prevention by Outpatient Nurse Specialists (RESPONSE) trial randomized patients after ACS to usual care or to nurse-coordinated prevention intervention of outpatient visits over 6 months: at 1 year, patients in the intervention group had better control of risk factors, fewer readmissions and emergency department visits and a predicted RR of mortality (using SCORE) 17% lower than the control group.\textsuperscript{561}

### 4a.1.4 Alternative rehabilitation models

**Key message**

- Home-based rehabilitation with and without telemonitoring holds promise for increasing participation and supporting behavioural change.

CR has predominantly been implemented in hospitals or in community centres with trained staff. Home-based rehabilitation programmes have the potential to increase patient participation by offering greater flexibility and options for activities. A systematic review of 12 trials (with 1978 patients) of home- vs. centre-based rehabilitation found no difference in outcomes, adherence or cost between the two in the short term and up to 24 months.\textsuperscript{566} The majority of studies recruited low-risk, predominantly male patients, and activities were self-regulated with intermittent support, usually by telephone. Home-based rehabilitation thus offers an alternative for some patients, although relatively few programmes in Europe offer it.\textsuperscript{563}

#### 4a.1.4.1 Telerehabilitation

Telerehabilitation, i.e. the use of electronic communication and information technologies to provide and support remote clinical care after an acute event, has been found to be more effective than usual care in achieving behavioural change, and equally effective as a CR programme.\textsuperscript{557,567} Simple telemonitoring, including ECG transmission by telephone in patients with CVD, has been found to be safe and acceptable to patients and results in improvements in physical capacity.\textsuperscript{566} Recent studies are also using smartphone applications for monitoring and delivery of content and support, with improvements in uptake, adherence and completion of rehabilitation in younger patients.\textsuperscript{569}

Thus telerehabilitation could further widen participation to more patients and provide monitoring and greater individualized behavioural support, but large-scale randomized trials are needed.

#### 4a.1.5 Maintaining lifestyle changes

Maintaining healthy behaviours after a specialized prevention programme is problematic for many patients.

Specialized prevention programmes and patient consultations should use a patient-centred approach that focuses on the patient’s priorities and goals and incorporates lifestyle changes within the context of the patient’s life. Behavioural change of personal value to the individual is more likely to be maintained (see section 3a.1).

Longer-term support for behaviour change may be needed and community maintenance programmes may be useful. In the Global Secondary Prevention Strategies to Limit Event Recurrence After MI (GOSPEL) trial, 3241 patients were randomized post-CR programme to an intensive multifactorial intervention over 3 years or usual care. Patients in the intervention group received monthly exercise and counselling sessions for 6 months, then every 6 months for 3 years. Compared with usual care, the intervention group had improved PA, diet and total cholesterol maintained throughout the study. The intervention significantly decreased several combined endpoints, such as CV mortality plus non-fatal MI and stroke by 33%, cardiac death plus non-fatal MI by 36% and non-fatal MI by 48% compared with usual care.\textsuperscript{570}

**Gaps in evidence**

- The optimal CR programme in the era of modern cardiology and the incremental benefits of various components of CR programmes, especially for underserved patient groups.
- Alternative and cost-effective models of CR are needed to ensure participation globally, including low- and middle-income countries.

### 4a.2 How to monitor preventive activities

**Key message**

- Standards of performance in CVD prevention may serve as vehicles to accelerate appropriate translation of scientific evidence into clinical practice.
Candidates for measures of performance are some of those processes of care that are recommended by the guideline either as class I, which identifies recommended procedures/treatments, or class III, which identifies procedures/treatments that are not recommended.

The development of standards of performance involves identification of a set of measures that target a specific patient population observed over a particular time period. Thus these performance measures are aimed at any clinician or health care professional who sees adult subjects (≥18 years of age) at risk for CVD. Table 18 provides examples of performance measurements of CVD prevention. Detailed specifications for each performance measure, including the numerator, denominator, period of assessment, method of reporting and sources of data, should be developed at the local level. An optimal target of 100% is recommended for all standards. If this is not achievable, an interim local target could be set.

### 4b. Where to intervene at the population level

#### Key message
- Governmental and non-governmental organizations (NGOs) such as heart foundations and other health-promoting organizations can be a powerful force in promoting a healthy lifestyle and healthy environments in CVD prevention.

#### 4b.1 Government and public health

Recommendations for population-based interventions to promote CVD health are described in section 3c. These preventive strategies to address unhealthy diets, smoking and physical inactivity must take place at different levels. At each level, different clusters of stakeholders are concerned and responsible for the interventions.495

- International level—WHO, World Trade Organization, EU
- National level—government departments, health authorities, health-promoting agencies, consumer organizations, health NGOs, industries
- Regional and local level—local governmental departments, communities, schools, workplaces, health professionals, catering sector, retailers, NGOs.

At the EU level as well as at the level of national governments, legislation should be developed regarding, for example, the nutritional composition of foods; nutrition labelling; smoke-free policies and environments; restrictions on marketing of unhealthy foods, alcohol and tobacco products and promoting environments that encourage PA in everyday life.311 Also, policy measures to reduce air pollution should be developed. Both levels may use economic instruments such as taxes and subsidies to support strategies on food and nutrition, tobacco and alcohol. It is not necessarily exclusively the responsibility of governments to ensure the availability of and accessibility to PA opportunities and healthy foods; this should be a joint effort by government, industry and businesses. Health authorities should monitor improvements, and if voluntary efforts by industry prove inadequate, governments must intervene.

#### 4b.2 Non-governmental organizations

NGOs are important stakeholders in advocating the development and maintenance of public health policies and are important partners with health care workers in promoting CV prevention.

Several Brussels-based NGOs aim at improving the CV health of the public and patients, including EHNP, health and medical professionals [ESC, European Chronic Disease Alliance (ECDAA) and consumer organizations [Bureau Européen des Unions de Consommateurs (BEUC)].

CV patients’ organizations provide their patient members with the opportunity to obtain support from their peers. They produce patient information in the form of booklets and web-based materials and promote CR.

Stakeholders such as NGOs and health professionals (e.g. cardiologists, internists and GPs) have a responsibility in agenda setting and monitoring interventions, and can initiate mass media campaigns to improve health.

In creating healthy and active environments, especially in schools, workplaces and the community, stakeholders such as teachers and parent organizations, the catering sector, employer organizations, trade unions, sport clubs and fitness centres and organizations promoting cycling, walking, public transport or involved in urban planning and mobility can play a role. An example is the French EPODE project, aimed at reducing overweight in children.502
### Recommendations for cardiovascular risk assessment

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>Class</th>
<th>Level</th>
</tr>
</thead>
<tbody>
<tr>
<td>Systematic CV risk assessment is recommended in individuals at increased CV risk, i.e. with family history of premature CVD, familial hyperlipidaemia, major CV risk factors (such as smoking, high BP, DM or raised lipid levels) or comorbidities increasing CV risk.</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>It is recommended to repeat CV risk assessment every 5 years, and more often for individuals with risks close to thresholds mandating treatment.</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>Systematic CV risk assessment in men &lt;40 of age and women &lt;50 years of age with no known CV risk factors is not recommended.</td>
<td>III</td>
<td>C</td>
</tr>
</tbody>
</table>

### Recommendations for how to estimate cardiovascular risk

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>Class</th>
<th>Level</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total CV risk estimation, using a risk estimation system such as SCORE, is recommended for adults &gt;40 years of age, unless they are automatically categorised as being at high risk or very high risk based on documented CVD, DM (&gt;40 years of age), kidney disease or a highly elevated single risk factor.</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>Routine assessment of circulating or urinary biomarkers is not recommended for refinement of CVD risk stratification.</td>
<td>III</td>
<td>B</td>
</tr>
<tr>
<td>Carotid ultrasound IMT screening for CV risk assessment is not recommended.</td>
<td>III</td>
<td>A</td>
</tr>
</tbody>
</table>

### Recommendations for how to intervene

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>Class</th>
<th>Level</th>
</tr>
</thead>
<tbody>
<tr>
<td>It is recommended for healthy adults of all ages to perform at least 150 minutes a week of moderate intensity or 75 minutes a week of vigorous intensity aerobic PA or an equivalent combination thereof.</td>
<td>I</td>
<td>A</td>
</tr>
<tr>
<td>PA is recommended in low risk individuals without further assessment.</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>It is recommended to identify smokers and provide repeated advice on stopping with offers to help, by the use of follow up support, nicotine replacement therapies, varenicline, and bupropion individually or in combination.</td>
<td>I</td>
<td>A</td>
</tr>
<tr>
<td>A healthy diet is recommended as a cornerstone of CVD prevention in all individuals.</td>
<td>I</td>
<td>B</td>
</tr>
<tr>
<td>It is recommended that subjects with healthy weight maintain their weight. It is recommended that overweight and obese people achieve a healthy weight (or aim for a reduction in weight).</td>
<td>I</td>
<td>A</td>
</tr>
<tr>
<td>In patients at VERY HIGH CV risk, an LDL-C goal &lt;1.8 mmol/L (&lt;70 mg/dL), or a reduction of at least 50% if the baseline is between 1.8 and 3.5 mmol/L (70 and 135 mg/dL) is recommended.</td>
<td>I</td>
<td>B</td>
</tr>
<tr>
<td>In patients at HIGH CV risk, an LDL-C goal &lt;2.6 mmol/L (&lt;100 mg/dL), or a reduction of at least 50% if the baseline is between 2.6 and 5.1 mmol/L (100 and 200 mg/dL) is recommended.</td>
<td>I</td>
<td>B</td>
</tr>
<tr>
<td>In treated hypertensive patients &lt;60 years old, SBP &lt;140 mmHg and DBP &lt;90 mmHg are recommended.</td>
<td>I</td>
<td>B</td>
</tr>
<tr>
<td>In patients &gt;60 years old with SBP ≥160 mmHg, it is recommended to reduce SBP to between 150 and 140 mmHg.</td>
<td>I</td>
<td>B</td>
</tr>
<tr>
<td>In individuals &gt;80 years and with initial SBP ≥160 mmHg, it is recommended to reduce SBP to between 150 and 140 mmHg, provided they are in good physical and mental conditions.</td>
<td>I</td>
<td>B</td>
</tr>
<tr>
<td>BP targets in type 2 DM are &lt;140/85 mmHg, but a lower target of &lt;130/80 mmHg is recommended in selected patients (e.g. younger patients at elevated risk for specific complications) for additional gains on stroke, retinopathy and albuminuria risk.</td>
<td>I</td>
<td>B</td>
</tr>
<tr>
<td>BP targets in patients with type 1 DM are &lt;130/80 mmHg.</td>
<td>I</td>
<td>B</td>
</tr>
<tr>
<td>Drug treatment is recommended in patients with grade 3 hypertension irrespective of CV risk, as well as in patients with grade 1 or 2 hypertension who are at very high CV risk.</td>
<td>I</td>
<td>B</td>
</tr>
<tr>
<td>All major BP lowering drug classes (i.e. diuretics, ACE-I, calcium antagonists, ARBs, and β-blockers) do not differ significantly in their BP-lowering efficacy and thus are recommended as BP lowering treatment.</td>
<td>I</td>
<td>A</td>
</tr>
<tr>
<td>Renin-angiotensin-aldosterone system blocker is recommended in the treatment of hypertension in DM, particularly in the presence of proteinuria or micro-albuminuria.</td>
<td>I</td>
<td>B</td>
</tr>
<tr>
<td>β-blockers and thiazide diuretics are not recommended in hypertensive patients with multiple metabolic risk factors due to the increased risk of DM.</td>
<td>III</td>
<td>B</td>
</tr>
<tr>
<td>A target HbA1c for the reduction in risk of CVD and microvascular complications in DM of &lt;7.0% (&lt;53 mmol/mol) is recommended for the majority of non-pregnant adults with either type 1 or type 2 DM.</td>
<td>I</td>
<td>A</td>
</tr>
<tr>
<td>In DM, metformin is recommended as first-line therapy, if tolerated and not contra-indicated, following evaluation of renal function.</td>
<td>I</td>
<td>B</td>
</tr>
<tr>
<td>Lipid lowering agents (principally statins) are recommended to reduce CV risk in all patients with type 2 or type 1 DM above the age of 40 years.</td>
<td>I</td>
<td>A</td>
</tr>
<tr>
<td>Antiplatelet therapy is not recommended in individuals without CVD due to the increased risk of major bleeding.</td>
<td>III</td>
<td>B</td>
</tr>
</tbody>
</table>

### Recommendations for achieving medication and healthy lifestyle adherence

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>Class</th>
<th>Level</th>
</tr>
</thead>
<tbody>
<tr>
<td>Simplifying the treatment regimen to the lowest acceptable level is recommended, with repetitive monitoring and feedback. In the case of persistent non-adherence, multi-session or combined behavioural interventions are recommended.</td>
<td>I</td>
<td>A</td>
</tr>
<tr>
<td>It is recommended that health personnel, caregivers set an example by following healthy lifestyle, such as not smoking or using tobacco products at work.</td>
<td>I</td>
<td>A</td>
</tr>
</tbody>
</table>
To do and not to do messages from the Guidelines (continued)

<table>
<thead>
<tr>
<th>Recommendation for CVD prevention implementation</th>
<th>Class</th>
<th>Level</th>
</tr>
</thead>
<tbody>
<tr>
<td>In primary care, it is recommended that GPs, nurses and allied health professionals within primary care deliver CVD prevention for high-risk patients.</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>In acute hospital setting, it is recommended to implement strategies for prevention in CVD patients, including lifestyle changes, risk factor management and pharmacological optimization, after an acute event before hospital discharge to lower risk of mortality and morbidity.</td>
<td>I</td>
<td>A</td>
</tr>
<tr>
<td>Participation in a cardiac rehabilitation programme for patients hospitalized for an acute coronary event or revascularization, and for patients with HF, is recommended.</td>
<td>I</td>
<td>A</td>
</tr>
</tbody>
</table>

ACE-I = angiotensin-converting enzyme inhibitor; ACS = acute coronary syndrome; ARBs = angiotensin receptor blockers; BP = blood pressure; CAD = coronary artery disease; CKD = chronic kidney disease; CV = cardiovascular; CVD = cardiovascular disease; DBP = diastolic blood pressure; DM = diabetes mellitus; GPs = general practitioners; Hba1c = glycated haemoglobin; HDL-C = high-density lipoprotein cholesterol; HF = heart failure; IMT = intima–media thickness; LDL-C = low-density lipoprotein cholesterol; PA = physical activity; SBP = systolic blood pressure; SCORE = Systematic Coronary Risk Estimation; TIA = transient ischaemic attack.

*Class of recommendation.

*Level of evidence.

6. Appendix

ESC Committee for Practice Guidelines (CPG): Jose Luis Zamorano (Chairperson) (Spain), Victor Aboyans (France), Stephan Achenbach (Germany), Stefan Agewall (Norway), Lina Badimon (Spain), Gonzalo Barón-Esquivias (Spain), Helmut Baumgartner (Germany), Jeroen J. Bax (The Netherlands), Héctor Bueno (Spain), Scipione Carerj (Italy), Veronica Dean (France), Çetin Erol (Turkey), Donna Fitzsimons (UK), Oliver Gaemperli (Switzerland), Philippe Kolh (Belgium), Patrizio Lancellotti (Belgium), Gregory Y.H. Lip (UK), Petros Nihoyannopoulos (UK), Kirchhof (UK/Germany), Philippe Kolh (Belgium), Patrizio Lancellotti (Belgium), Gregory Y.H. Lip (UK), Petros Nihoyannopoulos (UK), Massimo F. Piepoli (Italy), Piotr Ponikowski (Poland), Marco Roﬁ (Switzerland), Adam Torbicki (Poland), António Vaz Carneiro (Portugal), Stephan Windecker (Switzerland).

ESC National Cardiac Societies actively involved in the review process of the 2016 European Guidelines on cardiovascular disease prevention in clinical practice:

- **Austria:** Austrian Society of Cardiology, Bernhard Metzler; **Azerbaijan:** Azerbaijan Society of Cardiology, Ruslan Najafov; **Belarus:** Belorussian Scientific Society of Cardiologists, Valery Stelmashok; **Belgium:** Belgian Society of Cardiology, Catherine De Maeyer; **Bosnia and Herzegovina:** Association of Cardiologists of Bosnia and Herzegovina, Mirza Dilić; **Bulgaria:** Bulgarian Society of Cardiology, Ivan Gruev; **Croatia:** Croatian Cardiac Society, Davor Mišić; **Czech Republic:** Czech Society of Cardiology, Helena Vaverkova; **Denmark:** Danish Society of Cardiology, Ida Gustafsson; **Egypt:** Egyptian Society of Cardiology, Ibah Attia; **Estonia:** Estonian Society of Cardiology, Davit Duivishvili; **Former Yugoslav Republic of Macedonia:** Macedonian FYR Society of Cardiology, Nela Kostova; **France:** French Society of Cardiology, Jean Ferrière; **Georgia:** Georgian Society of Cardiology, Zurab Klimiashvili; **Germany:** German Cardiac Society, Rainer Hambrecht; **Greece:** Hellenic Cardiological Society, Konstantinos Tsoufis; **Hungary:** Hungarian Society of Cardiology, Eszter Szabados; **Iceland:** Icelandic Society of Cardiology, Karl Andersen; **Ireland:** Irish Cardiac Society, Cari Vaughan; **Israel:** Israel Heart Society, Barak Zafir; **Italy:** Italian Federation of Cardiology, Salvatore Novo; **Kazakhstan:** Association of Cardiologists of Kazakhstan, Kairat Davletov; **Kosovo:** Kosovo Society of Cardiology, Fisnik Jashari; **Kyrgyzstan:** Kyrgyz Society of Cardiology, Alina Kerimkulova; **Latvia:** Latvian Society of Cardiology, Iveta Mintale; **Lebanon:** Lebanese Society of Cardiology, Georges Saade; **Lithuania:** Lithuanian Society of Cardiology, Zaneta Petrušiniene; **Luxembourg:** Luxembourg Society of Cardiology, Charles Delagardelle; **Malta:** Maltese Cardiac Society, Caroline J. Magri; **Moldova:** Moldavian Society of Cardiology, Victor Rudi; **Morocco:** Moroccan Society of Cardiology, Latifa Oukerraj; **The Netherlands:** Netherlands Society of Cardiology, B. Erseń Čoksens; **Norway:** Norwegian Society of Cardiology, Henrik Schirmer; **Poland:** Polish Cardiac Society, Piotr Jankowski; **Portugal:** Portuguese Society of Cardiology, Roberto Palma dos Reis; **Romania:** Romanian Society of Cardiology, Daniel Gherasim; **Russian Federation:** Russian Society of Cardiology, Sergey Nedogoda; **San Marino:** San Marino Society of Cardiology, Marco Zavatta; **Serbia:** Cardiology Society of Serbia, Vojislav Giga; **Slovakia:** Slovak Society of Cardiology, Slavomíra Filipova; **Spain:** Spanish Society of Cardiology, Luis Rodríguez Palidal; **Sweden:** Swedish Society of Cardiology, Anna Kiessling; **Switzerland:** Swiss Society of Cardiology, François Mach; **Tunisia:** Tunisian Society of Cardiology and Cardio-Vascular Surgery, Abdallah Mahdouh; **Turkey:** Turkish Society of Cardiology, Dilek Ural; **Ukraine:** Ukrainian Association of Cardiology, Elena Nesukay; **United Kingdom:** British Cardiovascular Society, Chris Gale.

85. Bressler J, Folsom AR, Couper DJ, Volcik KA, Boerwinkle E. Genetic variants identified in a European genome-wide association study that were found to predict incident coronary heart disease in the atherosclerosis risk in communities (ARIC), but not in the Rotterdam and Framingham Offspring Studies. Atherosclerosis 2012;223:421–426.


90. Bressler J, Folsom AR, Couper DJ, Volcik KA, Boerwinkle E. Genetic variants identified in a European genome-wide association study that were found to predict incident coronary heart disease in the atherosclerosis risk in communities (ARIC), but not in the Rotterdam and Framingham Offspring Studies. Atherosclerosis 2012;223:421–426.

91. Bressler J, Folsom AR, Couper DJ, Volcik KA, Boerwinkle E. Genetic variants identified in a European genome-wide association study that were found to predict incident coronary heart disease in the atherosclerosis risk in communities (ARIC), but not in the Rotterdam and Framingham Offspring Studies. Atherosclerosis 2012;223:421–426.


Silber S. Comparison of electron beam tomography and the evaluation of coronary calcification in asymptomatic persons. *Int J Cardiol* 2002;82:297–298; author reply 299.


